NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
abacavir 20 mg/mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
abacavir 300 mg + lamivudine 150 mg + zidovudine 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
abacavir 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
abacavir 600 mg + lamivudine 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
abatacept 125 mg/mL injection, syringe	Yes	For use as per PBS criteria	
abatacept 250 mg injection, vial	Yes	For use as per PBS S100 HSD criteria	
acamprosate calcium 333 mg enteric tablet	Yes	On the advice of a drug and alcohol service or addiction psychiatrist for the management of alcohol dependance	
acarbose 100 mg tablet	Yes	For third line treatment of type 2 diabetes mellitus where other agents not suitable	
acarbose 50 mg tablet	Yes	For third line treatment of type 2 diabetes mellitus where other agents not suitable	
acetazolamide 250 mg tablet	No	N/A	
acetazolamide 500 mg injection, vial	No	N/A	
acetylcholine chloride 20 mg powder for intraocular irrigation solution, vial	Yes	For use by ophthalmology services OR off label use in accordance with a DTC approved protocol	
acetylcysteine 2 g/10 mL injection, ampoule	No	N/A	
acetylcysteine 800 mg/4 mL inhalation solution, vial	No	N/A	
aciclovir 200 mg dispersible tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
aciclovir 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
aciclovir 250 mg/10 mL injection, ampoule	Yes	Use in accordance with the local antimicrobial stewardship policy	
aciclovir 250 mg/10 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
aciclovir 3% eye ointment	Yes	Use in accordance with the local antimicrobial stewardship policy	
aciclovir 5% cream	No	N/A	
aciclovir 500 mg/20 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
aciclovir 800 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
acitretin 10 mg capsule	Yes	For use as per PBS criteria AND with authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008	
acitretin 25 mg capsule	Yes	For use as per PBS criteria AND with authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008	
aclidinium 322 microgram/actuation powder for inhalation, actuation	No	N/A	
aclidinium 340 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 12 microgram/actuation powder for inhalation, actuation	Yes	For use as per PBS criteria	
activated charcoal 200 mg/mL oral liquid	No	N/A	
adalimumab 20 mg/0.4 mL injection, syringe	Yes	For use by paediatric rheumatology services AND as per PBS S100 HSD criteria	
adalimumab 40 mg/0.4 mL injection, pen device	Yes	For use by paediatric rheumatology services AND as per PBS S100 HSD criteria	
adalimumab 40 mg/0.4 mL injection, syringe	Yes	For use by paediatric rheumatology services AND as per PBS S100 HSD criteria	
adalimumab 80 mg/0.8 mL injection, pen device	Yes	For use in paediatrics for the management of IBD on the advice of a paediatric gastroenterology service as per PBS criteria or in accordance with a DTC approved protocol	
adalimumab 80 mg/0.8 mL injection, syringe	Yes	For use in paediatrics for the management of IBD on the advice of a paediatric gastroenterology service as per PBS criteria or in accordance with a DTC approved protocol	
adapalene 0.1% + benzoyl peroxide 2.5% gel	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
adefovir dipivoxil 10 mg tablet	Yes	For use as per PBS S100 HSD criteria	
adenosine 30 mg/10 mL injection, vial	No	N/A	
adenosine 6 mg/2 mL injection, vial	No	N/A	
adrenaline (epinephrine) 1 in 10 000 (1 mg/10 mL) injection, ampoule	No	N/A	
adrenaline (epinephrine) 1 in 10 000 (1 mg/10 mL) injection, syringe	No	N/A	
adrenaline (epinephrine) 1 in 1000 (1 mg/mL) injection, ampoule	No	N/A	
adrenaline (epinephrine) 150 microgram/0.3 mL injection, pen device	Yes	For use as per PBS criteria OR for use by Hospital In The Home services	Refer to PD2022_032 Medication Handling for management of patient's own adrenaline (epinephrine) autoinjectors
adrenaline (epinephrine) 300 microgram/0.3 mL injection, pen device	Yes	For use as per PBS criteria OR for use by Hospital In The Home services	Refer to PD2022_032 Medication Handling for management of patient's own adrenaline (epinephrine) autoinjectors
adrenaline (epinephrine) 500 microgram/0.3 mL injection, pen device	Yes	For use as per PBS criteria OR for use by Hospital In The Home services	Refer to PD2022_032 Medication Handling for management of patient's own adrenaline (epinephrine) autoinjectors
adrenaline (epinephrine) acid tartrate 0.18% + tetracaine (amethocaine) hydrochloride 0.5% + lidocaine (lignocaine) hydrochloride 4% gel, vial	Yes	For use in paediatric patients only	
albendazole 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
alemtuzumab 12 mg/1.2 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
alendronate 70 mg tablet	No	N/A	
alfentanil 1 mg/2 mL injection, ampoule	Yes	For use by anaesthetic services only	
allopurinol 100 mg tablet	No	N/A	
allopurinol 300 mg tablet	No	N/A	
alprazolam 250 microgram tablet	Yes	For use by palliative care services only	
alprostadil 20 microgram injection, chamber	Yes	For use in diagnosis of erectile dysfunction due to veno-occlusive dysfunction	
alprostadil 500 microgram/mL injection, ampoule	Yes	For use in neonates OR off label use in accordance with a DTC approved protocol	
alteplase 10 mg injection, vial	Yes	For use in accordance with a DTC approved protocol	
alteplase 50 mg injection, vial	Yes	For use in accordance with a DTC approved protocol	
aluminium hydroxide 250 mg/5 mL + magnesium trisilicate 120 mg/5 mL + magnesium hydroxide 120 mg/5 mL oral liquid	No	N/A	
aluminium hydroxide 600 mg tablet	No	N/A	
amantadine hydrochloride 100 mg capsule	Yes	On the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	
ambrisentan 10 mg tablet	Yes	For use as per PBS S100 HSD criteria	
ambrisentan 5 mg tablet	Yes	For use as per PBS S100 HSD criteria	
amidotrizoate meglumine 66 g/100 mL + sodium amidotrizoate 10 g/100 mL solution	Yes	For the treatment of meconium ileus OR off label use in accordance with a DTC approved protocol	Due to a disruption to the supply of the Australian registered product, an alternative Gastrografin gastrointestinal solution product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 31 March 2024. Further information is available in the CEC Medication Safety Updates.
amikacin 500 mg/2 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
amino acid + glucose + electrolytes + trace elements (34 WEEK TO TERM) injection, 1.2 L bag	Yes	For use by neonatal TPN services	
amino acid + glucose + electrolytes + trace elements (7.5% GLUCOSE PRETERM) injection, 750 mL bag	Yes	For use by neonatal TPN services	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
amino acid + glucose + electrolytes + trace elements (CONCENTRATED PRETERM) injection, 750 mL bag	Yes	For use by neonatal TPN services	
amino acid + glucose + electrolytes + trace elements (HIGH SODIUM PRETERM) injection, 750 mL bag	Yes	For use by neonatal TPN services	
amino acid + glucose + electrolytes + trace elements (PERIPHERAL PRETERM) injection, 750 mL bag	Yes	For use by neonatal TPN services	
amino acid + glucose + electrolytes + trace elements (STANDARD PRETERM) injection, 750 mL bag	Yes	For use by neonatal TPN services	
amino acid + glucose + electrolytes + trace elements (STARTER CONCENTRATED) injection, 500 mL bag	Yes	For use by neonatal TPN services	
amino acid + glucose + electrolytes + trace elements (STARTER) injection, 500 mL bag	Yes	For use by neonatal TPN services	
aminophylline 250 mg/10 mL injection, ampoule	Yes	For management of acute asthma in paediatric patients as per the Paediatric Improvement Collaborative Clinical Practice Guidelines OR for use in reversal of vasodilator-related side effects at the end of myocardial perfusion testing	
amiodarone hydrochloride 100 mg tablet	No	N/A	
amiodarone hydrochloride 150 mg/3 mL injection, ampoule	No	N/A	
amiodarone hydrochloride 200 mg tablet	No	N/A	
amisulpride 100 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
amisulpride 100 mg/mL oral liquid	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) AND where solid oral dose form not suitable	
amisulpride 200 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
amisulpride 400 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
amitriptyline hydrochloride 10 mg tablet	No	N/A	
amitriptyline hydrochloride 25 mg tablet	No	N/A	
amitriptyline hydrochloride 50 mg tablet	No	N/A	
amlodipine 10 mg tablet	No	N/A	
amlodipine 5 mg tablet	No	N/A	
amorolfine 5% solution	Yes	Use in accordance with the local antimicrobial stewardship policy	
amoxicillin 1 g + clavulanic acid 200 mg injection, 1.2 g vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
amoxicillin 125 mg/5 mL + clavulanic acid 31.25 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
amoxicillin 2 g + clavulanic acid 200 mg injection, 2.2 g vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
amoxicillin 250 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
amoxicillin 250 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
amoxicillin 400 mg/5 mL + clavulanic acid 57 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
amoxicillin 500 mg + clavulanic acid 100 mg injection, 600 mg vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
amoxicillin 500 mg + clavulanic acid 125 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
amoxicillin 500 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
amoxicillin 875 mg + clavulanic acid 125 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
amphotericin B (as liposomal) 50 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
amphotericin B 10 mg lozenge	Yes	Use in accordance with the local antimicrobial stewardship policy	
ampicillin 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ampicillin 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
anakinra 100 mg/0.67 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for the management of severe/refractory cytokine-release syndrome or haemophagocytic lymphohistiocytosis/macrophage activating syndrome in accordance with an approved protocol	
anastrozole 1 mg tablet	No	N/A	
anidulafungin 100 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
antithymocyte immunoglobulin equine 250 mg/5 mL injection, ampoule	Yes	For prevention and treatment of cardiac and bone marrow transplant rejection OR management of aplastic anaemia OR prevention or treatment of graft-versus-host disease	Antithymocyte immunoglobulins and brands are not interchangeable
antithymocyte immunoglobulin rabbit 25 mg injection, vial	Yes	For prevention and treatment of renal, liver, lung and bone marrow transplant rejection	Antithymocyte immunoglobulins and brands are not interchangeable
apixaban 2.5 mg tablet	Yes	For use as per PBS criteria	
apixaban 5 mg tablet	Yes	For use as per PBS criteria	
apomorphine hydrochloride hemihydrate 100 mg/20 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
apomorphine hydrochloride hemihydrate 30 mg/3 mL injection, cartridge	Yes	For use as per PBS S100 HSD criteria	Apomine intermittent cartridge is not interchangeable with Movapo Pen cartridge.
apomorphine hydrochloride hemihydrate 30 mg/3 mL injection, pen device	Yes	For use as per PBS S100 HSD criteria	Apomine intermittent cartridge is not interchangeable with Movapo Pen cartridge.
apomorphine hydrochloride hemihydrate 50 mg/10 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
apraclonidine 0.5% eye drops	No	N/A	
aprepitant 165 mg capsule	Yes	For use by cancer services only	
aprotinin 2250 KI units/mL + factor XIII 1.2 units/mL + fibrinogen 72 mg/mL solution 2 mL chamber (&) human thrombin 400 units/mL + calcium chloride dihydrate 5.292 mg/mL solution 2 mL chamber	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
aprotinin 2250 KI units/mL + factor XIII 1.2 units/mL + fibrinogen 72 mg/mL solution 5 mL chamber (&) human thrombin 400 units/mL + calcium chloride dihydrate 5.292 mg/mL solution 5 mL chamber	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
arginine 750 mg capsule	Yes	For the management of urea cycle disorders	
arginine hydrochloride 60% (15 g/25 mL) injection, vial	Yes	For use by metabolic services only	
arginine with carbohydrate containing 2 g arginine powder for oral liquid, 4 g sachet	Yes	For the management of urea cycle disorders	For practical and safety purposes this medicine should be prescribed by brand name.
arginine with carbohydrate containing 5 g arginine powder for oral liquid, 7.6 g sachet	Yes	For the management of urea cycle disorders	For practical and safety purposes this medicine should be prescribed by brand name.
arginine with carbohydrate containing 500 mg arginine powder for oral liquid, 4 g sachet	Yes	For the management of urea cycle disorders	For practical and safety purposes this medicine should be prescribed by brand name.
argipressin 1 mg/mL (equivalent to vasopressin 20 units/mL) injection, ampoule	Yes	For use in critical care areas only	
aripiprazole 10 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
aripiprazole 15 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
aripiprazole 20 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
aripiprazole 300 mg modified release injection, vial	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
aripiprazole 400 mg modified release injection, vial	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
aripiprazole 5 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
arsenic trioxide 10 mg/10 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
artemether 20 mg + lumefantrine 120 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
articaine hydrochloride 4% (88 mg/2.2 mL) + adrenaline (epinephrine) 1 in 100 000 (22 microgram/2.2 mL) injection, cartridge	Yes	For dental use only	
ascorbic acid 1 g effervescent tablet	Yes	For use in paediatric patients only	
ascorbic acid 500 mg chewable tablet	No	N/A	
ascorbic acid 500 mg/3 mL injection, vial	No	N/A	
asenapine 10 mg sublingual wafer	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
asenapine 5 mg sublingual wafer	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
asparaginase erwinia 10 000 units injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	Special Access Scheme form must be submitted and informed consent for use obtained
aspirin 100 mg enteric tablet	No	N/A	
aspirin 100 mg tablet	No	N/A	
aspirin 300 mg dispersible tablet	No	N/A	
aspirin 300 mg effervescent tablet	No	N/A	
aspirin 300 mg effervescent tablet	No	N/A	
aspirin 300 mg suppository	Yes	For ischaemic stroke where oral and nasogastric routes are not suitable	Special Access Scheme form must be submitted and informed consent for use obtained
atazanavir 200 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
atazanavir 300 mg + cobicistat 150 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
atazanavir 300 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
atenolol 50 mg tablet	No	N/A	
atenolol 50 mg/10 mL oral liquid	Yes	For use in neonate and paediatric patients	
atezolizumab 1.2 g/20 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
atezolizumab 840 mg/14 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
atomoxetine 10 mg capsule	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist)	
atomoxetine 18 mg capsule	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist)	
atomoxetine 25 mg capsule	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist)	
atomoxetine 40 mg capsule	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist)	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
atomoxetine 60 mg capsule	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist)	
atomoxetine 80 mg capsule	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist)	
atorvastatin 10 mg tablet	No	N/A	
atorvastatin 20 mg tablet	No	N/A	
atorvastatin 40 mg tablet	No	N/A	
atorvastatin 80 mg tablet	No	N/A	
atovaquone 250 mg + proguanil hydrochloride 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
atovaquone 750 mg/5 mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
atracurium besilate 25 mg/2.5 mL injection, ampoule	Yes	For use by anaesthetic or critical care services	
atropine sulfate monohydrate 1 mg/5 mL injection, syringe	No	N/A	
atropine sulfate monohydrate 1% eye drops	Yes	For use by ophthalmology services (or in a rural/remote setting, an appropriate specialist) OR on the advice of a mental health service for the management of clozapine induced hypersalivation in accordance with a DTC approved protocol	Oral ingestion of atropine eye drops for treatment of hypersalivation has been associated with accidental oral ingestion of a toxic quantity causing patient harm.
atropine sulfate monohydrate 1% eye drops, unit dose	Yes	For use by ophthalmology services (or in a rural/remote setting, an appropriate specialist)	Oral ingestion of atropine eye drops for treatment of hypersalivation has been associated with accidental oral ingestion of a toxic quantity causing patient harm. Consider hyoscine hydrobromide chewable tablets as a formulary listed alternative.
atropine sulfate monohydrate 1.2 mg/mL injection, ampoule	No	N/A	
atropine sulfate monohydrate 600 microgram/mL injection, ampoule	No	N/A	
avelumab 200 mg/10 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
azacitidine 100 mg injection, vial	Yes	For use as per PBS S100 criteria AND in accordance with an eviQ or approved protocol	
azathioprine 100 mg injection, vial	Yes	For patients unable to tolerate oral therapy	Special Access Scheme form must be submitted and informed consent for use obtained
azathioprine 25 mg tablet	No	N/A	
azathioprine 50 mg tablet	No	N/A	
azithromycin 200 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
azithromycin 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
azithromycin 500 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
azithromycin 600 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
aztreonam 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
baclofen 10 mg tablet	No	N/A	
baclofen 10 mg/5 mL intrathecal injection, ampoule	Yes	For use as per PBS S100 HSD criteria	
baclofen 25 mg tablet	No	N/A	
baclofen 40 mg/20 mL intrathecal injection, ampoule	Yes	For use as per PBS S100 HSD criteria	
baclofen 50 microgram/mL intrathecal injection, ampoule	Yes	For use as a test dose for patients eligible for PBS criteria of 10 mg/5 mL or 40 mg/20 mL	
balsalazide sodium 750 mg capsule	No	N/A	
baricitinib 2 mg tablet	Yes	For use in accordance with the National Clinical Evidence Taskforce recommendations	For use by prescribers approved by the local DTC

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
baricitinib 4 mg tablet	Yes	For use in accordance with the National Clinical Evidence Taskforce recommendations	For use by prescribers approved by the local DTC
basiliximab 20 mg injection, vial	No	N/A	Off label use is only allowed if it is in accordance with a DTC approved protocol
beclometasone dipropionate 50 microgram/actuation nasal spray, actuation	No	N/A	
bedaquiline 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
bedaquiline 20 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
bendamustine hydrochloride 100 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
bendamustine hydrochloride 25 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
benralizumab 30 mg/mL injection, pen device	Yes	For use as per PBS S100 HSD criteria	
benzathine benzylpenicillin tetrahydrate 1.2 million units (1016.6 mg)/2.3 mL injection, syringe	Yes	Use in accordance with the local antimicrobial stewardship policy	Due to an anticipated disruption to the supply of the Australian registered product, an alternative benzathine benzylpenicillin tetrahydrate 1.2 million units (1016.6 mg)/2.3 mL injection product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 30 March 2024. Additionally, multiple international alternatives are available via the Special Access Scheme (SAS) under the Therapeutic Goods Administration. Further information is available in the CEC Medication Safety Updates.
benzatropine mesilate 2 mg tablet	No	N/A	
benzatropine mesilate 2 mg/2 mL injection, vial	No	N/A	
benzoyl peroxide 2.5% gel	No	N/A	
benzoyl peroxide 5% gel	No	N/A	
benzoyl peroxide 5% solution	No	N/A	
benzyl benzoate 25% lotion	Yes	For use in patients with permethrin allergy OR if permethrin ineffective	
benzylpenicillin 1.2 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
benzylpenicillin 3 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
benzylpenicillin 600 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
beractant 200 mg/8 mL intratracheal suspension, vial	Yes	For use in neonates when poractant alfa is inappropriate	
betacarotene 1.8 mg + vitamin A 300 microgram + colecalciferol 15 microgram (600 units) + dl-alpha-tocopheryl acetate 50 mg + thiamine nitrate 2.18 mg + riboflavin 3.2 mg + nicotinamide 15 mg + calcium pantothenate 10.8 mg + pyridoxine hydrochloride 6 mg + folic acid 300 microgram + cyanocobalamin 20 microgram + ascorbic acid 90 mg + biotin 45 microgram + phytomenadione 25 microgram + iron 5 mg + calcium 200 mg + magnesium 50 mg + zinc 7.5 mg + iodine 150 microgram + potassium 80 mg + copper 1 mg + chromium 35 microgram + manganese 5 mg + selenium 55 microgram + lutein 500 microgram + lycopene 600 microgram tablet	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
betacarotene 2.3 mg + retinol acetate 375 microgram RE + ascorbic acid 60 mg + colecalciferol 12.5 microgram (500 units) + d-alpha-tocopheryl acid succinate 12.4 mg (15 units) + thiamine nitrate 5 mg + riboflavin 5 mg + calcium pantothenate 5 mg + pyridoxine hydrochloride 5 mg + cyanocobalamin 125 microgram + mecobalamin (co-methylcobalamin) 125 microgram + folic acid 250 microgram + selenium 30 microgram + biotin 150 microgram + inositol 10 mg + calcium 300.42 mg + magnesium 52.5 mg + iodine 75 microgram + copper 375 microgram + zinc 7.5 mg + nicotinamide 25 mg + manganese 1 mg + iron 9 mg + chromium 60 microgram + molybdenum 37.5 microgram + choline bitartrate 2.5 mg chewable tablet	Yes	For use in paediatric patients only	
betahistine dihydrochloride 16 mg tablet	Yes	For second line treatment of Meniere's disease and vestibular vertigo where other agents failed	
betaine 1 g/g powder for oral liquid	Yes	For use by metabolic services	
betamethasone (as dipropionate) 0.05% cream	No	N/A	
betamethasone (as dipropionate) 0.05% ointment	No	N/A	
betamethasone (as valerate) 0.02% cream	No	N/A	
betamethasone (as valerate) 0.05% cream	No	N/A	
betamethasone (as valerate) 0.1% cream	No	N/A	
betamethasone (as valerate) 0.1% ointment	No	N/A	
betamethasone acetate 3 mg/mL + betamethasone sodium phosphate 3.9 mg/mL (total betamethasone 5.7 mg/mL) injection, ampoule	No	N/A	
betaxolol 0.5% eye drops	No	N/A	
bevacizumab 100 mg/4 mL injection, vial	Yes	For use by cancer services AND in accordance with an eviQ or approved protocol	
bevacizumab 400 mg/16 mL injection, vial	Yes	For use by cancer services AND in accordance with an eviQ or approved protocol	
bicalutamide 50 mg tablet	No	N/A	
bictegravir 50 mg + emtricitabine 200 mg + tenofovir alafenamide 25 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
Bifidobacterium bifidum 1 billion CFU + Lactobacillus acidophilus 1 billion CFU capsule	Yes	For prevention of necrotising enterocolitis (NEC) in neonates	
bimatoprost 0.03% + timolol 0.5% eye drops	Yes	For use on the advice of an ophthalmology service where rapid reduction of intraocular pressure in trauma or secondary glaucoma is required	This combination agent is recommended to be stocked in hospitals with specialist ophthalmology services. For practical and safety purposes this medicine should be prescribed by brand name.
bimatoprost 0.03% + timolol 0.5% eye drops, ampoule	Yes	For use on the advice of an ophthalmology service where rapid reduction of intraocular pressure in trauma or secondary glaucoma is required	This combination agent is recommended to be stocked in hospitals with specialist ophthalmology services. For practical and safety purposes this medicine should be prescribed by brand name.
bimatoprost 0.03% eye drops	No	N/A	
bimatoprost 0.03% eye drops, unit dose	No	N/A	
biotin 10 mg capsule	Yes	For management of metabolic conditions	
bisacodyl 10 mg suppository	No	N/A	
bisacodyl 10 mg/5 mL enema	Yes	For use as per PBS criteria	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
bisacodyl 5 mg enteric tablet	No	N/A	
bisoprolol fumarate 2.5 mg tablet	Yes	For use as per PBS criteria	
bisoprolol fumarate 5 mg tablet	Yes	For use as per PBS criteria	
bivalirudin 250 mg injection, vial	Yes	For use in Cardiac Catheterisation Lab OR where heparin and enoxaparin not suitable	
bleomycin sulfate 15 000 international units injection, vial	Yes	For use as per PBS criteria or as part of electrochemotherapy or in sclerotherapy in venous and lymphatic malformations or intra-lesional administration for treatment of hypertrophic and keloid scars AND in accordance with an eviQ or approved protocol	
blinatumomab 38.5 microgram injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
bortezomib 1 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
bortezomib 3 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
bortezomib 3.5 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
bosentan 125 mg tablet	Yes	For use as per PBS S100 HSD criteria	
bosentan 62.5 mg tablet	Yes	For use as per PBS S100 HSD criteria	
botulinum toxin type A 100 units injection, vial	Yes	For use as per PBS S100 Botulinum Toxin Program criteria OR additional indications as listed in the formulary note	_ Management of refractory anal fissure _ Management of refractory achalasia _ Management of severe hypersalivation _ Pre-operative treatment for complex ventral hernia repair _ For use in paediatric patients for the management of spasticity and dystonia, not covered by PBS S100 Botulinum Toxin Program criteria _ For the management of chronic idiopathic constipation or encopresis unresponsive to intensive bowel management
brentuximab vedotin 50 mg injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
brexpiprazole 1 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
brexpiprazole 2 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
brimonidine tartrate 0.15% eye drops	No	N/A	
brimonidine tartrate 0.2% + timolol 0.5% eye drops	Yes	For use on the advice of an ophthalmology service where rapid reduction of intraocular pressure in trauma or secondary glaucoma is required	This combination agent is recommended to be stocked in all acute hospital settings. For practical and safety purposes this medicine should be prescribed by brand name.
brimonidine tartrate 0.2% eye drops	No	N/A	
brinzolamide 1% + brimonidine tartrate 0.2% eye drops	Yes	For use on the advice of an ophthalmology service where rapid reduction of intraocular pressure in trauma or secondary glaucoma is required	This combination agent is recommended to be stocked in hospitals with specialist ophthalmology services. For practical and safety purposes this medicine should be prescribed by brand name.
brinzolamide 1% eye drops	No	N/A	
brivaracetam 25 mg tablet	Yes	For use when levetiracetam is not tolerated or contraindicated AND as per PBS criteria	
brivaracetam 50 mg tablet	Yes	For use when levetiracetam is not tolerated or contraindicated AND as per PBS criteria	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
bromocriptine 2.5 mg tablet	Yes	For use by obstetrics services for hyperprolactinaemia and lactation suppression OR for use by neurology services (or in a rural/remote setting, an appropriate specialist)	
brown snake antivenom 1000 units injection, vial	No	N/A	
budesonide 1 mg orally disintegrating tablet	Yes	For use by gastroenterologists for prevention of oesophageal strictures/stenosis in patients who have undergone oesophageal endoscopic submucosal dissection involving > 50% of the mucosal circumference	Maximum duration of 8 weeks
budesonide 1 mg/2 mL inhalation solution, ampoule	No	N/A	
budesonide 100 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 3 microgram/actuation inhalation, actuation	Yes	For use as per PBS criteria	
budesonide 100 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation powder for inhalation, actuation	Yes	For use as per PBS criteria	
budesonide 100 microgram/actuation powder for inhalation, actuation	No	N/A	
budesonide 160 microgram/actuation + glycopyrronium 7.2 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 5 microgram/actuation inhalation, actuation	Yes	For use as per PBS criteria	
budesonide 200 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation inhalation, actuation	Yes	For use as per PBS criteria	
budesonide 200 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation powder for inhalation, actuation	Yes	For use as per PBS criteria	
budesonide 200 microgram/actuation powder for inhalation, actuation	No	N/A	
budesonide 3 mg modified release capsule	Yes	For use as per PBS criteria OR on the advice of a haematology service for management of gastrointestinal acute graft versus host disease following allogeneic haematopoietic cell transplant	
budesonide 500 microgram/2 mL inhalation solution, ampoule	Yes	For use in neonate and paediatric patients	
budesonide 64 microgram/actuation nasal spray, actuation	No	N/A	
bumetanide 1 mg tablet	Yes	On the advice of a cardiology or renal service only (or in a rural/remote setting, an appropriate specialist)	
bupivacaine hydrochloride 0.125% (25 mg/20 mL) + fentanyl 100 microgram/20 mL injection, ampoule	No	N/A	
bupivacaine hydrochloride 0.5% (20 mg/4 mL) intrathecal injection, ampoule	Yes	For use by anaesthetic or pain services only	
bupivacaine hydrochloride monohydrate 0.125% (250 mg/200 mL) injection, bag	No	N/A	
bupivacaine hydrochloride monohydrate 0.25% (50 mg/20 mL) + adrenaline (epinephrine) 1 in 400 000 (50 microgram/20 mL) injection, vial	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
bupivacaine hydrochloride monohydrate 0.25% (50 mg/20 mL) injection, ampoule	No	N/A	
bupivacaine hydrochloride monohydrate 0.5% (100 mg/20 mL) + adrenaline (epinephrine) 1 in 200 000 (100 microgram/20 mL) injection, vial	No	N/A	
bupivacaine hydrochloride monohydrate 0.5% (100 mg/20 mL) injection, ampoule	No	N/A	
bupivacaine hydrochloride monohydrate 0.5% (20 mg/4 mL) + glucose monohydrate 320 mg/4 mL intrathecal injection, ampoule	Yes	For use by anaesthetic or pain services only	
bupivacaine hydrochloride monohydrate 0.5% (50 mg/10 mL) injection, ampoule	No	N/A	
buprenorphine 10 microgram/hour patch	Yes	For management of chronic pain unresponsive to non-opioid analgesia	
buprenorphine 100 mg/0.5 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 128 mg/0.36 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 16 mg/0.32 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
buprenorphine 160 mg/0.45 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 2 mg + naloxone 500 microgram sublingual film	Yes	On the advice of a drug and alcohol service	An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 2 mg sublingual tablet	Yes	On the advice of a drug and alcohol service	An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 20 microgram/hour patch	Yes	For management of chronic pain unresponsive to non-opioid analgesia	
buprenorphine 200 microgram sublingual tablet	Yes	On the advice of an anaesthetic or pain service	
buprenorphine 24 mg/0.48 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 300 mg/1.5 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
buprenorphine 32 mg/0.64 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 40 microgram/hour patch	Yes	For management of chronic pain unresponsive to non-opioid analgesia	
buprenorphine 400 microgram sublingual tablet	Yes	On the advice of a drug and alcohol service	An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 5 microgram/hour patch	Yes	For management of chronic pain unresponsive to non-opioid analgesia	
buprenorphine 64 mg/0.18 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 8 mg + naloxone 2 mg sublingual film	Yes	On the advice of a drug and alcohol service	An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 8 mg sublingual tablet	Yes	On the advice of a drug and alcohol service	An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
buprenorphine 8 mg/0.16 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
buprenorphine 96 mg/0.27 mL modified release injection, syringe	Yes	On the advice of a drug and alcohol service AND as per PBS S100 Opiate dependence criteria	Use in accordance with NSW Ministry of Health interim guideline (2019) "Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence" AND local risk assessment required. An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
burosumab 10 mg/mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
burosumab 20 mg/mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
burosumab 30 mg/mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
busulfan 60 mg/10 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
cabazitaxel 60 mg/1.5 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
cabergoline 1 mg tablet	Yes	For use by obstetrics services for hyperprolactinaemia and lactation suppression OR for use by neurology or endocrine services (or in a rural/remote setting, an appropriate specialist)	
cabergoline 500 microgram tablet	Yes	For use by obstetrics services for hyperprolactinaemia and lactation suppression OR for use by neurology or endocrine services (or in a rural/remote setting, an appropriate specialist)	
caffeine 100 mg tablet	Yes	For the treatment of post-dural puncture headache	
caffeine citrate 25 mg/5 mL oral liquid	Yes	For treatment of apnoea of prematurity	
caffeine citrate 40 mg/2 mL injection, vial	Yes	For treatment of apnoea of prematurity	
calcipotriol 0.005% + betamethasone (as dipropionate) 0.05% foam	No	N/A	
calcipotriol 0.005% + betamethasone (as dipropionate) 0.05% ointment	No	N/A	
calcitonin salmon (salcatonin) 100 units/mL injection, ampoule	No	N/A	
calcitriol 0.25 microgram capsule	No	N/A	
calcium carbonate 1.25 g (calcium 500 mg) chewable tablet	No	N/A	
calcium carbonate 1.5 g (calcium 600 mg) + colecalciferol 12.5 microgram (500 units) tablet	No	N/A	
calcium carbonate 1.5 g (calcium 600 mg) tablet	No	N/A	
calcium chloride dihydrate 1 g/10 mL injection, vial	Yes	For use in critical care areas only	
calcium citrate 1.579 g (calcium 333.33 mg) + colecalciferol 8.3 microgram (333 units) tablet	Yes	For use where calcium carbonate products are inappropriate	
calcium gluconate monohydrate 2.5% gel	No	N/A	
calcium gluconate monohydrate 931 mg/10 mL injection, vial	No	N/A	
calcium polystyrene sulfonate 999.3 mg/g powder	Yes	For use in patients on sodium restriction	
candesartan cilexetil 16 mg tablet	No	N/A	
candesartan cilexetil 32 mg tablet	No	N/A	
candesartan cilexetil 4 mg tablet	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
candesartan cilexetil 8 mg tablet	No	N/A	
capecitabine 500 mg tablet	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
captopril 12.5 mg tablet	No	N/A	
captopril 25 mg tablet	No	N/A	
captopril 5 mg/mL oral liquid	Yes	For use where a solid oral dose form of ACE-I not suitable OR for use in neonates	Due to a disruption to the supply of the Australian registered product, an alternative captopril 5 mg/mL oral liquid product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act. Please refer to the TGA S19a approvals database for further details
captopril 50 mg tablet	No	N/A	
carbachol 0.01% (150 microgram/1.5 mL) intraocular injection, vial	Yes	For use by ophthalmology services only	
carbamazepine 100 mg tablet	No	N/A	
carbamazepine 100 mg/5 mL oral liquid	Yes	For use where solid oral dose form not suitable	
carbamazepine 200 mg modified release tablet	No	N/A	
carbamazepine 200 mg tablet	No	N/A	
carbamazepine 400 mg modified release tablet	No	N/A	
carbetocin 100 microgram/mL injection, syringe	Yes	For post-partum haemorrhage (PPH) prophylaxis post caesarean section	
carbetocin 100 microgram/mL injection, vial	Yes	For post-partum haemorrhage (PPH) prophylaxis post caesarean section	
carbimazole 5 mg tablet	Yes	On the advice of an endocrine service (or in a rural/remote setting, an appropriate specialist)	
carbomer-980 0.2% eye drops, unit dose	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
carbomer-980 0.2% eye gel	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
carboplatin 150 mg/15 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
carboplatin 450 mg/45 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
carboprost 250 microgram/mL injection, vial	Yes	On the advice of an obstetrics service (or in a rural/remote setting, an appropriate specialist)	Not to be given intravenously. Special Access Scheme form must be submitted and informed consent for use obtained.
carfilzomib 10 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
carfilzomib 30 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
carglumic acid 200 mg dispersible tablet	Yes	For use by metabolic services	
carmellose sodium 1% eye drops, unit dose	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
carmustine 100 mg injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
carvedilol 12.5 mg tablet	Yes	For use as per PBS criteria	
carvedilol 25 mg tablet	Yes	For use as per PBS criteria	
carvedilol 3.125 mg tablet	Yes	For use as per PBS criteria	
carvedilol 6.25 mg tablet	Yes	For use as per PBS criteria	
casirivimab 120 mg/mL injection, 11.1 mL vial (&) imdevimab 120 mg/mL injection, 11.1 mL vial	Yes	For use in accordance with the Agency for Clinical Innovation guidance	For use by prescribers approved by the local DTC

Medicine name, strength, and form	Restricted?	Restriction	Additional information
casirivimab 120 mg/mL injection, 2.5 mL vial (&) imdevimab 120 mg/mL injection, 2.5 mL vial	Yes	For use in accordance with the Agency for Clinical Innovation guidance	For use by prescribers approved by the local DTC
cefaclor 250 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefalexin 250 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefalexin 250 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefalexin 500 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefazolin 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefazolin 2 g injection, bottle	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefazolin 2 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefazolin 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefepime 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefepime 2 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefotaxime 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefotaxime 2 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefoxitin 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ceftaroline fosamil 600 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ceftazidime 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ceftazidime 2 g + avibactam 500 mg injection, 2.5 g vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ceftazidime 2 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ceftolozane 1 g + tazobactam 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ceftriaxone 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ceftriaxone 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefuroxime 125 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
cefuroxime 250 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
celecoxib 100 mg capsule	No	N/A	
celecoxib 200 mg capsule	No	N/A	
cetirizine hydrochloride 10 mg tablet	Yes	For use where loratadine not suitable	
cetirizine hydrochloride 5 mg/5 mL oral liquid	Yes	For use where desloratadine is not suitable	
cetuximab 100 mg/20 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
cetuximab 500 mg/100 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
chloral hydrate 1 g/10 mL oral liquid	No	N/A	
chlorambucil 2 mg tablet	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
chloramphenicol 0.5% eye drops	Yes	Use in accordance with the local antimicrobial stewardship policy	
chloramphenicol 0.5% eye drops, unit dose	Yes	Use in accordance with the local antimicrobial stewardship policy	
chloramphenicol 1% eye ointment	Yes	Use in accordance with the local antimicrobial stewardship policy	
chlorpromazine hydrochloride 10 mg tablet	No	N/A	
chlorpromazine hydrochloride 100 mg tablet	No	N/A	
chlorpromazine hydrochloride 25 mg tablet	No	N/A	
chlorpromazine hydrochloride 5 mg/mL oral liquid	No	N/A	
chlorpromazine hydrochloride 50 mg/2 mL injection, ampoule	No	N/A	
chlortalidone 25 mg tablet	No	N/A	
choline salicylate 8.7% gel	No	N/A	
choriogonadotropin alfa 250 microgram/0.5 mL injection, pen device	Yes	For use by paediatric endocrine services only	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
chromic chloride hexahydrate 53.33 microgram/10 mL + cupric chloride dihydrate 1.02 mg/10 mL + ferric chloride hexahydrate 5.4 mg/10 mL + manganese chloride tetrahydrate 198 microgram/10 mL + potassium iodide 166 microgram/10 mL + sodium fluoride 2.1 mg/10 mL + sodium molybdate dihydrate 48.5 microgram/10 mL + sodium selenite 173 microgram/10 mL + zinc chloride 10.5 mg/10 mL injection, ampoule	Yes	For TPN use only	For practical and safety purposes this medicine should be prescribed by brand name.
ciclesonide 160 microgram/actuation inhalation, actuation	No	N/A	
ciclesonide 80 microgram/actuation inhalation, actuation	No	N/A	
ciclosporin 10 mg capsule	No	N/A	Careful monitoring of patients is mandatory
ciclosporin 100 mg capsule	No	N/A	Careful monitoring of patients is mandatory
ciclosporin 100 mg/mL oral liquid	Yes	For use where solid oral dose form not suitable	Careful monitoring of patients is mandatory
ciclosporin 25 mg capsule	No	N/A	Careful monitoring of patients is mandatory
ciclosporin 50 mg capsule	No	N/A	Careful monitoring of patients is mandatory
ciclosporin 50 mg/mL injection, ampoule	Yes	For patients unable to tolerate oral therapy	
cidofovir 375 mg/5 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cinacalcet 30 mg tablet	Yes	For use as per PBS S100 HSD criteria OR for patients with hypercalcemia associated with hyperparathyroidism when parathyroidectomy is not an option	
cinacalcet 60 mg tablet	Yes	For use as per PBS S100 HSD criteria OR for patients with hypercalcemia associated with hyperparathyroidism when parathyroidectomy is not an option	
cinacalcet 90 mg tablet	Yes	For use as per PBS S100 HSD criteria OR for patients with hypercalcemia associated with hyperparathyroidism when parathyroidectomy is not an option	
cinchocaine hydrochloride 0.5% + zinc oxide 20% ointment	Yes	For short-term use up to 7 days	For practical and safety purposes this medicine should be prescribed by brand name.
ciprofloxacin 0.2% + hydrocortisone 1% ear drops	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 0.3% ear drops	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 0.3% eye drops	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 100 mg/50 mL injection, bag	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 100 mg/50 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 200 mg/100 mL injection, bag	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 200 mg/100 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 250 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 400 mg/200 mL injection, bag	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 500 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
ciprofloxacin 750 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
cisatracurium 10 mg/5 mL injection, ampoule	Yes	For use by anaesthetic or critical care services only	
cisatracurium 10 mg/5 mL injection, vial	Yes	For use by anaesthetic or critical care services only	
cisatracurium 150 mg/30 mL injection, vial	Yes	For use by anaesthetic or critical care services only	
cisplatin 100 mg/100 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
cisplatin 50 mg/50 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
citalopram 10 mg tablet	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
citalopram 20 mg tablet	No	N/A	
citrulline with carbohydrate containing 1 g citrulline powder for oral liquid, 4 g sachet	Yes	For the management of urea cycle disorders	For practical and safety purposes this medicine should be prescribed by brand name.
cladribine 10 mg/5 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
clarithromycin 250 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
clarithromycin 250 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
clevidipine 25 mg/50 mL injection, vial	Yes	For use in critical care areas and by neonatology services only AND in accordance with a DTC approved protocol	
clindamycin 1% lotion	Yes	For treatment of hidradenitis suppurativa	
clindamycin 150 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
clindamycin 2% cream	Yes	Use in accordance with the local antimicrobial stewardship policy	
clindamycin 300 mg/2 mL injection, ampoule	Yes	Use in accordance with the local antimicrobial stewardship policy	
clindamycin 300 mg/2 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
clindamycin 600 mg/4 mL injection, ampoule	Yes	Use in accordance with the local antimicrobial stewardship policy	
clindamycin 600 mg/4 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
ClinOleic + Vitalipid N Infant + Soluvit N injection, 150 mL bag	Yes	For use by neonatal TPN services	
ClinOleic + Vitalipid N Infant + Soluvit N injection, 36 mL syringe	Yes	For use by neonatal TPN services	
ClinOleic + Vitalipid N Infant + Soluvit N injection, 50 mL syringe	Yes	For use by neonatal TPN services	
clobazam 10 mg tablet	Yes	On the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	
clofazimine 100 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
clofazimine 50 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
clomipramine hydrochloride 25 mg tablet	Yes	For second line treatment of obsessive compulsive disorder and panic disorders where other agents have failed OR for treatment of cataplexy associated with narcolepsy	
clonazepam 1 mg/mL injection, ampoule	No	N/A	
clonazepam 2 mg tablet	No	N/A	
clonazepam 2.5 mg/mL (0.1 mg/drop) oral liquid	No	N/A	
clonazepam 500 microgram tablet	No	N/A	
clonidine hydrochloride 100 microgram tablet	No	N/A	
clonidine hydrochloride 100 microgram tablet	No	N/A	
clonidine hydrochloride 150 microgram tablet	No	N/A	
clonidine hydrochloride 150 microgram tablet	No	N/A	
clonidine hydrochloride 150 microgram/mL injection, ampoule	No	N/A	
clonidine hydrochloride 150 microgram/mL injection, ampoule	No	N/A	
clopidogrel 75 mg tablet	No	N/A	
clostridium botulinum type A toxin-haemagglutinin complex 300 units injection, vial	Yes	For use as per PBS S100 Botulinum Toxin Program criteria	
clostridium botulinum type A toxin-haemagglutinin complex 500 units injection, vial	Yes	For use as per PBS S100 Botulinum Toxin Program criteria	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
clotrimazole 1% cream	No	N/A	
clotrimazole 1% lotion	No	N/A	
clotrimazole 2% vaginal cream	Yes	Use in accordance with the local antimicrobial stewardship policy	
clotrimazole 500 mg pessary	Yes	Use in accordance with the local antimicrobial stewardship policy	
clozapine 100 mg tablet	Yes	For use by prescribers who are registered with a clozapine monitoring program	Clozapine brands are not interchangeable
clozapine 200 mg tablet	Yes	For use by prescribers who are registered with a clozapine monitoring program	Clozapine brands are not interchangeable
clozapine 25 mg tablet	Yes	For use by prescribers who are registered with a clozapine monitoring program	Clozapine brands are not interchangeable
clozapine 50 mg tablet	Yes	For use by prescribers who are registered with a clozapine monitoring program	Clozapine brands are not interchangeable
clozapine 50 mg/mL oral liquid	Yes	For use by prescribers who are registered with a clozapine monitoring program	Clozapine brands are not interchangeable
coal tar solution 4.25% + salicylic acid 2% shampoo	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
codeine phosphate hemihydrate 30 mg tablet	Yes	For use in acute pain OR refractory gastrointestinal motility disorders	Not for use in children <12 years NOR in children aged 12-18 years post adenotonsillectomy for obstructive sleep apnoea NOR in patients known to be ultra rapid/low metabolisers of codeine NOR in lactation.
codeine phosphate hemihydrate 30 mg tablet	Yes	For use in acute pain OR refractory gastrointestinal motility disorders	Not for use in children <12 years NOR in children aged 12-18 years post adenotonsillectomy for obstructive sleep apnoea NOR in patients known to be ultra rapid/low metabolisers of codeine NOR in lactation.
codeine phosphate hemihydrate 5 mg/mL oral liquid	Yes	For use in refractory gastrointestinal motility disorders ONLY, where tablets are inappropriate	Not for use in children <12 years NOR in children aged 12-18 years post adenotonsillectomy for obstructive sleep apnoea NOR in patients known to be ultra rapid/low metabolisers of codeine NOR in lactation.
colchicine 500 microgram tablet	No	N/A	
colecalciferol 1.25 mg (50 000 units) capsule	Yes	For loading in vitamin D deficient patients prior to initiation of treatment for osteoporosis OR paediatric patients where daily supplemental therapy has failed or is inappropriate	
colecalciferol 25 microgram (1000 units) capsule	No	N/A	
colecalciferol 25 microgram (1000 units) tablet	No	N/A	
colecalciferol 25 microgram (1000 units)/0.2 mL oral liquid	No	N/A	
colecalciferol 25 microgram (1000 units)/0.5 mL oral liquid	No	N/A	
colecalciferol 5 microgram (200 units)/mL + thiamine 100 microgram/mL + riboflavin 150 microgram/mL + nicotinamide 1 mg/mL + pyridoxine 100 microgram/mL + cyanocobalamin 0.417 microgram/mL + levomefolic acid 80 microgram/mL + ascorbic acid 7.5 mg/mL + calcium 860 microgram/mL + betacarotene 3 mg/mL + d-alpha-tocopheryl acetate 4.04 mg (5.494 units)/mL + choline 37.5 mg/mL + biotin 1.5 microgram/mL oral liquid	No	N/A	
colestyramine 4 g powder for oral liquid, sachet	No	N/A	
colistimethate sodium 1 million units powder for inhalation, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
colistin 150 mg (4.5 million units) injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
cortisone acetate 25 mg tablet	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
cortisone acetate 5 mg tablet	No	N/A	
COVID-19 (NVX-CoV2373) vaccine injection, 5 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
COVID-19 ChAdOx1-S viral vector vaccine, 4 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
COVID-19 ChAdOx1-S viral vector vaccine, 5 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
creatine monohydrate 1 g/g powder for oral liquid	Yes	On the advice of a paediatric metabolic service	
crotamiton 10% cream	Yes	For use in paediatrics AND where permethrin 5% cream is not suitable/inappropriate	
cyanocobalamin 100 microgram tablet	No	N/A	
cyclizine hydrochloride 50 mg tablet	No	N/A	
cyclizine lactate 50 mg/mL injection, ampoule	No	N/A	
cyclopentolate hydrochloride 0.2% + phenylephrine hydrochloride 1% eye drops	Yes	For use in neonatal and paediatric patients	For practical and safety purposes this medicine should be prescribed by brand name. Special Access Scheme form must be submitted and informed consent for use obtained
cyclopentolate hydrochloride 0.5% eye drops, unit dose	No	N/A	
cyclopentolate hydrochloride 1% eye drops, unit dose	No	N/A	
cyclophosphamide 1 g injection, vial	Yes	For use in cancer services OR as an immunosuppressant under the care of the relevant service AND in accordance with an eviQ or approved protocol	
cyclophosphamide 2 g injection, vial	Yes	For use in cancer services OR as an immunosuppressant under the care of the relevant service AND in accordance with an eviQ or approved protocol	
cyclophosphamide 50 mg tablet	Yes	For use in cancer services OR as an immunosuppressant under the care of the relevant service AND in accordance with an eviQ or approved protocol	
cyclophosphamide 500 mg injection, vial	Yes	For use in cancer services OR as an immunosuppressant under the care of the relevant service AND in accordance with an eviQ or approved protocol	
cycloserine 250 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
cyproheptadine hydrochloride sesquihydrate 4 mg tablet	Yes	For management of serotonin toxicity, cyclic vomiting syndrome or abdominal migraine	
cyproheptadine hydrochloride sesquihydrate 4 mg tablet	Yes	For management of serotonin toxicity, cyclic vomiting syndrome or abdominal migraine	
cyproheptadine hydrochloride sesquihydrate 4 mg tablet	Yes	For management of serotonin toxicity, cyclic vomiting syndrome or abdominal migraine	
cyproterone acetate 100 mg tablet	No	N/A	
cyproterone acetate 2 mg + ethinylestradiol 35 microgram tablet	No	N/A	
cyproterone acetate 50 mg tablet	No	N/A	
cytarabine 1 g/10 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
cytarabine 100 mg/5 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
cytarabine 2 g/20 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
dabigatran etexilate 110 mg capsule	Yes	For use where apixaban and rivaroxaban not suitable AND use as per PBS criteria	
dabigatran etexilate 150 mg capsule	Yes	For use where apixaban and rivaroxaban not suitable AND use as per PBS criteria	
dabigatran etexilate 75 mg capsule	Yes	For use where apixaban and rivaroxaban not suitable AND use as per PBS criteria	
dacarbazine 200 mg injection, vial	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
dactinomycin (actinomycin D) 500 microgram injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
d-alpha-tocopherol 104.7 mg (156 units)/mL oral liquid	Yes	For use where solid oral dose form not suitable	
d-alpha-tocopherol 167.5 mg (250 units) capsule	No	N/A	
d-alpha-tocopherol 335 mg (500 units) capsule	No	N/A	
d-alpha-tocopheryl acetate 115 mg (156 units)/mL oral liquid	Yes	For use in paediatric patients only	
danaparoid sodium 750 anti-Xa units/0.6 mL injection, ampoule	Yes	For patients with heparin-induced-thrombocytopaenia or a history of heparin-induced-thrombocytopaenia, on the advice of a haematology service (or in a rural/remote setting, an appropriate specialist)	
dantrolene sodium hemiheptahydrate 20 mg injection, vial	No	N/A	
dantrolene sodium hemiheptahydrate 25 mg capsule	No	N/A	
dapagliflozin 10 mg tablet	Yes	For use as per PBS criteria	
dapsone 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
dapsone 25 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
daptomycin 350 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
daptomycin 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
daratumumab 100 mg/5 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
daratumumab 400 mg/20 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
darbepoetin alfa 10 microgram/0.4 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services OR off label use in accordance with a DTC approved protocol	
darbepoetin alfa 100 microgram/0.5 mL injection, pen device	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services	
darbepoetin alfa 100 microgram/0.5 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services OR off label use in accordance with a DTC approved protocol	
darbepoetin alfa 150 microgram/0.3 mL injection, pen device	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services	
darbepoetin alfa 150 microgram/0.3 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services OR off label use in accordance with a DTC approved protocol	
darbepoetin alfa 20 microgram/0.5 mL injection, pen device	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services	
darbepoetin alfa 20 microgram/0.5 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services OR off label use in accordance with a DTC approved protocol	
darbepoetin alfa 30 microgram/0.3 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services OR off label use in accordance with a DTC approved protocol	
darbepoetin alfa 40 microgram/0.4 mL injection, pen device	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services	
darbepoetin alfa 40 microgram/0.4 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services OR off label use in accordance with a DTC approved protocol	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
darbepoetin alfa 50 microgram/0.5 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services OR off label use in accordance with a DTC approved protocol	
darbepoetin alfa 60 microgram/0.3 mL injection, pen device	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services	
darbepoetin alfa 60 microgram/0.3 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services OR off label use in accordance with a DTC approved protocol	
darbepoetin alfa 80 microgram/0.4 mL injection, pen device	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services	
darbepoetin alfa 80 microgram/0.4 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria OR for use by neonatology services OR off label use in accordance with a DTC approved protocol	
darunavir 600 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
darunavir 800 mg + cobicistat 150 mg + emtricitabine 200 mg + tenofovir alafenamide 10 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	For practical and safety purposes this medicine should be prescribed by brand name.
darunavir 800 mg + cobicistat 150 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
darunavir 800 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
dasatinib 100 mg tablet	Yes	For initial treatment of Philadelphia +ve ALL and CML	
dasatinib 20 mg tablet	Yes	For initial treatment of Philadelphia +ve ALL and CML	
dasatinib 50 mg tablet	Yes	For initial treatment of Philadelphia +ve ALL and CML	
dasatinib 70 mg tablet	Yes	For initial treatment of Philadelphia +ve ALL and CML	
daunorubicin 20 mg/10 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
deferasirox 180 mg tablet	Yes	For use as per PBS S100 HSD criteria	
deferasirox 360 mg tablet	Yes	For use as per PBS S100 HSD criteria	
deferasirox 90 mg tablet	Yes	For use as per PBS S100 HSD criteria	
deferiprone 1 g tablet	Yes	For use as per PBS S100 HSD criteria	
deferiprone 100 mg/mL oral liquid	Yes	For use as per PBS S100 HSD criteria	
deferiprone 500 mg tablet	Yes	For use as per PBS S100 HSD criteria	
defibrotide 200 mg/2.5 mL injection, vial	Yes	For the prophylaxis of hepatic sinusoidal obstruction syndrome (SOS) in high-risk blood and marrow transplant patients OR for the treatment of severe hepatic SOS following blood and marrow transplantation or gemtuzumab treatment	
degarelix 120 mg injection, vial	Yes	For use as per PBS criteria where goserelin not appropriate for patients with significant cancer symptoms (fever, pain, disseminated intravascular coagulation), visceral crisis, imminent spinal cord compression or risk of urinary retention	
denosumab 120 mg/1.7 mL injection, vial	Yes	For use in hypercalcaemia of malignancy for patients refractory to IV bisphosphonates or where IV bisphosphonates are contraindicated	
denosumab 60 mg/mL injection, syringe	Yes	For the management of osteoporosis where bisphosphonates are contraindicated AND as per PBS criteria	The effect of denosumab is not durable and is rapidly reversible after cessation. Communication with primary care regarding ongoing doses is essential. Denosumab is associated with hypocalcaemia (especially in patients with renal impairment) and osteonecrosis of the jaw.
desferrioxamine mesilate 2 g injection, vial	Yes	For chronic iron overload on the advice of a haematology service (or in a rural/remote setting, an appropriate specialist) OR on the advice of a clinical toxicology service for iron poisoning OR for use as per PBS S100 HSD criteria	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126
desferrioxamine mesilate 500 mg injection, vial	Yes	For chronic iron overload on the advice of a haematology service (or in a rural/remote setting, an appropriate specialist) OR on the advice of a clinical toxicology service for iron poisoning OR for use as per PBS S100 HSD criteria	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126

Medicine name, strength, and form	Restricted?	Restriction	Additional information
desflurane 1 mL/mL inhalation solution	Yes	For use by anaesthetic services only	Desflurane will be removed from the Formulary on 1 March 2024 in line with NSW Health's environmental sustainability strategy
desloratadine 500 microgram/mL oral liquid	No	N/A	
desmopressin acetate 10 microgram/actuation nasal spray, actuation	Yes	On the advice of an endocrine, haematology or renal service (or in a rural/remote setting, an appropriate specialist) OR for use in theatres	
desmopressin acetate 15 microgram/mL injection, ampoule	Yes	On the advice of an endocrine, haematology or renal service (or in a rural/remote setting, an appropriate specialist) OR for use in theatres	
desmopressin acetate 200 microgram tablet	Yes	On the advice of an endocrine, haematology or renal service (or in a rural/remote setting, an appropriate specialist) OR for use in theatres	
desmopressin acetate 4 microgram/mL injection, ampoule	Yes	On the advice of an endocrine, haematology or renal service (or in a rural/remote setting, an appropriate specialist) OR for use in theatres	
desvenlafaxine 100 mg modified release tablet	No	N/A	
desvenlafaxine 50 mg modified release tablet	No	N/A	
dexamethasone 0.1% eye drops	Yes	On the advice of an ophthalmology service or for use with high dose cytarabine in accordance with an eviQ or approved protocol	
dexamethasone 4 mg tablet	No	N/A	
dexamethasone 500 microgram tablet	No	N/A	
dexamethasone 700 microgram implant	Yes	For use by ophthalmology services AND as per PBS criteria	
dexamethasone phosphate 4 mg/mL injection, vial	No		Due to a disruption to the supply of the Australian registered product, an alternative dexamethasone 4 mg/mL product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 30 April 2024, if required. Further information is available in the CEC Medication Safety Updates.
dexamethasone phosphate 8 mg/2 mL injection, vial	No	N/A	
dexamfetamine sulfate 5 mg tablet	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
dexchlorpheniramine maleate 2 mg tablet	Yes	For use where promethazine not suitable OR for use in pregnancy	
dexchlorpheniramine maleate 2 mg/5 mL oral liquid	Yes	For use where promethazine not suitable OR for use in pregnancy	
dexmedetomidine 200 microgram/2 mL injection, vial	Yes	For use by anaesthetic or intensive care services only	
dexmedetomidine 200 microgram/50 mL injection, bottle	Yes	For use by anaesthetic or intensive care services only	
dextran-70 0.1% + hypromellose 0.3% eye drops	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
dextran-70 0.1% + hypromellose 0.3% eye drops, unit dose	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
diazepam 10 mg/10 mL oral liquid	Yes	For use where solid oral dose form not suitable	
diazepam 10 mg/2 mL injection, ampoule	No	N/A	
diazepam 2 mg tablet	No	N/A	
diazepam 5 mg tablet	No	N/A	
diazoxide 100 mg capsule	Yes	For treatment of hyperinsulinaemic hypoglycaemia	Special Access Scheme form must be submitted and informed consent for use obtained
diazoxide 25 mg capsule	Yes	For treatment of hyperinsulinaemic hypoglycaemia	Special Access Scheme form must be submitted and informed consent for use obtained
diazoxide 300 mg/20 mL injection, ampoule	Yes	For use in critical care areas only	
diclofenac diethylamine 1.16% gel	No	N/A	
diclofenac sodium 0.1% eye drops	Yes	On the advice of an ophthalmology service for therapy beyond 6 weeks	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
diclofenac sodium 1% gel	No	N/A	
diclofenac sodium 100 mg suppository	Yes	For use where solid oral dose form not suitable/inappropriate	
diclofenac sodium 25 mg enteric tablet	No	N/A	
diclofenac sodium 50 mg enteric tablet	No	N/A	
diclofenac sodium 50 mg suppository	Yes	For use where solid oral dose form not suitable/inappropriate	
dicloxacillin 500 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
dicobalt edetate 300 mg/20 mL injection, ampoule	Yes	On the advice of a clinical toxicology service for treatment of cyanide poisoning	Special Access Scheme form must be submitted and informed consent for use obtained. Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
digoxin 250 microgram tablet	No	N/A	
digoxin 50 microgram/2 mL injection, ampoule	No	N/A	Only one strength should be stocked per clinical area where practicable.
digoxin 50 microgram/mL oral liquid	No	N/A	
digoxin 500 microgram/2 mL injection, ampoule	No	N/A	Only one strength should be stocked per clinical area where practicable.
digoxin 62.5 microgram tablet	No	N/A	
digoxin-specific antibody fragment F(Ab) 40 mg injection, vial	Yes	On the advice of a clinical toxicology, clinical pharmacology or cardiology service for treatment of cardiac glycoside toxicity	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
diltiazem hydrochloride 180 mg modified release capsule	No	N/A	
diltiazem hydrochloride 240 mg modified release capsule	No	N/A	
diltiazem hydrochloride 60 mg tablet	No	N/A	
dimercaprol 100 mg/2 mL injection, ampoule	Yes	On the advice of a clinical toxicology service for treatment of arsenic poisoning	Special Access Scheme form must be submitted and informed consent for use obtained. Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
dimercaprol 200 mg/2 mL injection, ampoule	Yes	On the advice of a clinical toxicology service for treatment of arsenic poisoning	Special Access Scheme form must be submitted and informed consent for use obtained. Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
dimercaptopropanesulfonate (2,3) sodium 250 mg/5 mL injection, ampoule	Yes	On the advice of a clinical toxicology service for treatment of heavy metal poisoning	Special Access Scheme form must be submitted and informed consent for use obtained. Contact NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
dinoprostone 1 mg/3 g vaginal gel, syringe	No	N/A	Authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008 required

Medicine name, strength, and form	Restricted?	Restriction	Additional information
dinoprostone 10 mg pessary	No	N/A	Authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008 required
dinoprostone 2 mg/3 g vaginal gel, syringe	No	N/A	Authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008 required
dinutuximab beta 20 mg/4.5 mL injection, vial	Yes	For use in maintenance therapy for HR neuroblastoma	
diphenoxylate hydrochloride 2.5 mg + atropine sulfate monohydrate 25 microgram tablet	Yes	For use in adults only	
diphtheria + tetanus + pertussis 3 component + hepatitis B + polio trivalent vaccine injection, 0.5 mL syringe (&) haemophilus influenzae type b conjugate (PRP-T) vaccine injection, vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
diphtheria + tetanus + pertussis 3 component adolescent/adult vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases. For practical and safety purposes this medicine should be prescribed by brand name.
diphtheria + tetanus + pertussis 3 component child vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
diphtheria + tetanus + pertussis 5 component + hepatitis B + polio trivalent + Haemophilus influenzae type b conjugate (PRP-OMP) vaccine, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
diphtheria + tetanus + pertussis 5 component + hepatitis B + polio trivalent + Haemophilus influenzae type b conjugate (PRP-OMP) vaccine, 0.5 mL vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
diphtheria + tetanus + pertussis 5 component adolescent/adult vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases. For practical and safety purposes this medicine should be prescribed by brand name.
diphtheria + tetanus + pertussis 5 component child vaccine injection, 0.5 mL vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
diphtheria 2 units + tetanus 20 units vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
dipyridamole 10 mg/2 mL injection, ampoule	Yes	For use by nuclear medicine services	Due to a disruption to the supply of the Australian registered product, an alternative dipyridamole 10 mg/2 mL injection product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 30 April 2024. Please refer to the TGA S19a approvals database for further details
disulfiram 200 mg effervescent tablet	Yes	On the advice of a drug and alcohol service	This medicine is not PBS listed, please discuss ongoing costs with the patient.
dobutamine 250 mg/20 mL injection, ampoule	Yes	For use in ICU, CCU, ED, NICU and Theatres OR other settings where cardiac monitoring can be performed	
dobutamine 250 mg/20 mL injection, vial	Yes	For use in ICU, CCU, ED, NICU and Theatres OR other settings where cardiac monitoring can be performed	
docetaxel 160 mg/16 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
docetaxel 160 mg/8 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
docetaxel 80 mg/4 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
docetaxel 80 mg/8 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
docusate sodium 0.5% ear drops	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
docusate sodium 120 mg tablet	No	N/A	
docusate sodium 50 mg + sennoside B 8 mg tablet	No	N/A	
docusate sodium 50 mg tablet	No	N/A	
dolutegravir 50 mg + abacavir 600 mg + lamivudine 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
dolutegravir 50 mg + lamivudine 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
dolutegravir 50 mg + rilpivirine 25 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
dolutegravir 50 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
domperidone 10 mg tablet	No	N/A	
donepezil hydrochloride 10 mg tablet	Yes	For use as per PBS criteria	
donepezil hydrochloride 5 mg tablet	Yes	For use as per PBS criteria	
dopamine hydrochloride 200 mg/5 mL injection, ampoule	Yes	For use in ICU, CCU, ED, NICU and Theatres OR other settings where cardiac monitoring can be performed	
dornase alfa 2.5 mg/2.5 mL inhalation solution, ampoule	Yes	For use in cystic fibrosis patients as per PBS criteria OR for use by respiratory/thoracic services in adult patients for intra-pleural fibrinolysis (in combination with alteplase) in accordance with a DTC approved protocol	
dorzolamide 2% + timolol 0.5% eye drops	Yes	For use on the advice of an ophthalmology service where rapid reduction of intraocular pressure in trauma or secondary glaucoma is required	This combination agent is recommended to be stocked in all acute hospital settings. For practical and safety purposes this medicine should be prescribed by brand name.
dorzolamide 2% + timolol 0.5% eye drops, ampoule	Yes	For use on the advice of an ophthalmology service where rapid reduction of intraocular pressure in trauma or secondary glaucoma is required	This combination agent is recommended to be stocked in all acute hospital settings. For practical and safety purposes this medicine should be prescribed by brand name.
dosulepin (dothiepin) hydrochloride 25 mg capsule	Yes	For treatment of fibromyalgia	
dosulepin (dothiepin) hydrochloride 75 mg tablet	Yes	For treatment of fibromyalgia	
doxorubicin hydrochloride (as pegylated liposomal) 20 mg/10 mL injection, vial	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
doxorubicin hydrochloride (as pegylated liposomal) 50 mg/25 mL injection, vial	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
doxorubicin hydrochloride 200 mg/100 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
doxorubicin hydrochloride 50 mg/25 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
doxycycline 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
doxylamine succinate 25 mg tablet	Yes	For use in pregnancy for treatment of nausea, vomiting and hyperemesis OR for management of insomnia in pregnancy that has not responded to non-pharmacological therapies	
droperidol 10 mg/2 mL injection, vial	No	N/A	Only one strength should be stocked per clinical area where practicable.
droperidol 2.5 mg/mL injection, ampoule	No	N/A	Only one strength should be stocked per clinical area where practicable.
droperidol 2.5 mg/mL injection, ampoule	No	N/A	Only one strength should be stocked per clinical area where practicable.

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
dry psyllium husk 3.5 g powder for oral liquid, sachet	No	N/A	
dulaglutide 1.5 mg/0.5 mL injection, pen device	Yes	For use as per PBS criteria	
duloxetine 30 mg enteric capsule	No	N/A	
duloxetine 60 mg enteric capsule	No	N/A	
dupilumab 200 mg/1.14 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
dupilumab 200 mg/1.14 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
dupilumab 300 mg/2 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
dupilumab 300 mg/2 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
durvalumab 120 mg/2.4 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
durvalumab 500 mg/10 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
dutasteride 500 microgram capsule	Yes	For management of lower urinary tract symptoms in benign prostatic hyperplasia	
eculizumab 300 mg/30 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
edetate calcium disodium 1 g/5 mL injection, ampoule	Yes	On the advice of a clinical toxicology service for treatment of heavy metal poisoning	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
elasomeran 200 microgram/mL injection, 5 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
elasomeran 25 microgram/0.5 mL + davesomeran 25 microgram/0.5 mL injection, syringe	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
elasomeran 25 microgram/0.5 mL + imelasomeran 25 microgram/0.5 mL injection, 2.5 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
elasomeran 25 microgram/0.5 mL + imelasomeran 25 microgram/0.5 mL injection, 5 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg tablet (&) ivacaftor 150 mg tablet	Yes	For use as per PBS S100 HSD criteria	For practical and safety purposes this medicine should be prescribed by brand name.
elexacaftor 50 mg + tezacaftor 25 mg + ivacaftor 37.5 mg tablet (&) ivacaftor 75 mg tablet	Yes	For use as per PBS S100 HSD criteria	For practical and safety purposes this medicine should be prescribed by brand name.
eltrombopag 25 mg tablet	Yes	For use as per PBS S100 HSD criteria	
eltrombopag 50 mg tablet	Yes	For use as per PBS S100 HSD criteria	
empagliflozin 10 mg tablet	Yes	For use as per PBS criteria	
empagliflozin 25 mg tablet	Yes	For use as per PBS criteria	
emtricitabine 200 mg + rilpivirine 25 mg + tenofovir alafenamide 25 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
emtricitabine 200 mg + tenofovir alafenamide 10 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
emtricitabine 200 mg + tenofovir alafenamide 25 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
enalapril maleate 10 mg tablet	No	N/A	
enalapril maleate 20 mg + hydrochlorothiazide 6 mg tablet	No	N/A	
enalapril maleate 20 mg tablet	No	N/A	
enalapril maleate 5 mg tablet	No	N/A	
enoxaparin sodium 100 mg/mL injection, syringe	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
enoxaparin sodium 120 mg/0.8 mL injection, syringe	No	N/A	
enoxaparin sodium 150 mg/mL injection, syringe	No	N/A	
enoxaparin sodium 20 mg/0.2 mL injection, syringe	No	N/A	
enoxaparin sodium 40 mg/0.4 mL injection, syringe	No	N/A	
enoxaparin sodium 60 mg/0.6 mL injection, syringe	No	N/A	
enoxaparin sodium 80 mg/0.8 mL injection, syringe	No	N/A	
entacapone 200 mg tablet	Yes	For use as an adjunct to levodopa for treatment of Parkinson's disease	
entecavir 1 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
entecavir 500 microgram tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
ephedrine sulfate 30 mg/mL injection, ampoule	No	N/A	
epirubicin hydrochloride 100 mg/50 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
epirubicin hydrochloride 200 mg/100 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
epirubicin hydrochloride 50 mg/25 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
eplerenone 25 mg tablet	Yes	For use as per PBS criteria OR for use in primary aldosteronism where spironolactone is not tolerated	
eplerenone 50 mg tablet	Yes	For use as per PBS criteria OR for use in primary aldosteronism where spironolactone is not tolerated	
epoetin alfa 40 000 units/mL injection, syringe	Yes	On the advice of a haematology service for the management of severe anaemia or optimisation of haemoglobin in patients that refuse blood products	
epoprostenol 1.5 mg injection, vial	Yes	For use as per PBS S100 HSD criteria OR nebulised use in ventilated patients on the advice of an Intensive Care Physician OR off label use in accordance with a DTC approved protocol	
epoprostenol 500 microgram injection, vial	Yes	For use as per PBS S100 HSD criteria OR nebulised use in ventilated patients on the advice of an Intensive Care Physician OR off label use in accordance with a DTC approved protocol	
eptacog alfa (activated) 1 mg injection, vial	Yes	For the management of a life threatening bleed under the direction of a Haematologist, Intensivist or Anaesthetist	
eptacog alfa (activated) 2 mg injection, vial	Yes	For the management of a life threatening bleed under the direction of a Haematologist, Intensivist or Anaesthetist	
eptacog alfa (activated) 5 mg injection, vial	Yes	For the management of a life threatening bleed under the direction of a Haematologist, Intensivist or Anaesthetist	
ergometrine maleate 500 microgram/mL injection, ampoule	No	N/A	
eribulin mesilate 1 mg/2 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
ertapenem 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
erythromycin (as ethylsuccinate) 400 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
erythromycin 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
erythromycin 250 mg enteric capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
escitalopram 10 mg tablet	No	N/A	
escitalopram 20 mg tablet	No	N/A	
escitalopram 20 mg/mL oral liquid	No	N/A	
esmolol hydrochloride 100 mg/10 mL injection, vial	Yes	For use by cardiology, emergency or intensive care and anaesthetics services only	
esmolol hydrochloride 2.5 g injection, vial	Yes	For use by cardiology, emergency or intensive care and anaesthetics services only	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
esomeprazole 10 mg enteric coated granules, sachet	Yes	For use with size 6-8 French enteral feeding tubes only	
estradiol 1 mg tablet	No	N/A	
estradiol 10 microgram modified release pessary	No	N/A	
estradiol 100 microgram/24 hours patch	No	N/A	
estradiol 2 mg + norethisterone acetate 1 mg tablet	No	N/A	
estradiol 2 mg tablet	No	N/A	
estradiol 25 microgram/24 hours patch	No	N/A	
estradiol 37.5 microgram/24 hours patch	No	N/A	
estradiol 50 microgram/24 hours + norethisterone acetate 140 microgram/24 hours patch	No	N/A	
estradiol 50 microgram/24 hours + norethisterone acetate 250 microgram/24 hours patch	No	N/A	
estradiol 50 microgram/24 hours patch	No	N/A	
estradiol 75 microgram/24 hours patch	No	N/A	
estradiol valerate 1 mg tablet	No	N/A	
estradiol valerate 2 mg tablet	No	N/A	
estriol 0.1% (1 mg/g) cream	No	N/A	
etanercept 25 mg injection, vial	Yes	For use as per PBS S100 HSD criteria	
ethambutol hydrochloride 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
ethambutol hydrochloride 400 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
ethanol 96% (0.96 mL/mL) injection, 10 mL ampoule	Yes	For treatment of toxic alcohol poisoning on the advice of a clinical toxicology service (or in a rural/remote setting, an appropriate specialist)	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126. Special Access Scheme form must be submitted and informed consent for use obtained
ethionamide 250 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
ethosuximide 250 mg capsule	Yes	On the advice of neurology services only	
ethosuximide 250 mg/5 mL oral liquid	Yes	On the advice of neurology services only	
etonogestrel 68 mg implant	Yes	For treatment of menorrhagia or endometrial hyperplasia OR for use in patients with psychosocial vulnerability OR patients who are unable to source through community	
etoposide 100 mg capsule	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
etoposide 100 mg/5 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
etoposide 50 mg capsule	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
etoposide phosphate 1.136 g (etoposide 1 g) injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
etravirine 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
everolimus 1 mg tablet	Yes	On the advice of a transplant service	
everolimus 10 mg tablet	Yes	For use as per PBS criteria	
everolimus 2.5 mg tablet	Yes	For use as per PBS criteria	
everolimus 250 microgram tablet	Yes	On the advice of a transplant service	
everolimus 5 mg tablet	Yes	For use as per PBS criteria	
everolimus 500 microgram tablet	Yes	On the advice of a transplant service	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
everolimus 750 microgram tablet	Yes	On the advice of a transplant service	
exemestane 25 mg tablet	No	N/A	
ezetimibe 10 mg tablet	No	N/A	
famciclovir 250 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
famciclovir 500 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
famotidine 20 mg tablet	No	N/A	
febuxostat 80 mg tablet	Yes	For use where allopurinol not suitable	
felodipine 10 mg modified release tablet	No	N/A	
felodipine 2.5 mg modified release tablet	No	N/A	
felodipine 5 mg modified release tablet	No	N/A	
fenofibrate 145 mg tablet	No	N/A	
fenofibrate 48 mg tablet	No	N/A	
fentanyl 100 microgram sublingual tablet	Yes	For use by palliative care services only. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	Oral fentanyl products are not interchangeable.
fentanyl 100 microgram/2 mL injection, ampoule	No	N/A	
fentanyl 100 microgram/hour patch	Yes	Not for use in opioid naive patients. Prescribers are approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045).	
fentanyl 12 microgram/hour patch	Yes	Not for use in opioid naive patients. Prescribers are approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045).	
fentanyl 200 microgram sublingual tablet	Yes	For use by palliative care services only. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	Oral fentanyl products are not interchangeable.
fentanyl 25 microgram/hour patch	Yes	Not for use in opioid naive patients. Prescribers are approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045).	
fentanyl 300 microgram sublingual tablet	Yes	For use by palliative care services only. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	Oral fentanyl products are not interchangeable.
fentanyl 400 microgram sublingual tablet	Yes	For use by palliative care services only. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	Oral fentanyl products are not interchangeable.
fentanyl 50 microgram/hour patch	Yes	Not for use in opioid naive patients. Prescribers are approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045).	
fentanyl 500 microgram/10 mL injection, ampoule	No	N/A	
fentanyl 600 microgram sublingual tablet	Yes	For use by palliative care services only. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	Oral fentanyl products are not interchangeable.
fentanyl 75 microgram/hour patch	Yes	Not for use in opioid naive patients. Prescribers are approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045).	
fentanyl 800 microgram sublingual tablet	Yes	For use by palliative care services only. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	Oral fentanyl products are not interchangeable.

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
ferric subsulfate (iron 21%) gel, 15 mL bottle	No	N/A	
ferrous fumarate 310 mg (iron 100 mg) + folic acid 350 microgram tablet	No	N/A	
ferrous sulfate 325 mg (iron 105 mg) modified release tablet	No	N/A	
ferrous sulfate heptahydrate 30 mg/mL (iron 6 mg/mL) oral liquid	No	N/A	
fidaxomicin 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
filgrastim 120 microgram/0.2 mL injection, syringe	Yes	On the advice of a cancer OR haematology service	
filgrastim 300 microgram/0.5 mL injection, syringe	Yes	On the advice of a cancer OR haematology service	
filgrastim 300 microgram/mL injection, vial	Yes	On the advice of a cancer OR haematology service	The Therapeutic Goods Administration announced the deletion of filgrastim (Neupogen) 300 microg/mL injection vial from 1 March 2024. There will be a decrease in the supply of this product until the remaining stock is exhausted. Further information is available in the CEC Medication Safety Updates.
filgrastim 480 microgram/0.5 mL injection, syringe	Yes	On the advice of a cancer OR haematology service	
filgrastim 480 microgram/1.6 mL injection, vial	Yes	On the advice of a cancer OR haematology service	The Therapeutic Goods Administration announced the deletion of filgrastim (Neupogen) 480 microg/1.6 mL injection vial from 1 October 2023. There will be a decrease in the supply of this product until the remaining stock is exhausted. Further information is available in the CEC Medication Safety Updates.
fish oil 1 g capsule	No	N/A	
flecainide acetate 100 mg tablet	No	N/A	
flecainide acetate 150 mg/15 mL injection, ampoule	Yes	For use on the advice of cardiology service (or in a rural/remote setting, an appropriate specialist) AND in settings where cardiac monitoring can be performed	
flecainide acetate 50 mg tablet	No	N/A	
flucloxacillin 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
flucloxacillin 250 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
flucloxacillin 250 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
flucloxacillin 500 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
flucloxacillin 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
fluconazole 100 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
fluconazole 100 mg/50 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
fluconazole 200 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
fluconazole 200 mg/100 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
fluconazole 50 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
fluconazole 50 mg/5 mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
fludarabine phosphate 10 mg tablet	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
fludarabine phosphate 50 mg injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	Due to a disruption to the supply of the Australian registered product, alternative fludarabine products have been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 30 April 2024
fludrocortisone acetate 100 microgram tablet	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
flumazenil 500 microgram/5 mL injection, ampoule	Yes	For reversal of benzodiazepine sedation in anaesthesia OR on the advice of a clinical toxicology service for use in benzodiazepine overdose	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
flumetasone pivalate 0.02% + clioquinol 1% ear drops	Yes	Use in accordance with the local antimicrobial stewardship policy	
fluorescein sodium 1 mg diagnostic strip	No	N/A	
fluorescein sodium 1% eye drops, unit dose	No	N/A	
fluorescein sodium 2% eye drops, unit dose	No	N/A	
fluorescein sodium 500 mg/5 mL injection, vial	Yes	For use in diagnostic angiography of the eye	
fluorometholone 0.1% eye drops	Yes	On the advice of an ophthalmology service or for use with high dose cytarabine as per eviQ protocol	
fluorometholone acetate 0.1% eye drops	Yes	On the advice of an ophthalmology service or for use with high dose cytarabine as per eviQ protocol	
fluorouracil 1 g/20 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
fluorouracil 2.5 g/50 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
fluorouracil 5 g/100 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
fluorouracil 5% cream	No	N/A	
fluorouracil 500 mg/10 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
fluoxetine 20 mg capsule	No	N/A	
fluoxetine 20 mg tablet	No	N/A	
flupentixol decanoate 100 mg/mL injection, ampoule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
flupentixol decanoate 20 mg/mL injection, ampoule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
flupentixol decanoate 40 mg/2 mL injection, ampoule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
fluticasone furoate 100 microgram/actuation + umeclidinium 62.5 microgram/actuation + vilanterol 25 microgram/actuation powder for inhalation, actuation	Yes	For use as per PBS criteria	
fluticasone furoate 100 microgram/actuation + vilanterol 25 microgram/actuation powder for inhalation, actuation	Yes	For use as per PBS criteria	
fluticasone propionate 125 microgram/actuation + salmeterol 25 microgram/actuation inhalation, actuation	Yes	For use in paediatric patients as per PBS criteria	
fluticasone propionate 125 microgram/actuation inhalation, actuation	No	N/A	
fluticasone propionate 50 microgram/actuation + salmeterol 25 microgram/actuation inhalation, actuation	Yes	For use in paediatric patients as per PBS criteria	
fluticasone propionate 50 microgram/actuation inhalation, actuation	Yes	For use as per PBS criteria	
fluvoxamine maleate 100 mg tablet	No	N/A	
fluvoxamine maleate 50 mg tablet	No	N/A	
folic acid 15 mg/mL injection, ampoule	No	N/A	
folic acid 15 mg/mL injection, vial	No	N/A	
folic acid 5 mg tablet	No	N/A	
folic acid 500 microgram + iodine 150 microgram tablet	Yes	For use in pregnant and breastfeeding women	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
folic acid 500 microgram tablet	No	N/A	
folinic acid 15 mg tablet	Yes	For use in megaloblastic anaemias resulting from the use of folic acid antagonists OR for use in accordance with approved rescue protocols OR for use in neonates OR for use by metabolic services	
folinic acid 15 mg tablet	Yes	For use in megaloblastic anaemias resulting from the use of folic acid antagonists OR for use in accordance with approved rescue protocols OR for use in neonates OR for use by metabolic services	
folinic acid 50 mg/5 mL injection, vial	Yes	For use in megaloblastic anaemias resulting from the use of folic acid antagonists OR for use in accordance with approved rescue protocols	
fomepizole 1.5 g/1.5 mL injection, vial	Yes	On the advice of a clinical toxicology service for treatment of toxic alcohol poisoning	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
fondaparinux sodium 2.5 mg/0.5 mL injection, syringe	Yes	For use as per registered indications OR accepted off-label indications listed in the Australian Medicines Handbook	
formoterol (eformoterol) fumarate dihydrate 12 microgram/actuation powder for inhalation, actuation	No	N/A	
fosamprenavir 700 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
fosaprepitant 150 mg injection, vial	Yes	For use by cancer services only AND in accordance with an approved protocol	
foscarnet sodium 6 g/250 mL injection, bottle	Yes	Use in accordance with the local antimicrobial stewardship policy	
fosfomycin 3 g granules, sachet	Yes	Use in accordance with the local antimicrobial stewardship policy	
framycetin sulfate 0.5% + gramicidin 0.005% + dexamethasone 0.05% ear drops	Yes	Use in accordance with the local antimicrobial stewardship policy	
funnel web spider antivenom 125 units injection, vial	No	N/A	
furosemide (frusemide) 10 mg/mL oral liquid	No	N/A	
furosemide (frusemide) 20 mg tablet	No	N/A	
furosemide (frusemide) 20 mg/2 mL injection, ampoule	No	N/A	
furosemide (frusemide) 250 mg/25 mL injection, ampoule	No	N/A	Off label use is only allowed if it is in accordance with a DTC approved protocol
furosemide (frusemide) 40 mg tablet	No	N/A	
furosemide (frusemide) 40 mg/4 mL injection, ampoule	No	N/A	
furosemide (frusemide) 500 mg tablet	No	N/A	
ganciclovir 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
gemcitabine 1 g/26.3 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
gemcitabine 2 g/52.6 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
gemeprost 1 mg pessary	No	N/A	
gemtuzumab ozogamicin 5 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
gentamicin 80 mg/2 mL injection, ampoule	Yes	Use in accordance with the local antimicrobial stewardship policy	
gentamicin 80 mg/2 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
glecaprevir 100 mg + pibrentasvir 40 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
gliclazide 30 mg modified release tablet	No	N/A	
gliclazide 60 mg modified release tablet	No	N/A	
gliclazide 80 mg tablet	No	N/A	
glipizide 5 mg tablet	No	N/A	
glucagon hydrochloride 1 mg injection, vial	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
glucarpidase 1000 units injection, vial	Yes	On the advice of a cancer service for the management of significantly impaired methotrexate clearance AND in accordance with an approved protocol	Special Access Scheme form must be submitted and informed consent for use obtained
glucose 10% (100 g/L) injection, bag	No	N/A	
glucose 10% (50 g/500 mL) + sodium chloride 0.22% (1.1 g/500 mL) injection, bag	Yes	For use in neonates only	To be stored only in dedicated maternity / neonatal storage unit.
glucose 10% (50 g/500 mL) + sodium chloride 0.45% (2.25 g/500 mL) injection, bag	Yes	On the advice of a critical care service	
glucose 10% (50 g/500 mL) injection, bag	No	N/A	
glucose 15 g/32 mL gel	No	N/A	
glucose 15 g/60 mL oral liquid	No	N/A	
glucose 25% (250 g/L) injection, bag	No	N/A	
glucose 4% (40 g/L) + sodium chloride 0.18% (1.8 g/L) injection, bag	Yes	For use in adults only	
glucose 40% gel	No	N/A	
glucose 5% (12.5 g/250 mL) injection, bag	No	N/A	
glucose 5% (12.5 g/250 mL) injection, bottle	No	N/A	
glucose 5% (2.5 g/50 mL) injection, bag	No	N/A	
glucose 5% (25 g/500 mL) injection, bag	No	N/A	
glucose 5% (25 g/500 mL) injection, bottle	No	N/A	
glucose 5% (5 g/100 mL) injection, bag	No	N/A	
glucose 5% (5 g/100 mL) injection, bottle	No	N/A	
glucose 5% (5 g/100 mL) injection, vial	No	N/A	
glucose 5% (50 g/L) + sodium chloride 0.45% (4.5 g/L) injection, bag	No	N/A	
glucose 5% (50 g/L) + sodium chloride 0.9% (9 g/L) injection, bag	No	N/A	
glucose 5% (50 g/L) injection, bag	No	N/A	
glucose 5% (50 g/L) injection, bottle	No	N/A	
glucose 50% (25 g/50 mL) injection, vial	No	N/A	
glucose 50% (250 g/500 mL) injection, bag	No	N/A	
glucose 50% (50 g/100 mL) injection, bag	No	N/A	
glycerol 1.4 g suppository	No	N/A	
glycerol 2.8 g suppository	No	N/A	
glycerol 700 mg suppository	No	N/A	
glycerol liquid	No	N/A	
glyceryl trinitrate 0.2% ointment	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
glyceryl trinitrate 10 mg/24 hours patch	No	N/A	
glyceryl trinitrate 300 microgram sublingual tablet	No	N/A	
glyceryl trinitrate 400 microgram/actuation spray, actuation	No	N/A	
glyceryl trinitrate 5 mg/24 hours patch	No	N/A	
glyceryl trinitrate 50 mg/10 mL injection, ampoule	No	N/A	
glyceryl trinitrate 50 mg/50 mL injection, vial	No	N/A	
glyceryl trinitrate 600 microgram sublingual tablet	No	N/A	
glycopyrronium 50 microgram powder for inhalation, 1 capsule	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
glycopyrronium bromide (glycopyrrolate) 200 microgram/mL injection, vial	No	N/A	
glycopyrronium bromide (glycopyrrolate) 500 microgram/mL + neostigmine methylsulfate 2.5 mg/mL injection, ampoule	No	N/A	
goserelin 10.8 mg implant	Yes	For use in paediatric patients only	
goserelin 3.6 mg implant	Yes	For paediatric use OR for use by cancer services OR as per PBS criteria	
granisetron 1 mg/mL injection, ampoule	Yes	For use by cancer or palliative care services only (or in a rural/remote setting, an appropriate specialist) OR for treatment of post-operative nausea and vomiting where other agents failed	
granisetron 2 mg tablet	Yes	For use by cancer services where alternative anti-emetics are not appropriate	
granisetron 3 mg/3 mL injection, ampoule	Yes	For use by cancer or palliative care services only (or in a rural/remote setting, an appropriate specialist) OR for treatment of post-operative nausea and vomiting where other agents failed	
griseofulvin 125 mg tablet	Yes	For use when terbinafine is inappropriate in accordance with the local antimicrobial stewardship policy	
griseofulvin 500 mg tablet	Yes	For use when terbinafine is inappropriate in accordance with the local antimicrobial stewardship policy	
guanfacine 1 mg modified release tablet	Yes	On the advice of mental health or paediatric services for paediatric or rehabilitation long stay patients OR for use by Justice Health.	
guanfacine 2 mg modified release tablet	Yes	On the advice of mental health or paediatric services for paediatric or rehabilitation long stay patients OR for use by Justice Health.	
Haemophilus influenzae type b conjugate (PRP-T) vaccine injection, vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
haloperidol (as decanoate) 150 mg/3 mL injection, ampoule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
haloperidol (as decanoate) 50 mg/mL injection, ampoule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
haloperidol 1.5 mg tablet	No	N/A	
haloperidol 2 mg/mL oral liquid, drop	No	N/A	
haloperidol 5 mg tablet	No	N/A	
haloperidol 5 mg/mL injection, ampoule	No	N/A	Use in short-term management of behavioural disturbance must be in accordance with a DTC approved protocol
haloperidol 500 microgram tablet	No	N/A	
heparin sodium 1000 units/500 mL + sodium chloride 0.9% (4.5 g/500 mL) injection, bag	No	N/A	
heparin sodium 1000 units/mL injection, ampoule	Yes	For use in neonates only	
heparin sodium 25 000 units/250 mL + sodium chloride 0.9% (2.25 g/250 mL) injection, bag	No	N/A	
heparin sodium 25 000 units/5 mL injection, ampoule	No	N/A	
heparin sodium 25 000 units/50 mL + sodium chloride 0.9% (450 mg/50 mL) injection, bag	No	N/A	
heparin sodium 25 000 units/50 mL + sodium chloride 0.9% (450 mg/50 mL) injection, syringe	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
heparin sodium 50 units/5 mL injection, ampoule	Yes	For use with Intravascular Access Devices (IVAD) in accordance with NSW Health Policy Directive PD2019_040 where the manufacturer of the device specifically recommends locking with heparinised saline AND in accordance with a DTC approved protocol	
heparin sodium 5000 units/0.2 mL injection, ampoule	No	N/A	
heparin sodium 5000 units/5 mL injection, ampoule	No	N/A	Due to a disruption to the supply of the Australian registered product, an alternative heparin 5000 units/5 mL product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 31 August 2023. Please refer to Safety Notice 009/23 for further information
heparin sodium 5000 units/mL injection, ampoule	No	N/A	
heparinoids 0.3% cream	No	N/A	
hepatitis A + hepatitis B adult vaccine injection, 1 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
hepatitis A adult vaccine 1440 ELISA units/mL injection, syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
hepatitis A adult vaccine 50 units/mL injection, syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
hepatitis A child/adult vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
hepatitis B adult vaccine 10 microgram/mL injection, syringe	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases AND PD2020_006 Responding to Sexual Assault (adult and child) Policy and Procedures. For practical and safety purposes this medicine should be prescribed by brand name.
hepatitis B adult vaccine 10 microgram/mL injection, vial	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases AND PD2020_006 Responding to Sexual Assault (adult and child) Policy and Procedures. For practical and safety purposes this medicine should be prescribed by brand name.
hepatitis B adult vaccine 20 microgram/mL injection, syringe	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases AND PD2020_006 Responding to Sexual Assault (adult and child) Policy and Procedures. For practical and safety purposes this medicine should be prescribed by brand name.
hepatitis B child vaccine 10 microgram/0.5 mL injection, syringe	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2017_036: Neonatal Hepatitis B Prevention and Vaccination Program. For practical and safety purposes this medicine should be prescribed by brand name.
hepatitis B child vaccine 5 microgram/0.5 mL injection, syringe	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2017_036: Neonatal Hepatitis B Prevention and Vaccination Program. For practical and safety purposes this medicine should be prescribed by brand name.

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
hepatitis B child vaccine 5 microgram/0.5 mL injection, vial	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2017_036: Neonatal Hepatitis B Prevention and Vaccination Program. For practical and safety purposes this medicine should be prescribed by brand name.
hepatitis B dialysis vaccine injection, 1 mL vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
high selenium yeast 83.4 mg (selenium 100 microgram) tablet	No	N/A	
human papillomavirus 9 valent vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
hyaluronidase 1500 units injection, ampoule	No	N/A	
hydralazine hydrochloride 20 mg injection, ampoule	No	N/A	
hydralazine hydrochloride 25 mg tablet	No	N/A	
hydralazine hydrochloride 50 mg tablet	No	N/A	
hydrochlorothiazide 25 mg tablet	No	N/A	
hydrocortisone (as sodium succinate) 100 mg injection, chamber	No	N/A	
hydrocortisone (as sodium succinate) 100 mg injection, vial	No	N/A	
hydrocortisone (as sodium succinate) 250 mg injection, chamber	No	N/A	
hydrocortisone 0.5% + cinchocaine hydrochloride 0.5% ointment	Yes	For short-term use up to 7 days	For practical and safety purposes this medicine should be prescribed by brand name.
hydrocortisone 1% + clotrimazole 1% cream	No	N/A	
hydrocortisone 1% + miconazole nitrate 2% cream	No	N/A	
hydrocortisone 1% cream	No	N/A	
hydrocortisone 20 mg tablet	No	N/A	
hydrocortisone 4 mg tablet	No	N/A	
hydrocortisone 5 mg + cinchocaine hydrochloride 5 mg suppository	Yes	For short-term use up to 7 days	For practical and safety purposes this medicine should be prescribed by brand name.
hydrocortisone acetate 1% cream	No	N/A	
hydrocortisone acetate 1% eye ointment	Yes	On the advice of an ophthalmology service	
hydrocortisone acetate 1% ointment	No	N/A	
hydrocortisone acetate 10% enema	No	N/A	
hydromorphone hydrochloride 10 mg/mL injection, ampoule	Yes	On the advice of a pain, palliative care, cancer or renal service. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	This listing refers to the 1 mL ampoule only.
hydromorphone hydrochloride 2 mg tablet	Yes	On the advice of a pain, palliative care, cancer or renal service. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
hydromorphone hydrochloride 2 mg/mL injection, ampoule	Yes	On the advice of a pain, palliative care, cancer or renal service. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
hydromorphone hydrochloride 4 mg tablet	Yes	On the advice of a pain, palliative care, cancer or renal service. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
hydromorphone hydrochloride 8 mg tablet	Yes	On the advice of a pain, palliative care, cancer or renal service. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
hydroxocobalamin 1 mg/mL injection, ampoule	No	N/A	
hydroxocobalamin 5 g injection, vial	Yes	On the advice of a clinical toxicology service for treatment of cyanide poisoning	Special Access Scheme form must be submitted and informed consent for use obtained. Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
hydroxycarbamide (hydroxyurea) 500 mg capsule	Yes	For use by haematology and oncology services (or in a rural/ remote setting, an appropriate specialist)	
hydroxychloroquine sulfate 200 mg tablet	No	N/A	Authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008 required. Off label use is only allowed if it is in accordance with a DTC approved protocol.
hyoscine butylbromide 10 mg tablet	No	N/A	
hyoscine butylbromide 20 mg/mL injection, ampoule	No	N/A	
hyoscine hydrobromide 300 microgram tablet	Yes	For use in accordance with a DTC approved protocol	
hypromellose 0.3% + carbomer-980 0.2% eye gel	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
ibuprofen 10 mg/2 mL injection, ampoule	Yes	For use in neonates for the management of patent ductus arteriosus (PDA)	
ibuprofen 100 mg/5 mL oral liquid	No	N/A	
ibuprofen 200 mg tablet	No	N/A	
ibuprofen 800 mg/8 mL injection, vial	Yes	For use where solid oral dose form not suitable/inappropriate	
icatibant 30 mg/3 mL injection, syringe	Yes	For use as per PBS criteria OR off label use in accordance with a DTC approved protocol	
ichthammol 10% ointment	No	N/A	
idarubicin hydrochloride 10 mg/10 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
idarubicin hydrochloride 5 mg/5 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
idarucizumab 2.5 g/50 mL injection, vial	Yes	For rapid dabigatran reversal on the advice of a haematology, clinical toxicology or neurology service (or in a rural/remote setting, an appropriate specialist)	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126
ifosfamide 1 g injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
ifosfamide 2 g injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
iloprost 20 microgram/2 mL inhalation solution, ampoule	Yes	For use as per PBS S100 HSD criteria OR nebulised use in ventilated patients on the advice of an Intensive Care Physician OR off label use in accordance with a DTC approved protocol	
imatinib 100 mg tablet	Yes	For initial treatment of Philadelphia +ve ALL and CML	
imatinib 400 mg tablet	Yes	For initial treatment of Philadelphia +ve ALL and CML	
imipenem 500 mg + cilastatin 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
imiquimod 5% cream, sachet	Yes	On the advice of a dermatology service (or in a rural/remote setting, an appropriate specialist) OR for treatment of external anogenital warts where other treatments are not suitable	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
indacaterol 110 microgram + glycopyrronium 50 microgram powder for inhalation, capsule	Yes	For use as per PBS criteria AND where other devices not appropriate	
indacaterol 150 microgram powder for inhalation, 1 capsule	No	N/A	
indacaterol 300 microgram powder for inhalation, 1 capsule	No	N/A	
indapamide hemihydrate 1.5 mg modified release tablet	No	N/A	
indapamide hemihydrate 2.5 mg tablet	No	N/A	
indometacin 1 mg injection, vial	Yes	For use in neonates for the prevention of severe intraventricular haemorrhage OR for the management of patent ductus arteriosus (PDA) when ibuprofen is inappropriate	Special Access Scheme form must be submitted and informed consent for use obtained
indometacin 100 mg suppository	No	N/A	
indometacin 25 mg capsule	No	N/A	
infliximab 100 mg injection, vial	Yes	For use as per PBS S100 HSD criteria OR for use by rheumatology services for severe rheumatoid vasculitis OR for acute ulcerative colitis salvage therapy or acute severe steroid refractory immune colitis on the advice of a gastroenterology service OR for use in paediatric patients for the management of IBD on the advice of a paediatric gastroenterology service in accordance with a DTC approved protocol	
influenza quadrivalent adjuvanted geriatric vaccine 2023 injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases. For practical and safety purposes this medicine should be prescribed by brand name.
influenza quadrivalent vaccine 2023 injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases. For practical and safety purposes this medicine should be prescribed by brand name.
insulin aspart 100 units/mL injection, cartridge	No	N/A	NovoRapid is the only brand approved for initiation. Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin aspart 100 units/mL injection, pen device	No	N/A	NovoRapid is the only brand approved for initiation. Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin aspart 100 units/mL injection, vial	No	N/A	NovoRapid is the only brand approved for initiation. Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).

Medicine name, strength, and form	Restricted?	Restriction	Additional information
insulin aspart 30 units/mL + insulin aspart protamine 70 units/mL injection, cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin aspart 30 units/mL + insulin aspart protamine 70 units/mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin degludec 70 units/mL + insulin aspart 30 units/mL injection, 3 mL cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin degludec 70 units/mL + insulin aspart 30 units/mL injection, 3 mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin detemir 100 units/mL injection, 3 mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin detemir 100 units/mL injection, cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin glargine 100 units/mL injection, 3 mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin glargine 100 units/mL injection, cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin glargine 100 units/mL injection, vial	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin glargine 300 units/mL injection, pen device	Yes	For treatment of severe insulin resistance, requiring high dose insulin AND for use by endocrine services only	High concentration insulin Not directly interchangeable with 100units/mL insulins. Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin glulisine 100 units/mL injection, 3 mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).

Medicine name, strength, and form	Restricted?	Restriction	Additional information
insulin glulisine 100 units/mL injection, cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin glulisine 100 units/mL injection, vial	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin isophane human 100 units/mL injection, 3 mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin isophane human 100 units/mL injection, cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin isophane human 100 units/mL injection, vial	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin lispro 100 units/mL injection, 3 mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin lispro 100 units/mL injection, cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin lispro 100 units/mL injection, vial	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin lispro 25 units/mL + insulin lispro protamine 75 units/mL injection, 3 mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin lispro 25 units/mL + insulin lispro protamine 75 units/mL injection, cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin lispro 50 units/mL + insulin lispro protamine 50 units/mL injection, 3 mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).

Medicine name, strength, and form	Restricted?	Restriction	Additional information
insulin lispro 50 units/mL + insulin lispro protamine 50 units/mL injection, cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin neutral human 100 units/mL injection, cartridge	No	N/A	
insulin neutral human 100 units/mL injection, vial	No	N/A	
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, 3 mL cartridge	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, 3 mL pen device	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, vial	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
insulin neutral human 50 units/mL + insulin isophane human 50 units/mL injection, vial	No	N/A	Disposable insulin pens are preferred for all types of insulin for sub-cutaneous administration. A syringe should never be used to withdraw insulin from these pen devices due to the high potential for dosing errors (SN007/19).
interferon gamma-1b 2 million units (100 microgram)/0.5 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
iodine 5% (50 mg/mL) + potassium iodide 10% (100 mg/mL) solution	No	N/A	
iodised oil 10 mL (iodine 4.8 g)/10 mL injection, ampoule	Yes	For use by endoscopy services only	
ipilimumab 200 mg/40 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
ipilimumab 50 mg/10 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
ipratropium bromide 250 microgram/mL inhalation solution, ampoule	No	N/A	
ipratropium bromide 500 microgram/mL inhalation solution, ampoule	No	N/A	
ipratropium bromide monohydrate 21 microgram/actuation inhalation, actuation	No	N/A	
irbesartan 150 mg tablet	No	N/A	
irbesartan 300 mg tablet	No	N/A	
irbesartan 75 mg tablet	No	N/A	
irinotecan hydrochloride trihydrate 100 mg/5 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
irinotecan hydrochloride trihydrate 40 mg/2 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
irinotecan hydrochloride trihydrate 500 mg/25 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
iron (as ferric carboxymaltose) 500 mg/10 mL injection, vial	Yes	For use where iron polymaltose is inappropriate AND in accordance with a DTC approved protocol	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
iron (as polymaltose) 100 mg/2 mL injection, ampoule	No	N/A	Use in accordance with a DTC approved protocol
iron (as sucrose) 100 mg/5 mL injection, ampoule	Yes	For use in patients unable to tolerate other parenteral iron products AND use in accordance with a DTC approved protocol	
isavuconazole 100 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
isavuconazole 200 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
isoflurane 1 mL/mL inhalation solution	Yes	For use by anaesthetic or intensive care services only	
isoleucine with carbohydrate containing 50 mg isoleucine powder for oral liquid, 4 g sachet	Yes	For the management of maple syrup urine disease	For practical and safety purposes this medicine should be prescribed by brand name.
isoniazid 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
isoprenaline hydrochloride 1 in 5000 (1 mg/5 mL) injection, ampoule	Yes	For use in critical care areas only	
isoprenaline hydrochloride 1 in 5000 (200 microgram/mL) injection, ampoule	Yes	For use in critical care areas only	
isosorbide mononitrate 60 mg modified release tablet	No	N/A	
isotretinoin 10 mg capsule	Yes	For use in maintenance therapy for HR neuroblastoma AND with authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008	
isotretinoin 20 mg capsule	Yes	For use in maintenance therapy for HR neuroblastoma AND with authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008	
isotretinoin 40 mg capsule	Yes	For use in maintenance therapy for HR neuroblastoma AND with authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008	
itraconazole 10 mg/mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	Itraconazole MUST be prescribed by the generic AND brand name AND formulation as the different brands and formulations are NOT interchangeable.
itraconazole 50 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	Itraconazole MUST be prescribed by the generic AND brand name AND formulation as the different brands and formulations are NOT interchangeable.
ivabradine 5 mg tablet	Yes	On the advice of a cardiology service AND for use as per PBS criteria OR for use by CT Coronary Angiography physicians to reduce heart rate when beta blockers are contraindicated	
ivacaftor 150 mg tablet	Yes	For use as per PBS S100 HSD criteria	
ivacaftor 50 mg granules, sachet	Yes	For use as per PBS S100 HSD criteria	
ivacaftor 75 mg granules, sachet	Yes	For use as per PBS S100 HSD criteria	
ivermectin 3 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
ketamine 200 mg/2 mL injection, ampoule	Yes	On the advice of an anaesthetic, pain or palliative care service OR for use in critical care areas	
ketoconazole 2% shampoo	No	N/A	
ketorolac trometamol 0.5% eye drops	Yes	On the advice of an ophthalmology service for therapy beyond 6 weeks	
ketorolac trometamol 10 mg/mL injection, ampoule	Yes	For management of acute pain	Use with caution in the elderly, dehydrated or renally impaired patients.
ketorolac trometamol 30 mg/mL injection, vial	Yes	For management of acute pain in adults only	Use with caution in the elderly, dehydrated or renally impaired patients.
labetalol hydrochloride 100 mg tablet	Yes	For obstetric or paediatric patients only OR on the advice of a renal service	
labetalol hydrochloride 200 mg tablet	Yes	For obstetric or paediatric patients only OR on the advice of a renal service	
labetalol hydrochloride 50 mg/10 mL injection, ampoule	Yes	For treatment of severe hypertension when urgent reduction of blood pressure is essential	
lacosamide 100 mg tablet	Yes	For use as per PBS criteria	
lacosamide 150 mg tablet	Yes	For use as per PBS criteria	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
lacosamide 200 mg tablet	Yes	For use as per PBS criteria	
lacosamide 200 mg/20 mL injection, vial	Yes	On the advice of a neurology service	
lacosamide 50 mg tablet	Yes	For use as per PBS criteria	
lactulose 3.3 g/5 mL oral liquid	No	N/A	
lamivudine 10 mg/mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
lamivudine 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
lamivudine 150 mg + zidovudine 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
lamivudine 150 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
lamivudine 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
lamotrigine 100 mg tablet	Yes	On the advice of a neurology or mental health service OR off label use in accordance with a DTC approved protocol	
lamotrigine 25 mg tablet	Yes	On the advice of a neurology or mental health service OR off label use in accordance with a DTC approved protocol	
lamotrigine 5 mg tablet	Yes	On the advice of a neurology or mental health service OR off label use in accordance with a DTC approved protocol	
lamotrigine 50 mg tablet	Yes	On the advice of a neurology or mental health service OR off label use in accordance with a DTC approved protocol	
lansoprazole 15 mg orally disintegrating tablet	Yes	For use where solid oral dose form not suitable OR for use in enteral feeding tubes	
lansoprazole 30 mg orally disintegrating tablet	Yes	For use where solid oral dose form not suitable OR for use in enteral feeding tubes	
lanthanum 1 g chewable tablet	Yes	For the management of hyperphosphataemia AND as per PBS S100 HSD criteria on the advice of a renal service (or in a rural/remote setting, an appropriate specialist)	
lanthanum 500 mg chewable tablet	Yes	For the management of hyperphosphataemia AND as per PBS S100 HSD criteria on the advice of a renal service (or in a rural/remote setting, an appropriate specialist)	
lanthanum 750 mg chewable tablet	Yes	For the management of hyperphosphataemia AND as per PBS S100 HSD criteria on the advice of a renal service (or in a rural/remote setting, an appropriate specialist)	
latanoprost 0.005% + timolol 0.5% eye drops	Yes	For use in patients inadequately managed on monotherapy	
latanoprost 0.005% eye drops	No	N/A	
leflunomide 10 mg tablet	Yes	On the advice of a rheumatology service AND as per PBS criteria OR on the advice of a renal service (or in a rural/remote setting, an appropriate specialist)	If use is not per PBS criteria, ongoing cost must be discussed with the patient.
leflunomide 20 mg tablet	Yes	On the advice of a rheumatology service AND as per PBS criteria OR on the advice of a renal service	If use is not per PBS criteria, ongoing cost must be discussed with the patient.
lenalidomide 10 mg capsule	Yes	For use as per PBS S100 HSD criteria	
lenalidomide 15 mg capsule	Yes	For use as per PBS S100 HSD criteria	
lenalidomide 25 mg capsule	Yes	For use as per PBS S100 HSD criteria	
lenalidomide 5 mg capsule	Yes	For use as per PBS S100 HSD criteria	
lercanidipine hydrochloride 10 mg tablet	No	N/A	
lercanidipine hydrochloride 20 mg tablet	No	N/A	
letermovir 240 mg tablet	Yes	For prophylaxis of cytomegalovirus (CMV) infection in adult allogeneic haematopoietic stem cell transplant (alloHSCT) recipients who are CMV seropositive recipients [R+] with CMV seronegative donors [D-] (R+/D-), for up to 100 days post-transplant	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
letermovir 240 mg/12 mL injection, vial	Yes	For prophylaxis of cytomegalovirus (CMV) infection in adult allogeneic haematopoietic stem cell transplant (alloHSCT) recipients who are CMV seropositive recipients [R+] with CMV seronegative donors [D-] (R+/D-), for up to 100 days post-transplant	
letrozole 2.5 mg tablet	No	N/A	
levetiracetam 1 g tablet	Yes	For the prevention or management of seizures when other agents are inappropriate	
levetiracetam 100 mg/mL oral liquid	Yes	For use where solid oral dose form not suitable	
levetiracetam 250 mg tablet	Yes	For the prevention or management of seizures when other agents are inappropriate	
levetiracetam 500 mg tablet	Yes	For the prevention or management of seizures when other agents are inappropriate	
levetiracetam 500 mg/5 mL injection, vial	Yes	For the prevention or management of seizures when other agents are inappropriate or where oral levetiracetam not suitable	Off label use is only allowed if it is in accordance with a DTC approved protocol
levobupivacaine 50 mg/10 mL injection, ampoule	Yes	For use by anaesthetic services only	
levocarnitine tartrate 500 mg capsule	Yes	On the advice of a metabolic, clinical toxicology, clinical pharmacology or gastroenterology service	
levodopa 100 mg + benserazide 25 mg capsule	No	N/A	
levodopa 100 mg + benserazide 25 mg dispersible tablet	No	N/A	
levodopa 100 mg + benserazide 25 mg modified release capsule	No	N/A	
levodopa 100 mg + benserazide 25 mg tablet	No	N/A	
levodopa 100 mg + carbidopa 25 mg + entacapone 200 mg tablet	No	N/A	
levodopa 100 mg + carbidopa 25 mg tablet	No	N/A	
levodopa 125 mg + carbidopa 31.25 mg + entacapone 200 mg tablet	No	N/A	
levodopa 150 mg + carbidopa 37.5 mg + entacapone 200 mg tablet	No	N/A	
levodopa 20 mg/mL + carbidopa monohydrate 5 mg/mL intestinal gel	Yes	For use as per PBS S100 HSD criteria	
levodopa 200 mg + benserazide 50 mg capsule	No	N/A	
levodopa 200 mg + benserazide 50 mg tablet	No	N/A	
levodopa 200 mg + carbidopa 50 mg + entacapone 200 mg tablet	No	N/A	
levodopa 200 mg + carbidopa 50 mg modified release tablet	No	N/A	
levodopa 250 mg + carbidopa 25 mg tablet	No	N/A	
levodopa 50 mg + benserazide 12.5 mg capsule	No	N/A	
levodopa 50 mg + benserazide 12.5 mg dispersible tablet	No	N/A	
levodopa 50 mg + carbidopa 12.5 mg + entacapone 200 mg tablet	No	N/A	
levodopa 75 mg + carbidopa 18.75 mg + entacapone 200 mg tablet	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
levofloxacin 250 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
levofloxacin 500 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
levomepromazine hydrochloride 25 mg/mL injection, ampoule	Yes	For use in palliation for the treatment of agitation, nausea and vomiting	Special Access Scheme form must be submitted and informed consent for use obtained
levonorgestrel 1.5 mg tablet	No	N/A	
levonorgestrel 125 microgram + ethinylestradiol 50 microgram tablet	Yes	For treatment of menorrhagia	
levonorgestrel 150 microgram + ethinylestradiol 30 microgram tablet	No	N/A	
levonorgestrel 19.5 mg intrauterine drug delivery system	Yes	For treatment of menorrhagia or endometrial hyperplasia OR for use in patients with psychosocial vulnerability OR patients who are unable to source through community	
levonorgestrel 52 mg intrauterine drug delivery system, 1 system	Yes	For treatment of menorrhagia or endometrial hyperplasia OR for use in patients with psychosocial vulnerability OR patients who are unable to source through community	
levothyroxine sodium 100 microgram tablet	No	N/A	
levothyroxine sodium 200 microgram injection, vial	Yes	On the advice of an endocrine service for patients unable to tolerate oral therapy	Special Access Scheme form must be submitted and informed consent for use obtained
levothyroxine sodium 200 microgram tablet	No	N/A	
levothyroxine sodium 200 microgram/mL injection, ampoule	Yes	On the advice of an endocrine service for patients unable to tolerate oral therapy	Special Access Scheme form must be submitted and informed consent for use obtained
levothyroxine sodium 50 microgram tablet	No	N/A	
levothyroxine sodium 75 microgram tablet	No	N/A	
lidocaine (lignocaine) 10% ointment	Yes	For dental use only	
lidocaine (lignocaine) 10% spray, actuation	No	N/A	
lidocaine (lignocaine) 2.5% + prilocaine 2.5% cream	No	N/A	
lidocaine (lignocaine) 4% cream	No	N/A	
lidocaine (lignocaine) 5% ointment	Yes	For use where gels not suitable	
lidocaine (lignocaine) 5% patch	Yes	For treatment of post-herpetic neuralgia OR on the advice of a pain, palliative care or spinal service	This medicine is not PBS listed, please discuss ongoing costs with the patient.
lidocaine (lignocaine) hydrochloride 0.5% (100 mg/20 mL) + adrenaline (epinephrine) 1 in 200 000 (100 microgram/20 mL) injection, vial	No	N/A	
lidocaine (lignocaine) hydrochloride 1% (20 mg/2 mL) injection, ampoule	No	N/A	
lidocaine (lignocaine) hydrochloride 1% (200 mg/20 mL) + adrenaline (epinephrine) 1 in 200 000 (100 microgram/20 mL) injection, vial	No	N/A	
lidocaine (lignocaine) hydrochloride 1% (200 mg/20 mL) injection, vial	No	N/A	
lidocaine (lignocaine) hydrochloride 1% (50 mg/5 mL) + adrenaline (epinephrine) 1 in 100 000 (50 microgram/5 mL) injection, ampoule	No	N/A	
lidocaine (lignocaine) hydrochloride 1% (50 mg/5 mL) injection, ampoule	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
lidocaine (lignocaine) hydrochloride 10% (500 mg/5 mL) injection, ampoule	Yes	For use in accordance with a DTC approved protocol	
lidocaine (lignocaine) hydrochloride 2% (100 mg/5 mL) + adrenaline (epinephrine) 1 in 80 000 (62.5 microgram/5 mL) injection, ampoule	No	N/A	
lidocaine (lignocaine) hydrochloride 2% (100 mg/5 mL) injection, ampoule	No	N/A	
lidocaine (lignocaine) hydrochloride 2% (400 mg/20 mL) + adrenaline (epinephrine) 1 in 200 000 (100 microgram/20 mL) injection, vial	No	N/A	
lidocaine (lignocaine) hydrochloride 2% (400 mg/20 mL) injection, vial	No	N/A	
lidocaine (lignocaine) hydrochloride 2% gel	No	N/A	
lidocaine (lignocaine) hydrochloride 2% gel, ampoule	No	N/A	
lidocaine (lignocaine) hydrochloride 2% oral liquid	No	N/A	
lidocaine (lignocaine) hydrochloride 5% + phenylephrine hydrochloride 0.5% nasal spray	Yes	For ear, nose and throat indications only AND use in accordance with a local DTC approved protocol	Possibility of systemic absorption and associated side effects. Review the site before applying to make sure that all skin and mucous membranes are intact. Refer to approved product information for dosage and administration. Allow a minimum of two hours before re-dosing, if required.
lidocaine (lignocaine) hydrochloride monohydrate 2% (44 mg/2.2 mL) + adrenaline (epinephrine) 1 in 80 000 (27.5 microgram/2.2 mL) injection, cartridge	No	N/A	
lidocaine (lignocaine) hydrochloride monohydrate 4% + fluorescein sodium 0.25% eye drops, unit dose	No	N/A	
linagliptin 5 mg tablet	Yes	For use as per PBS criteria	
linezolid 20 mg/mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
linezolid 600 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
linezolid 600 mg/300 mL injection, bottle	Yes	Use in accordance with the local antimicrobial stewardship policy	
liothyronine sodium 20 microgram injection, vial	Yes	For treatment of severe hypothyroidism on the advice of an endocrine service (or in a rural/remote setting, an appropriate specialist) OR on the advice of a paediatric endocrine service for treatment of sick euthyroidism in neonates OR for use in critical care areas	Special Access Scheme form must be submitted and informed consent for use obtained
liothyronine sodium 20 microgram tablet	Yes	On the advice of an endocrine service (or in a rural/remote setting, an appropriate specialist)	
lipase 10 000 units + amylase 8000 units + protease 600 units enteric capsule	No	N/A	
lipase 25 000 units + amylase 18 000 units + protease 1000 units enteric capsule	No	N/A	
lipase 5000 units/100 mg + amylase 3600 units/100 mg + protease 200 units/100 mg enteric coated granules	No	N/A	
lisdexamfetamine dimesilate 20 mg capsule	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
lisdexamfetamine dimesilate 30 mg capsule	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
lisdexamfetamine dimesilate 50 mg capsule	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
lisinopril 5 mg tablet	Yes	For use in paediatric patients only	
lithium carbonate 250 mg tablet	Yes	On the advice of a mental health service	
lithium carbonate 450 mg modified release tablet	Yes	On the advice of a mental health service	Due to a disruption to the supply of the Australian registered product, an alternative lithium carbonate 450 mg slow release product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 31 January 2024. Please refer to the TGA S19a approvals database for further details.
lomustine 10 mg capsule	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
lomustine 40 mg capsule	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
loperamide hydrochloride 2 mg capsule	No	N/A	
loperamide hydrochloride 2 mg orally disintegrating tablet	Yes	For use where capsule is not suitable	
lopinavir 100 mg + ritonavir 25 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
lopinavir 200 mg + ritonavir 50 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
lopinavir 400 mg/5 mL + ritonavir 100 mg/5 mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
loratadine 10 mg tablet	No	N/A	
lorazepam 1 mg tablet	No	N/A	
lorazepam 4 mg/mL injection, ampoule	Yes	For use in accordance with a DTC approved protocol	
lumacaftor 100 mg + ivacaftor 125 mg granules, 1 sachet	Yes	For use as per PBS S100 HSD criteria	
lumacaftor 100 mg + ivacaftor 125 mg tablet	Yes	For use as per PBS S100 HSD criteria	
lumacaftor 150 mg + ivacaftor 188 mg granules, 1 sachet	Yes	For use as per PBS S100 HSD criteria	
lumacaftor 200 mg + ivacaftor 125 mg tablet	Yes	For use as per PBS S100 HSD criteria	
lurasidone hydrochloride 40 mg tablet	Yes	On the advice of a mental health service	
lurasidone hydrochloride 80 mg tablet	Yes	On the advice of a mental health service	
lysine hydrochloride 300 mg/10 mL + thiamine hydrochloride 10 mg/10 mL + pyridoxine hydrochloride 5 mg/10 mL + cyanocobalamin 25 microgram/10 mL + iron (as ferric pyrophosphate) 10 mg/10 mL oral liquid	No	N/A	
macitentan 10 mg tablet	Yes	For use as per PBS S100 HSD criteria	
macrogol-3350 1 g/g powder for oral liquid	No	N/A	
macrogol-3350 13.125 g + sodium chloride 350.7 mg + sodium bicarbonate 178.5 mg + potassium chloride 46.6 mg powder for oral liquid, sachet	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
macrogol-3350 52.9 g + sodium chloride 2.6 g + potassium chloride 740 mg (potassium 9.9 mmol) + sodium sulfate 5.6 g powder for oral liquid, 70 g sachet	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
macrogol-3350 59 g + sodium chloride 1.46 g + potassium chloride 750 mg (potassium 10 mmol) + sodium sulfate 5.68 g + sodium bicarbonate 1.69 g powder for oral liquid, 68.58 g sachet	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
macrogol-3350 6.563 g + sodium chloride 175.4 mg + sodium bicarbonate 89.3 mg + potassium chloride 25.1 mg powder for oral liquid, 1 sachet	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
magnesium 37.4 mg tablet	No	N/A	
magnesium 400 mg + zinc 2 mg capsule	Yes	For use in patients with high dose magnesium replacement requirements	
magnesium 50 mg/mL oral liquid	No	N/A	
magnesium amino acid chelate 500 mg (magnesium 100 mg) + zinc amino acid chelate 25 mg (zinc 5 mg) + manganese amino acid chelate 10 mg (manganese 1 mg) capsule	Yes	For use in paediatric patients with high dose magnesium replacement requirements	
magnesium chloride 480 mg/5 mL injection, ampoule	Yes	For patients receiving total parenteral nutrition	
magnesium sulfate heptahydrate 2.47 g/5 mL injection, ampoule	No	N/A	
magnesium sulfate heptahydrate 2.5 g/5 mL injection, vial	No	N/A	
magnesium sulfate heptahydrate 8 g/100 mL injection, bag	Yes	On the advice of an obstetrics service for fetal neuroprotection in accordance with NSW Health Guideline PD2011_064 Maternity - Management of Hypertensive Disorders of Pregnancy OR GL2022_006 Management of Threatened Preterm Labour guideline	
malathion 1% foam	No	N/A	
mannitol 20% (100 g/500 mL) injection, bag	No	N/A	
mannitol 40 mg powder for inhalation, 1 capsule	Yes	For use as per PBS S100 HSD criteria	
maraviroc 150 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
maraviroc 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
measles 1000 CCID50 units + mumps 5000 CCID50 units + rubella 1000 CCID50 units live vaccine injection, vial	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2016_035: Statewide Standing orders for the Supply or Administration of Medication for Public Health Response AND PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases. For practical and safety purposes this medicine should be prescribed by brand name.
measles 1000 TCID50 units + mumps 12 500 TCID50 units + rubella 1000 TCID50 units live vaccine injection, vial	Yes	For use as per the Australian Immunisation Handbook	Additional information is available in PD2016_035: Statewide Standing orders for the Supply or Administration of Medication for Public Health Response AND PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases. For practical and safety purposes this medicine should be prescribed by brand name.
mebendazole 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
mebendazole 100 mg/5 mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
medium chain triglycerides oral oil	Yes	For use in neonates only	For practical and safety purposes this medicine should be prescribed by brand name.
medroxyprogesterone acetate 100 mg tablet	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
medroxyprogesterone acetate 150 mg/mL injection, vial	No	N/A	
medroxyprogesterone acetate 200 mg tablet	No	N/A	
mefenamic acid 250 mg capsule	No	N/A	
meloxicam 15 mg tablet	No	N/A	
meloxicam 7.5 mg tablet	No	N/A	
melphalan 50 mg injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
memantine hydrochloride 10 mg tablet	Yes	For use as per PBS criteria	
meningococcal A 10 microgram/0.5 mL + meningococcal C 10 microgram/0.5 mL + meningococcal W135 10 microgram/0.5 mL + meningococcal Y 10 microgram/0.5 mL conjugate vaccine injection, vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
meningococcal A 5 microgram + meningococcal C 5 microgram + meningococcal W135 5 microgram + meningococcal Y 5 microgram conjugate vaccine injection, vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
meningococcal A conjugate vaccine injection, vial (&) meningococcal C + meningococcal W135 + meningococcal Y conjugate vaccine injection, syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
meningococcal A conjugate vaccine injection, vial (&) meningococcal C + meningococcal W135 + meningococcal Y conjugate vaccine injection, vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
meningococcal B 4 component vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
mepivacaine hydrochloride 3% (66 mg/2.2 mL) injection, cartridge	Yes	For dental use only	
mepolizumab 100 mg/mL injection, pen device	Yes	For use as per PBS S100 HSD criteria	
mercaptamine (cysteamine) 150 mg capsule	Yes	For the management of nephropathic cystinosis	
mercaptamine (cysteamine) 50 mg capsule	Yes	For the management of nephropathic cystinosis	
mercaptopurine monohydrate 50 mg tablet	Yes	For use by gastroenterology and cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an approved protocol	
meropenem 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
meropenem 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
mesalazine 1 g modified release granules, sachet	Yes	For patients with sulphonamide allergy OR where sulfasalazine not suitable	
mesalazine 1 g modified release tablet	Yes	For patients with sulphonamide allergy OR where sulfasalazine not suitable	
mesalazine 1 g suppository	Yes	For treatment of ulcerative colitis	
mesalazine 1 g/100 mL enema	Yes	For treatment of ulcerative colitis	
mesalazine 2 g/60 mL enema	Yes	For treatment of ulcerative colitis	
mesalazine 3 g modified release granules, sachet	Yes	For patients with sulphonamide allergy OR where sulfasalazine not suitable	
mesalazine 4 g/60 mL enema	Yes	For treatment of ulcerative colitis	
mesalazine 500 mg enteric tablet	Yes	For patients with sulphonamide allergy OR where sulfasalazine not suitable	
mesalazine 500 mg modified release granules, sachet	Yes	For patients with sulphonamide allergy OR where sulfasalazine not suitable	
mesna 1 g/10 mL injection, ampoule	No	N/A	
mesna 400 mg tablet	No	N/A	
mesna 400 mg/4 mL injection, ampoule	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
mesna 600 mg tablet	No	N/A	
metaraminol 10 mg/mL injection, ampoule	No	N/A	
metaraminol 3 mg/6 mL injection, vial	No	N/A	
metaraminol 5 mg/10 mL injection, syringe	No	N/A	
metformin hydrochloride 1 g modified release tablet	No	N/A	
metformin hydrochloride 1 g tablet	No	N/A	
metformin hydrochloride 500 mg modified release tablet	No	N/A	
metformin hydrochloride 500 mg tablet	No	N/A	
metformin hydrochloride 850 mg tablet	No	N/A	
methadone hydrochloride 10 mg tablet	Yes	For use by pain or palliative care services only	
methadone hydrochloride 10 mg/mL injection, vial	Yes	For use by pain or palliative care services OR for management of acute pain intra-operatively	
methadone hydrochloride 5 mg/mL oral liquid	Yes	For use by pain or palliative care services OR on the advice of a drug and alcohol service	An authority to prescribe to a drug dependent person is to be obtained within 14 days of inpatient initiation under the Poisons and Therapeutic Goods Act 1966. Ensure availability of an authorised prescriber in the community for continuing supply prior to discharge.
methionine 500 mg tablet	Yes	On the advice of a clinical toxicology or metabolic service	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126. Special Access Scheme form must be submitted and informed consent for use obtained
methionine 500 mg tablet	Yes	On the advice of a clinical toxicology or metabolic service	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126. Special Access Scheme form must be submitted and informed consent for use obtained
methotrexate 1 g/10 mL injection, vial	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
methotrexate 10 mg tablet	Yes	For use by cancer, rheumatology, immunology, dermatology and gastroenterology services only (or in a rural/ remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
methotrexate 100 mg/4 mL injection, syringe	Yes	For use by cancer and obstetrics services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
methotrexate 15 mg/0.3 mL injection, syringe	Yes	For use by cancer, gastroenterology and rheumatology services only AND in accordance with an eviQ or approved protocol	
methotrexate 2.5 mg tablet	Yes	For use by cancer, rheumatology, immunology, dermatology and gastroenterology services only (or in a rural/ remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
methotrexate 20 mg/0.4 mL injection, syringe	Yes	For use by cancer, gastroenterology and rheumatology services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
methotrexate 25 mg/0.5 mL injection, syringe	Yes	For use by cancer, gastroenterology and rheumatology services only AND in accordance with an eviQ or approved protocol	
methotrexate 5 g/50 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
methotrexate 5 mg/2 mL injection, vial	Yes	For use by cancer services AND in accordance with an eviQ or approved protocol	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
methotrexate 50 mg/2 mL injection, vial	Yes	For use by cancer and obstetrics services only (or in a rural/ remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
methoxy polyethylene glycol-epoetin beta 100 microgram/0.3 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
methoxy polyethylene glycol-epoetin beta 120 microgram/0.3 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
methoxy polyethylene glycol-epoetin beta 200 microgram/0.3 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
methoxy polyethylene glycol-epoetin beta 30 microgram/0.3 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
methoxy polyethylene glycol-epoetin beta 360 microgram/0.6 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
methoxy polyethylene glycol-epoetin beta 50 microgram/0.3 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
methoxy polyethylene glycol-epoetin beta 75 microgram/0.3 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
methoxyflurane 99.9% (999 mg/g) inhalation solution, 3 mL bottle	Yes	For inhaled analgesia in conjunction with a local DTC approved protocol that includes consideration of appropriate staff exposure	
methyl salicylate 28.3% + eucalyptus oil 8.8% + menthol 2% cream	No	N/A	
methyldopa 250 mg tablet	No	N/A	
methylene blue trihydrate 50 mg/10 mL solution, ampoule	No	N/A	
methylene blue trihydrate 50 mg/5 mL injection, vial	No	N/A	
methylnaltrexone bromide 12 mg/0.6 mL injection, vial	Yes	For use by palliative care services only for treatment of opioid induced constipation in advanced illness with insufficient response to laxative therapy	
methylphenidate hydrochloride 10 mg modified release capsule	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
methylphenidate hydrochloride 10 mg tablet	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
methylphenidate hydrochloride 18 mg modified release tablet	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
methylphenidate hydrochloride 20 mg modified release capsule	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
methylphenidate hydrochloride 27 mg modified release tablet	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
methylphenidate hydrochloride 30 mg modified release capsule	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
methylphenidate hydrochloride 36 mg modified release tablet	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
methylphenidate hydrochloride 40 mg modified release capsule	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
methylphenidate hydrochloride 54 mg modified release tablet	Yes	On the advice of a mental health, paediatric or neurology service	Prescribers must be authorised to prescribe a psychostimulant by NSW MOH. Consider availability of authorised prescriber in the community for continuing supply.
methylprednisolone 1 g injection, vial	No	N/A	
methylprednisolone 125 mg injection, chamber	No		Due to a disruption to the supply of the Australian registered product, alternative methylprednisolone injections have been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 29 February 2024. Further information is available in the CEC Medication Safety Updates.
methylprednisolone 40 mg injection, chamber	No		Due to a disruption to the supply of the Australian registered product, alternative methylprednisolone injections have been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 29 February 2024. Further information is available in the CEC Medication Safety Updates.
methylprednisolone 500 mg injection, vial	No	N/A	
methylprednisolone aceponate 0.1% cream	No	N/A	
methylprednisolone aceponate 0.1% ointment	No	N/A	
methylprednisolone acetate 40 mg/mL modified release injection, vial	No	N/A	
metoclopramide hydrochloride 10 mg tablet	No	N/A	
metoclopramide hydrochloride 10 mg/2 mL injection, ampoule	No	N/A	
metoprolol succinate 23.75 mg modified release tablet	Yes	For use as per PBS criteria	
metoprolol succinate 47.5 mg modified release tablet	Yes	For use as per PBS criteria	
metoprolol tartrate 100 mg tablet	No	N/A	
metoprolol tartrate 5 mg/5 mL injection, vial	No		
metoprolol tartrate 50 mg tablet	No	N/A	
metronidazole 0.5% (500 mg/100 mL) injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
metronidazole 0.75% gel	No	N/A	
metronidazole 0.75% vaginal gel	Yes	Use in accordance with the local antimicrobial stewardship policy	
metronidazole 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
metronidazole 200 mg/5 mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
metronidazole 400 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
metronidazole 500 mg suppository	Yes	Use in accordance with the local antimicrobial stewardship policy	
metronidazole 500 mg/100 mL injection, bag	Yes	Use in accordance with the local antimicrobial stewardship policy	
metronidazole 500 mg/100 mL injection, bottle	Yes	Use in accordance with the local antimicrobial stewardship policy	
metyrapone 250 mg capsule	Yes	On the advice of an endocrine service for use in severe Cushing's syndrome	
mianserin hydrochloride 10 mg tablet	Yes	On the advice of a mental health service	
mianserin hydrochloride 20 mg tablet	Yes	On the advice of a mental health service	
micafungin 100 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
micafungin 50 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
miconazole 2% gel	No	N/A	
miconazole nitrate 2% cream	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
midazolam 15 mg/3 mL injection, ampoule	Yes	For use by critical care, palliative care or neonatal services only	Wherever possible, only one strength of midazolam should be kept in each clinical area, being the most appropriate strength for the main clinical use of that area (as per NSW Health Safety Notice 022/09).
midazolam 15 mg/3 mL injection, ampoule	Yes	For use by critical care, palliative care or neonatal services only	Wherever possible, only one strength of midazolam should be kept in each clinical area, being the most appropriate strength for the main clinical use of that area (as per NSW Health Safety Notice 022/09).
midazolam 5 mg/5 mL injection, ampoule	No	N/A	Wherever possible, only one strength of midazolam should be kept in each clinical area, being the most appropriate strength for the main clinical use of that area (as per NSW Health Safety Notice 022/09).
midazolam 5 mg/mL injection, ampoule	No	N/A	Wherever possible, only one strength of midazolam should be kept in each clinical area, being the most appropriate strength for the main clinical use of that area (as per NSW Health Safety Notice 022/09).
midazolam 5 mg/mL injection, ampoule	No	N/A	Wherever possible, only one strength of midazolam should be kept in each clinical area, being the most appropriate strength for the main clinical use of that area (as per NSW Health Safety Notice 022/09).
midazolam 50 mg/10 mL injection, ampoule	Yes	For use by critical care or palliative care services only	Wherever possible, only one strength of midazolam should be kept in each clinical area, being the most appropriate strength for the main clinical use of that area (as per NSW Health Safety Notice 022/09).
midazolam 50 mg/10 mL injection, ampoule	Yes	For use by critical care or palliative care services only	Wherever possible, only one strength of midazolam should be kept in each clinical area, being the most appropriate strength for the main clinical use of that area (as per NSW Health Safety Notice 022/09).
midodrine hydrochloride 2.5 mg tablet	No	N/A	This medicine is not PBS listed, please discuss ongoing costs with the patient.
midodrine hydrochloride 5 mg tablet	No	N/A	This medicine is not PBS listed, please discuss ongoing costs with the patient.
midostaurin 25 mg capsule	Yes	For use as per PBS S100 HSD criteria	
mifepristone 200 mg tablet	Yes	For use by medical practitioners up to 63 days gestation, after 63 days gestation prescribing must be in consultation with a specialist obstetrician or gynaecologist OR for the management of intrauterine fetal death or miscarriage in accordance with a DTC approved protocol	Under the NSW Abortion Law Reform Act 2019, a termination of pregnancy can only be performed by a medical practitioner. Under the NSW Crimes Act 1900 (s82 Termination of pregnancy performed by unqualified person), it is an offence for an unqualified person (a person who is not a medical practitioner) to perform a termination.
milrinone 10 mg/10 mL injection, ampoule	Yes	For use in ICU, CCU, ED or OT where cardiac monitoring is available	
minocycline 50 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
minoxidil 10 mg tablet	Yes	On the advice of a cardiology or renal service only (or in a rural/remote setting, an appropriate specialist)	
mirabegron 25 mg modified release tablet	Yes	For use in detrusor overactivity where anticholinergic medicines are contraindicated	This medicine is not PBS listed, please discuss ongoing costs with the patient.
mirabegron 50 mg modified release tablet	Yes	For use in detrusor overactivity where anticholinergic medicines are contraindicated	This medicine is not PBS listed, please discuss ongoing costs with the patient.

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
mirtazapine 15 mg orally disintegrating tablet	No	N/A	
mirtazapine 15 mg tablet	No	N/A	
mirtazapine 30 mg tablet	No	N/A	
mirtazapine 45 mg tablet	No	N/A	
misoprostol 200 microgram tablet	Yes	For use as per registered indications OR off label use in accordance with a DTC approved protocol	
misoprostol 200 microgram tablet	Yes	For use as per registered indications OR off label use in accordance with a DTC approved protocol	
misoprostol 25 microgram tablet	Yes	For the induction of labour in full term patients with an unfavourable cervix in accordance with a DTC approved protocol	
mitomycin 2 mg injection, vial	Yes	For use by cancer, ophthalmology or Ear Nose and Throat (ENT) services AND in accordance with an eviQ or approved protocol	
mitomycin 20 mg injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
mitozantrone 20 mg/10 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
moclobemide 150 mg tablet	Yes	On the advice of a psychiatrist when other anti-depressants are ineffective or inappropriate	
moclobemide 300 mg tablet	Yes	On the advice of a psychiatrist when other anti-depressants are ineffective or inappropriate	
molnupiravir 200 mg capsule	Yes	For use in accordance with the Agency for Clinical Innovation guidance	For use by prescribers approved by the local DTC
mometasone furoate 0.1% cream	No	N/A	
mometasone furoate 0.1% gel	No	N/A	
mometasone furoate 0.1% lotion	No	N/A	
mometasone furoate 0.1% ointment	No	N/A	
mometasone furoate 50 microgram/actuation nasal spray, actuation	No	N/A	
monobasic potassium phosphate 1.361 g (potassium 10 mmol)/10 mL injection, ampoule	Yes	For use in critical care areas OR in accordance with a DTC approved protocol where premixed solutions unsuitable	
monobasic potassium phosphate 1.361 g (potassium 10 mmol)/10 mL injection, vial	Yes	For use in critical care areas OR in accordance with a DTC approved protocol where premixed solutions unsuitable	
monobasic potassium phosphate 1.361 g (potassium 10 mmol)/250 mL + sodium chloride 0.9% (2.25 g/250 mL) injection, bag	No	N/A	
monobasic sodium phosphate dihydrate 1.56 g/10 mL injection, vial	No	N/A	
monobasic sodium phosphate monohydrate 19 g/118 mL + dibasic sodium phosphate heptahydrate 7 g/118 mL enema	No	N/A	
montelukast 10 mg tablet	Yes	On the advice of a respiratory service	
montelukast 4 mg chewable tablet	Yes	For use as per PBS criteria	
montelukast 5 mg chewable tablet	Yes	For use as per PBS criteria	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
morphine hydrochloride trihydrate 1 mg/mL oral liquid	No		Due to the anticipated discontinuation of the Australian registered product, alternative morphine oral liquid products have been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act from 1 December 2023, if required. Please refer to your facility pharmacy for advice on formulations available locally. Further information is available on the CEC Medication Safety Updates webpage. Only one strength should be stocked per clinical area where practicable.
morphine hydrochloride trihydrate 10 mg/mL injection, ampoule	No	N/A	
morphine hydrochloride trihydrate 2 mg/mL oral liquid	No		Due to the anticipated discontinuation of the Australian registered product, alternative morphine oral liquid products have been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act from 1 December 2023, if required. Please refer to your facility pharmacy for advice on formulations available locally. Further information is available on the CEC Medication Safety Updates webpage. Only one strength should be stocked per clinical area where practicable.
morphine hydrochloride trihydrate 200 microgram/mL intrathecal injection, vial	Yes	For use in operating theatres only	Only one strength (either 200microg/1mL or 500microg/1mL) to be stocked per hospital.
morphine hydrochloride trihydrate 5 mg/mL oral liquid	No		Due to the anticipated discontinuation of the Australian registered product, alternative morphine oral liquid products have been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act from 1 December 2023, if required. Please refer to your facility pharmacy for advice on formulations available locally. Further information is available on the CEC Medication Safety Updates webpage. Only one strength should be stocked per clinical area where practicable.
morphine hydrochloride trihydrate 500 microgram/mL intrathecal injection, vial	Yes	For use in operating theatres only	Only one strength (either 200microg/1mL or 500microg/1mL) to be stocked per hospital.
morphine sulfate pentahydrate 10 mg modified release capsule	Yes	For management of chronic pain unresponsive to non-opioid analgesia where modified release tablet not suitable/inappropriate OR for chronic breathlessness as per PBS criteria	
morphine sulfate pentahydrate 10 mg modified release tablet	Yes	For management of chronic pain unresponsive to non-opioid analgesia	
morphine sulfate pentahydrate 10 mg tablet	Yes	For use in severe disabling pain unresponsive to non-opioid analgesia AND where liquid form not suitable/inappropriate	
morphine sulfate pentahydrate 10 mg/mL injection, ampoule	No	N/A	Only one strength should be stocked per clinical area where practicable.
morphine sulfate pentahydrate 100 mg modified release capsule	Yes	For management of chronic pain unresponsive to non-opioid analgesia AND where modified release tablet not suitable/inappropriate	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
morphine sulfate pentahydrate 100 mg modified release tablet	Yes	For management of chronic pain unresponsive to non-opioid analgesia	
morphine sulfate pentahydrate 20 mg modified release capsule	Yes	For management of chronic pain unresponsive to non-opioid analgesia where modified release tablet not suitable/inappropriate OR for chronic breathlessness as per PBS criteria	
morphine sulfate pentahydrate 30 mg modified release tablet	Yes	For management of chronic pain unresponsive to non-opioid analgesia	
morphine sulfate pentahydrate 30 mg/mL injection, ampoule	No	N/A	Only one strength should be stocked per clinical area where practicable.
morphine sulfate pentahydrate 5 mg modified release tablet	Yes	For management of chronic pain unresponsive to non-opioid analgesia	
morphine sulfate pentahydrate 5 mg/mL injection, ampoule	No	N/A	Only one strength should be stocked per clinical area where practicable.
morphine sulfate pentahydrate 50 mg modified release capsule	Yes	For management of chronic pain unresponsive to non-opioid analgesia AND where modified release tablet not suitable/inappropriate	
morphine sulfate pentahydrate 60 mg modified release tablet	Yes	For management of chronic pain unresponsive to non-opioid analgesia	
moxifloxacin 400 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
moxifloxacin 400 mg/250 mL injection, bag	Yes	Use in accordance with the local antimicrobial stewardship policy	
moxifloxacin 400 mg/250 mL injection, bottle	Yes	Use in accordance with the local antimicrobial stewardship policy	
moxonidine 200 microgram tablet	Yes	On the advice of a cardiology or renal service (or in a rural/remote setting, an appropriate specialist)	
moxonidine 400 microgram tablet	Yes	On the advice of a cardiology or renal service (or in a rural/remote setting, an appropriate specialist)	
mupirocin 2% cream	Yes	Use in accordance with the local antimicrobial stewardship policy	
mupirocin 2% ointment	Yes	Use in accordance with the local antimicrobial stewardship policy	
mycobacterium bovis (BCG) live vaccine 1.5 mg injection, vial	Yes	For use by TB services only as per NSW Health GL2023_003 BCG (Bacille Calmette Guerin) Vaccination for Tuberculosis (TB)	
mycobacterium bovis (BCG) live vaccine 500 microgram injection, ampoule	Yes	For use by TB services only as per NSW Health GL2023_003 BCG (Bacille Calmette Guerin) Vaccination for Tuberculosis (TB)	
mycobacterium bovis (BCG) live vaccine 750 microgram injection, vial	Yes	For use by TB services only as per NSW Health GL2023_003 BCG (Bacille Calmette Guerin) Vaccination for Tuberculosis (TB)	
Mycobacterium bovis BCG Tice strain 500 million CFU injection, vial	Yes	For primary and relapsing superficial urothelial carcinoma of the bladder	Due to a disruption to the supply of the Australian registered product, an alternative Mycobacterium bovis BCG Tice strain product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 31 January 2024. Please refer to the TGA S19a database for further details.
mycophenolate 180 mg enteric tablet	Yes	On the advice of a transplant, renal, immunology or rheumatology service (or in a rural/remote setting, an appropriate specialist)	
mycophenolate 360 mg enteric tablet	Yes	On the advice of a transplant, renal, immunology or rheumatology service (or in a rural/remote setting, an appropriate specialist)	
mycophenolate mofetil 1 g/5 mL powder for oral liquid	Yes	On the advice of a transplant, renal, immunology or rheumatology service (or in a rural/remote setting, an appropriate specialist) AND where solid oral dose form not suitable	
mycophenolate mofetil 250 mg capsule	Yes	On the advice of a transplant, renal, immunology or rheumatology service (or in a rural/remote setting, an appropriate specialist)	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
mycophenolate mofetil 500 mg injection, vial	Yes	On the advice of a transplant, renal, immunology or rheumatology service (or in a rural/remote setting, an appropriate specialist)	
mycophenolate mofetil 500 mg tablet	Yes	On the advice of a transplant, renal, immunology or rheumatology service (or in a rural/remote setting, an appropriate specialist)	
naloxone 1.8 mg/actuation nasal spray, actuation	Yes	For use in accordance with PD2020_027 Opioid Overdose Response and Take Home Naloxone Policy	Due to disruption of supply of the Australian registered product, this product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 31 October 2023.
naloxone hydrochloride 1 mg/mL injection, syringe	Yes	For use in accordance with PD2020_027 Opioid Overdose Response and Take Home Naloxone Policy	
naloxone hydrochloride 400 microgram/mL injection, ampoule	No	N/A	
naltrexone hydrochloride 50 mg tablet	Yes	On the advice of a drug and alcohol service or addiction psychiatrist for the management of alcohol dependance	
naproxen 1 g modified release tablet	Yes	For treatment of chronic inflammatory arthropathies OR management of bone pain due to malignant disease	
naproxen 125 mg/5 mL oral liquid	Yes	For use in paediatric patients only	
naproxen 250 mg tablet	No	N/A	
naproxen 500 mg tablet	No	N/A	
naproxen 750 mg modified release tablet	Yes	For treatment of chronic inflammatory arthropathies OR management of bone pain due to malignant disease	
natalizumab 300 mg/15 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
nebivolol 1.25 mg tablet	Yes	For use as per PBS criteria	
nebivolol 10 mg tablet	Yes	For use as per PBS criteria	
nebivolol 5 mg tablet	Yes	For use as per PBS criteria	
neomycin sulfate 500 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
neostigmine methylsulfate 2.5 mg/mL injection, ampoule	No	N/A	
netupitant 300 mg + palonosetron 500 microgram capsule	Yes	For use by cancer services only as per PBS criteria	
nevirapine 10 mg/mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
nevirapine 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
nevirapine 400 mg modified release tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
nicorandil 10 mg tablet	No	N/A	
nicotinamide 500 mg tablet	No	N/A	
nicotine 1 mg/actuation spray, 1 actuation	No	N/A	
nicotine 14 mg/24 hours patch	No	N/A	
nicotine 15 mg inhalation, cartridge	No	N/A	
nicotine 2 mg chewing gum	No	N/A	
nicotine 2 mg lozenge	No	N/A	
nicotine 21 mg/24 hours patch	No	N/A	
nicotine 4 mg chewing gum	No	N/A	
nicotine 4 mg lozenge	No	N/A	
nicotine 7 mg/24 hours patch	No	N/A	
nicotinic acid 250 mg tablet	No	N/A	
nifedipine 10 mg tablet	No	N/A	Special Access Scheme form must be submitted and informed consent for use obtained

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
nifedipine 20 mg modified release tablet	No		Special Access Scheme form must be submitted and informed consent for use obtained
nifedipine 20 mg/mL oral liquid, drop	Yes	For use where solid oral dose form not suitable	Special Access Scheme form must be submitted and informed consent for use obtained
nifedipine 20 mg/mL oral liquid, drop	Yes	For use where solid oral dose form not suitable	Special Access Scheme form must be submitted and informed consent for use obtained
nifedipine 30 mg modified release tablet	No	N/A	
nifedipine 60 mg modified release tablet	No	N/A	
nimodipine 10 mg/50 mL injection, vial	Yes	For use where solid oral dose form not suitable	
nimodipine 30 mg tablet	No	N/A	
nirmatrelvir 150 mg tablet (&) ritonavir 100 mg tablet	Yes	For management of COVID-19 in accordance with Agency for Clinical Innovation guidelines or a DTC approved protocol	For use by prescribers approved by the local DTC
nitrazepam 5 mg tablet	Yes	On the advice of a neurology service for the management of epilepsy only	
nitric oxide 800 ppm medicinal gas	Yes	For use in neonates less than 29 days old	
nitrofurantoin 100 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
nitrofurantoin 50 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
nivolumab 100 mg/10 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
nivolumab 40 mg/4 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
nizatidine 150 mg capsule	No	N/A	
nizatidine 300 mg capsule	No	N/A	
noradrenaline (norepinephrine) 1 in 1000 (4 mg/4 mL) injection, vial	No	N/A	
norethisterone 1 mg + ethinylestradiol 35 microgram tablet	No	N/A	
norethisterone 350 microgram tablet	No	N/A	
norethisterone 5 mg tablet	No	N/A	
norethisterone 500 microgram + ethinylestradiol 35 microgram tablet	No	N/A	
norfloxacin 400 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
nortriptyline 10 mg tablet	No	N/A	
nortriptyline 25 mg tablet	No	N/A	
nusinersen 12 mg/5 mL intrathecal injection, vial	Yes	For use as per PBS S100 HSD criteria	
nystatin 100 000 units/g cream	No	N/A	
nystatin 100 000 units/mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
nystatin 20 000 units/g vaginal cream	Yes	Use in accordance with the local antimicrobial stewardship policy	
nystatin 500 000 units tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
obinutuzumab 1 g/40 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
ocrelizumab 300 mg/10 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
octreotide 10 mg modified release injection, vial	Yes	For use as per PBS S100 HSD criteria	
octreotide 100 microgram/mL injection, ampoule	No	N/A	
octreotide 20 mg modified release injection, vial	Yes	For use as per PBS S100 HSD criteria	
octreotide 30 mg modified release injection, vial	Yes	For use as per PBS S100 HSD criteria	
octreotide 50 microgram/mL injection, ampoule	No	N/A	
octreotide 500 microgram/mL injection, ampoule	No	N/A	
ofloxacin 0.3% eye drops	Yes	Use in accordance with the local antimicrobial stewardship policy	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
olanzapine (as pamoate) 210 mg modified release injection, vial	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) where appropriate post dose monitoring is available	Use in accordance with a DTC approved protocol. There is a disruption to the supply of the Australian registered product. Alternative olanzapine depot injections are available via the Special Access Scheme (SAS). Special Access Scheme form must be submitted and informed consent for use obtained. Further information is available in the CEC Medication Safety Updates.
olanzapine (as pamoate) 300 mg modified release injection, vial	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) where appropriate post dose monitoring is available	Use in accordance with a DTC approved protocol. There is a disruption to the supply of the Australian registered product. Alternative olanzapine depot injections are available via the Special Access Scheme (SAS). Special Access Scheme form must be submitted and informed consent for use obtained. Further information is available in the CEC Medication Safety Updates.
olanzapine (as pamoate) 405 mg modified release injection, vial	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) where appropriate post dose monitoring is available	Use in accordance with a DTC approved protocol. There is a disruption to the supply of the Australian registered product. Alternative olanzapine depot injections are available via the Special Access Scheme (SAS). Special Access Scheme form must be submitted and informed consent for use obtained. Further information is available in the CEC Medication Safety Updates.
olanzapine 10 mg injection, vial	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance in accordance with a DTC approved protocol	
olanzapine 10 mg orally disintegrating tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
olanzapine 10 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
olanzapine 10 mg wafer	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
olanzapine 15 mg orally disintegrating tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
olanzapine 15 mg wafer	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
olanzapine 2.5 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
olanzapine 5 mg orally disintegrating tablet	Yes	On the advice of a mental health service or cancer services (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
olanzapine 5 mg tablet	Yes	On the advice of a mental health service or cancer services (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
olanzapine 5 mg wafer	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
olive oil 16 g/100 mL + soya oil 4 g/100 mL injection, bag	Yes	For use by TPN or metabolic services OR for use in local anaesthetic poisoning OR on advice of a clinical toxicology service for other poisoning indications	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126
olive oil 16 g/100 mL + soya oil 4 g/100 mL injection, bottle	Yes	For use by TPN or metabolic services OR for use in local anaesthetic poisoning OR on advice of a clinical toxicology service for other poisoning indications	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126
olive oil 40 g/250 mL + soya oil 10 g/250 mL injection, bag	Yes	For use by TPN or metabolic services OR for use in local anaesthetic poisoning OR on advice of a clinical toxicology service for other poisoning indications	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126
olive oil 40 g/250 mL + soya oil 10 g/250 mL injection, bottle	Yes	For use by TPN or metabolic services OR for use in local anaesthetic poisoning OR on advice of a clinical toxicology service for other poisoning indications	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126
olive oil 80 g/500 mL + soya oil 20 g/500 mL injection, bag	Yes	For use by TPN or metabolic services OR for use in local anaesthetic poisoning OR on advice of a clinical toxicology service for other poisoning indications	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126
olive oil 80 g/500 mL + soya oil 20 g/500 mL injection, bottle	Yes	For use by TPN or metabolic services OR for use in local anaesthetic poisoning OR on advice of a clinical toxicology service for other poisoning indications	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126
omalizumab 150 mg/mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
omalizumab 75 mg/0.5 mL injection, syringe	Yes	For use as per PBS S100 HSD criteria	
omeprazole 10 mg enteric tablet	No	N/A	
omeprazole 20 mg enteric capsule	No	N/A	
omeprazole 20 mg enteric tablet	No	N/A	
omeprazole 40 mg injection, vial	Yes	For use in neonate and paediatric patients	
ondansetron 4 mg orally disintegrating tablet	No	N/A	
ondansetron 4 mg tablet	No	N/A	
ondansetron 4 mg/2 mL injection, ampoule	No	N/A	
ondansetron 4 mg/5 mL oral liquid	Yes	For use in paediatric patients where solid oral dose form not suitable	
ondansetron 8 mg orally disintegrating tablet	No	N/A	
ondansetron 8 mg tablet	No	N/A	
ondansetron 8 mg/4 mL injection, ampoule	Yes	For use by cancer services only	
oseltamivir 30 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
oseltamivir 6 mg/mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
oseltamivir 75 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
oxaliplatin 100 mg/20 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
oxazepam 15 mg tablet	No	N/A	
oxazepam 30 mg tablet	No	N/A	
oxcarbazepine 150 mg tablet	Yes	On the advice of a neurology service	
oxcarbazepine 300 mg tablet	Yes	On the advice of a neurology service	
oxcarbazepine 60 mg/mL oral liquid	Yes	For use where solid oral dose form not suitable	
oxybuprocaine hydrochloride 0.4% eye drops, unit dose	No	N/A	
oxybutynin 3.9 mg/24 hours patch	Yes	For detrusor overactivity when oral oxybutynin is not tolerated	
oxybutynin hydrochloride 5 mg tablet	No	N/A	
oxycodone hydrochloride 1 mg/mL oral liquid	No		
oxycodone hydrochloride 10 mg + naloxone hydrochloride 5 mg modified release tablet	Yes	For use by pain services OR for short term use in acute pain conditions where opioid-induced constipation is likely to be significantly detrimental e.g. CABG and rib fracture patients. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
oxycodone hydrochloride 10 mg capsule	No		
oxycodone hydrochloride 10 mg modified release tablet	Yes	For use by pain or palliative care services only (or in a rural/remote setting, an appropriate specialist)	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
oxycodone hydrochloride 10 mg/mL injection, ampoule	No	N/A	
oxycodone hydrochloride 15 mg + naloxone hydrochloride 7.5 mg modified release tablet	Yes	For use by pain services OR for short term use in acute pain conditions where opioid-induced constipation is likely to be significantly detrimental e.g. CABG and rib fracture patients. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
oxycodone hydrochloride 15 mg modified release tablet	Yes	For use by pain or palliative care services only (or in a rural/remote setting, an appropriate specialist)	
oxycodone hydrochloride 2.5 mg + naloxone hydrochloride 1.25 mg modified release tablet	Yes	For use by pain services OR for short term use in acute pain conditions where opioid-induced constipation is likely to be significantly detrimental e.g. CABG and rib fracture patients. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
oxycodone hydrochloride 20 mg + naloxone hydrochloride 10 mg modified release tablet	Yes	For use by pain services OR for short term use in acute pain conditions where opioid-induced constipation is likely to be significantly detrimental e.g. CABG and rib fracture patients. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
oxycodone hydrochloride 20 mg capsule	No		
oxycodone hydrochloride 20 mg modified release tablet	Yes	For use by pain or palliative care services only (or in a rural/remote setting, an appropriate specialist)	
oxycodone hydrochloride 30 mg + naloxone hydrochloride 15 mg modified release tablet	Yes	For use by pain services OR for short term use in acute pain conditions where opioid-induced constipation is likely to be significantly detrimental e.g. CABG and rib fracture patients. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
oxycodone hydrochloride 40 mg + naloxone hydrochloride 20 mg modified release tablet	Yes	For use by pain services OR for short term use in acute pain conditions where opioid-induced constipation is likely to be significantly detrimental e.g. CABG and rib fracture patients. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
oxycodone hydrochloride 40 mg modified release tablet	Yes	For use by pain or palliative care services only (or in a rural/remote setting, an appropriate specialist)	
oxycodone hydrochloride 5 mg + naloxone hydrochloride 2.5 mg modified release tablet	Yes	For use by pain services OR for short term use in acute pain conditions where opioid-induced constipation is likely to be significantly detrimental e.g. CABG and rib fracture patients. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
oxycodone hydrochloride 5 mg modified release tablet	Yes	For use by pain or palliative care services only (or in a rural/remote setting, an appropriate specialist)	
oxycodone hydrochloride 5 mg tablet	No		
oxycodone hydrochloride 80 mg modified release tablet	Yes	For use by pain or palliative care services only	
oxymetazoline hydrochloride 0.05% nasal spray	No	N/A	
oxytocin 10 units/mL injection, ampoule	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
oxytocin 5 units/mL + ergometrine maleate 500 microgram/mL injection, ampoule	No	N/A	
paclitaxel (as nanoparticle albumin-bound) 100 mg injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
paclitaxel 100 mg/16.7 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
paclitaxel 150 mg/25 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
paclitaxel 30 mg/5 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
paclitaxel 300 mg/50 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
paliperidone 100 mg modified release injection, syringe	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
paliperidone 150 mg modified release injection, syringe	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
paliperidone 175 mg/0.875 mL modified release injection, syringe	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) for long stay rehabilitation patients only	
paliperidone 25 mg modified release injection, syringe	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
paliperidone 263 mg/1.315 mL modified release injection, syringe	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) for long stay rehabilitation patients only	
paliperidone 3 mg modified release tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
paliperidone 350 mg/1.75 mL modified release injection, syringe	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) for long stay rehabilitation patients only	
paliperidone 50 mg modified release injection, syringe	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
paliperidone 525 mg/2.625 mL modified release injection, syringe	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) for long stay rehabilitation patients only	
paliperidone 6 mg modified release tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
paliperidone 75 mg modified release injection, syringe	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
paliperidone 9 mg modified release tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
palivizumab 100 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
palivizumab 50 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
palonosetron 250 microgram/5 mL injection, vial	Yes	For use by cancer or palliative care services only OR for treatment of post-operative nausea and vomiting where other agents failed	
pamidronate disodium 15 mg/5 mL injection, vial	Yes	For use as per PBS S100 HSD criteria OR for use in neonate and paediatric patients for the management of osteogenesis imperfecta, severe hypercalcaemia, or secondary osteoporosis	
pamidronate disodium 30 mg/10 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
pamidronate disodium 60 mg/10 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
pamidronate disodium 90 mg/10 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
pancuronium bromide 4 mg/2 mL injection, ampoule	Yes	For use in cardiothoracic surgery	Special Access Scheme form must be submitted and informed consent for use obtained
panitumumab 100 mg/5 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
panitumumab 400 mg/20 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
pantoprazole 20 mg enteric tablet	No	N/A	
pantoprazole 40 mg enteric coated granules, sachet	No	N/A	
pantoprazole 40 mg enteric tablet	No	N/A	
pantoprazole 40 mg injection, vial	No	N/A	
papaverine hydrochloride 120 mg/10 mL injection, ampoule	Yes	For use in operating theatres only	
paracetamol 1 g/100 mL injection, bag	Yes	For use when oral/NG route not available AND to be reviewed every 24 hours AND change to oral as soon as possible	
paracetamol 1 g/100 mL injection, vial	Yes	For use when oral/NG route not available AND to be reviewed every 24 hours AND change to oral as soon as possible	
paracetamol 100 mg/mL oral liquid	Yes	For use in infants less than 10kg	
paracetamol 125 mg suppository	No	N/A	
paracetamol 250 mg suppository	No	N/A	
paracetamol 48 mg/mL oral liquid	No	N/A	
paracetamol 50 mg/mL oral liquid	No	N/A	
paracetamol 500 mg + codeine phosphate hemihydrate 30 mg tablet	Yes	Not for use in children <12 years NOR in children aged 12-18 years post adenotonsillectomy for obstructive sleep apnoea NOR in patients known to be ultra rapid/low metabolisers of codeine NOR in lactation	
paracetamol 500 mg effervescent tablet	No	N/A	
paracetamol 500 mg suppository	No	N/A	
paracetamol 500 mg tablet	No	N/A	
paracetamol 500 mg/50 mL injection, bag	Yes	For use when oral/NG route not available AND to be reviewed every 24 hours AND change to oral as soon as possible	
paracetamol 500 mg/50 mL injection, vial	Yes	For use when oral/NG route not available AND to be reviewed every 24 hours AND change to oral as soon as possible	
paracetamol 665 mg modified release tablet	Yes	For the management of chronic or acute pain where there is a clinical advantage over immediate release tablets	
paraffin 1 g/g eye ointment	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
parecoxib 40 mg injection, vial	Yes	For use as a single peri-operative dose for the management of post-operative pain	
paroxetine 20 mg tablet	No	N/A	
pegaspargase 3750 units injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
pegfilgrastim 6 mg/0.6 mL injection, syringe	Yes	For use as per PBS S100 criteria or on the advice of a cancer OR haematology service	
peginterferon alfa-2a 135 microgram/0.5 mL injection, syringe	Yes	For use as per PBS criteria	
pegvisomant 10 mg injection, vial	Yes	For use as per PBS S100 HSD criteria	
pegvisomant 15 mg injection, vial	Yes	For use as per PBS S100 HSD criteria	
pegvisomant 20 mg injection, vial	Yes	For use as per PBS S100 HSD criteria	
pembrolizumab 100 mg/4 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
pemetrexed 1 g injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
pemetrexed 100 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
pemetrexed 500 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
penicillamine 125 mg tablet	No	N/A	
penicillamine 125 mg tablet	No	N/A	
penicillamine 250 mg tablet	No	N/A	
penicillamine 250 mg tablet	No	N/A	
pentamidine isetionate 300 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
peppermint oil 0.2 mL enteric capsule	No	N/A	
peppermint water oral liquid	No	N/A	
perampanel 2 mg tablet	Yes	For use as per PBS criteria	
perampanel 4 mg tablet	Yes	For use as per PBS criteria	
perampanel 6 mg tablet	Yes	For use as per PBS criteria	
perampanel 8 mg tablet	Yes	For use as per PBS criteria	
perhexiline maleate 100 mg tablet	Yes	On the advice of a cardiology service (or in a rural/remote setting, an appropriate specialist) AND for use as per PBS criteria	
perindopril arginine 10 mg tablet	No	N/A	
perindopril arginine 2.5 mg tablet	No	N/A	
perindopril arginine 5 mg tablet	No	N/A	
permethrin 5% cream	Yes	Use in accordance with the local antimicrobial stewardship policy	
permethrin 5% lotion	Yes	Use in accordance with the local antimicrobial stewardship policy	
pertuzumab 420 mg/14 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
phenazone 5.4% + benzocaine 1.4% ear drops	Yes	For use in paediatric patients only	
phenelzine 15 mg tablet	Yes	On the advice of a mental health service	
phenobarbital (phenobarbitone) 15 mg/5 mL oral liquid	Yes	For use where solid oral dose form not suitable	
phenobarbital (phenobarbitone) 200 mg (equivalent to phenobarbital (phenobarbitone) sodium 219 mg)/mL injection, ampoule	Yes	On the advice of a critical care or neurology service (or in a rural/remote setting, an appropriate specialist). On the advice of a palliative care service in accordance with a DTC approved protocol	
phenobarbital (phenobarbitone) 30 mg tablet	Yes	On the advice of a neonatal or neurology service	
phenol 250 mg/5 mL injection, vial	Yes	On the advice of a gastroenterology service	
phenoxybenzamine hydrochloride 10 mg capsule	Yes	For use as per PBS criteria	
phenoxymethylpenicillin 250 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
phenoxymethylpenicillin 250 mg/5 mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
phenoxymethylpenicillin 500 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
phentolamine mesylate 10 mg/mL injection, ampoule	Yes	For use in critical care areas only	Special Access Scheme form must be submitted and informed consent for use obtained
phenylephrine hydrochloride 1 mg/10 mL (0.01%) + sodium chloride 0.9% (90 mg/10 mL) injection, syringe	No	N/A	
phenylephrine hydrochloride 10 mg/mL (1%) injection, ampoule	No	N/A	
phenylephrine hydrochloride 10% eye drops, unit dose	No	N/A	
phenylephrine hydrochloride 2.5% eye drops, unit dose	No	N/A	
phenytoin 30 mg/5 mL oral liquid	Yes	For use where solid oral dose form not suitable	
phenytoin 50 mg chewable tablet	No	N/A	
phenytoin sodium 100 mg capsule	No	N/A	
phenytoin sodium 100 mg/2 mL injection, ampoule	Yes	For use in neonatal and paediatric patients	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
phenytoin sodium 250 mg/5 mL injection, ampoule	No	N/A	
phenytoin sodium 30 mg capsule	No	N/A	
phosphorus 500 mg effervescent tablet	No	N/A	
physostigmine 2 mg/5 mL injection, ampoule	Yes	On the advice of a clinical toxicology service for treatment of anticholinergic delirium	Special Access Scheme form must be submitted and informed consent for use obtained. Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
phytomenadione 10 mg capsule	Yes	For use where injectable formulation not suitable	
phytomenadione 10 mg/mL injection, ampoule	No	N/A	
phytomenadione 2 mg/0.2 mL injection, ampoule	No	N/A	
pilocarpine hydrochloride 1% eye drops	No	N/A	
pilocarpine hydrochloride 2% eye drops	No	N/A	
pilocarpine hydrochloride 4% eye drops	No	N/A	
pilocarpine nitrate 2% eye drops, unit dose	No	N/A	
pimecrolimus 1% cream	Yes	For use as a steroid sparing topical treatment for facial atopic dermatitis	
piperacillin 4 g + tazobactam 500 mg injection, 4.5 g vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
pirfenidone 267 mg tablet	Yes	For use as per PBS criteria	
pizotifen 500 microgram tablet	No	N/A	
plerixafor 24 mg/1.2 mL injection, vial	Yes	For use as per PBS S100 HSD criteria OR for use by a paediatric cellular therapy transplant service in accordance with an approved protocol	
pneumococcal 13 valent conjugate vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
pneumococcal 23 valent vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
podophyllotoxin 0.15% cream	Yes	For use by dermatology or sexual health services	
podophyllotoxin 0.5% solution	Yes	For use by dermatology or sexual health services	
polio trivalent inactivated vaccine injection, 0.5 mL syringe	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
poloxamer 100 mg/mL oral liquid, drop	No	N/A	
polyvalent Australian snake antivenom injection, vial	No	N/A	
pomalidomide 3 mg capsule	Yes	For use as per PBS S100 criteria AND in accordance with an eviQ or approved protocol	
pomalidomide 4 mg capsule	Yes	For use as per PBS S100 criteria AND in accordance with an eviQ or approved protocol	
poractant alfa 120 mg/1.5 mL intratracheal suspension, vial	Yes	For treatment of respiratory distress syndrome in premature infants OR for treatment of meconium aspiration syndrome	
poractant alfa 240 mg/3 mL intratracheal suspension, vial	Yes	For treatment of respiratory distress syndrome in premature infants OR for treatment of meconium aspiration syndrome	
posaconazole 100 mg modified release tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
posaconazole 300 mg/16.7 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	Patients should be transitioned to oral therapy as soon as feasible
posaconazole 40 mg/mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
potassium acetate 2.45 g (potassium 25 mmol)/5 mL injection, ampoule	Yes	For use in critical care areas OR for patients receiving total parenteral nutrition	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
potassium chloride 1.49 g (potassium 20 mmol)/L + glucose 5% (50 g/L) + sodium chloride 0.45% (4.5 g/L) injection, bag	Yes	For use in neonatal and paediatric patients only	
potassium chloride 1.49 g (potassium 20 mmol)/L + glucose 5% (50 g/L) + sodium chloride 0.9% (9 g/L) injection, bag	Yes	For use in paediatric patients only	
potassium chloride 1.5 g (potassium 20 mmol)/L + sodium chloride 0.9% (9 g/L) injection, bag	Yes	For use in neonatal and paediatric patients only	
potassium chloride 10% oral liquid	No	N/A	
potassium chloride 2.24 g (potassium 30 mmol)/L + glucose 4% (40 g/L) + sodium chloride 0.18% (1.8 g/L) injection, bag	Yes	For use in adults only	
potassium chloride 2.24 g (potassium 30 mmol)/L + glucose 5% (50 g/L) injection, bag	No	N/A	
potassium chloride 2.24 g (potassium 30 mmol)/L + sodium chloride 0.9% (9 g/L) injection, bag	No	N/A	
potassium chloride 2.98 g (potassium 40 mmol)/100 mL + sodium chloride 0.9% (900 mg/100 mL) injection, bag	Yes	For use via a central line in critical care units. Other clinical areas may be approved by your local DTC (refer to high risk medicines management policy PD2020_045)	
potassium chloride 2.98 g (potassium 40 mmol)/L + sodium chloride 0.9% (9 g/L) injection, bag	Yes	For use in neonatal or paediatric patients OR for use in critical care areas	
potassium chloride 595 mg + potassium bicarbonate 384 mg + potassium carbonate 152 mg (total potassium 14 mmol) effervescent tablet	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
potassium chloride 600 mg (potassium 8 mmol) modified release tablet	No	N/A	
potassium chloride 750 mg (potassium 10 mmol)/10 mL injection, ampoule	Yes	For use in critical care areas OR in accordance with a DTC approved protocol where premixed solutions unsuitable	
potassium chloride 750 mg (potassium 10 mmol)/100 mL + sodium chloride 0.29% (292 mg/100 mL) injection, bag	Yes	For use in adults only	
potassium chloride 750 mg (potassium 10 mmol)/500 mL + glucose 10% (50 g/500 mL) + sodium chloride 0.225% (1.125 g/500 mL) injection, bag	Yes	For use in neonatal and paediatric patients only	
potassium chloride 750 mg (potassium 10 mmol)/500 mL + glucose 10% (50 g/500 mL) + sodium chloride 0.45% (2.25 g/500 mL) injection, bag	Yes	For use in neonatal and paediatric patients only	
potassium citrate 1.08 g (potassium 10 mmol) modified release tablet	Yes	On the advice of a genitourinary/urology or renal service (or in a rural/remote setting, an appropriate specialist)	
potassium citrate 2 g/10 mL + citric acid monohydrate 400 mg/10 mL oral liquid	Yes	On the advice of a genitourinary/urology service or metabolic service (or in a rural/remote setting, an appropriate specialist)	
pralidoxime iodide 2.5% (500 mg/20 mL) injection, ampoule	Yes	On the advice of a clinical toxicology service for treatment of organophosphorus pesticide/organophosphate poisoning	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
pramipexole dihydrochloride monohydrate 1.5 mg modified release tablet	Yes	For treatment of Parkinson's disease on the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	
pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet	Yes	For treatment of Parkinson's disease on the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
pramipexole dihydrochloride monohydrate 250 microgram tablet	Yes	For treatment of Parkinson's disease on the advice of a neurology service (or in a rural/remote setting, an appropriate specialist) OR for treatment of restless leg syndrome as per PBS criteria	
pramipexole dihydrochloride monohydrate 3 mg modified release tablet	Yes	For treatment of Parkinson's disease on the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	
pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet	Yes	For treatment of Parkinson's disease on the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	
pramipexole dihydrochloride monohydrate 375 microgram modified release tablet	Yes	For treatment of Parkinson's disease on the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	
pramipexole dihydrochloride monohydrate 750 microgram modified release tablet	Yes	For treatment of Parkinson's disease on the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	
prasugrel 10 mg tablet	Yes	For prevention of thrombotic complications post neurointerventional stenting procedures	
prasugrel 5 mg tablet	Yes	For prevention of thrombotic complications post neurointerventional stenting procedures	
pravastatin sodium 10 mg tablet	No	N/A	
pravastatin sodium 20 mg tablet	No	N/A	
pravastatin sodium 40 mg tablet	No	N/A	
pravastatin sodium 80 mg tablet	No	N/A	
praziquantel 600 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
prazosin 1 mg tablet	No	N/A	
prazosin 2 mg tablet	No	N/A	
prazosin 5 mg tablet	No	N/A	
prednisolone (as sodium phosphate) 20 mg/100 mL enema	No	N/A	
prednisolone (as sodium phosphate) 5 mg suppository	No	N/A	
prednisolone (as sodium phosphate) 5 mg/mL oral liquid	No	N/A	
prednisolone 1 mg tablet	No	N/A	
prednisolone 25 mg tablet	No	N/A	
prednisolone 5 mg tablet	No	N/A	
prednisolone acetate 1% + phenylephrine hydrochloride 0.12% eye drops	Yes	On the advice of an ophthalmology service	
prednisolone sodium phosphate 0.5% eye drops, unit dose	Yes	On the advice of an ophthalmology service or for use with high dose cytarabine in accordance with an eviQ or approved protocol	
pregabalin 150 mg capsule	Yes	For use in refractory neuropathic pain	
pregabalin 25 mg capsule	Yes	For use in refractory neuropathic pain	
pregabalin 75 mg capsule	Yes	For use in refractory neuropathic pain	
pretomanid 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
prilocaine hydrochloride 0.5% (250 mg/50 mL) injection, vial	No	N/A	
prilocaine hydrochloride 3% (66 mg/2.2 mL) + felypressin 0.066 units/2.2 mL injection, cartridge	Yes	For dental use only	
primaquine 7.5 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
primidone 250 mg tablet	Yes	On the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
probenecid 500 mg tablet	No	N/A	
procaine benzylpenicillin (procaine penicillin) 1.5 g/3.4 mL injection, syringe	Yes	Use in accordance with the local antimicrobial stewardship policy	
procarbazine 50 mg capsule	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
prochlorperazine maleate 5 mg tablet	No	N/A	
prochlorperazine mesilate 12.5 mg/mL injection, ampoule	No	N/A	
progesterone 200 mg pessary	Yes	For use as per PBS criteria	
promethazine hydrochloride 10 mg tablet	No	N/A	
promethazine hydrochloride 25 mg tablet	No	N/A	
promethazine hydrochloride 5 mg/5 mL oral liquid	No	N/A	
promethazine hydrochloride 50 mg/2 mL injection, ampoule	Yes	For use where oral antihistamine not suitable	
propofol 1 g/100 mL injection, vial	Yes	For use by critical care services only	
propofol 200 mg/20 mL injection, vial	Yes	For use by critical care services only	
propofol 500 mg/50 mL injection, vial	Yes	For use by critical care services only	
propranolol hydrochloride 10 mg tablet	No	N/A	
propranolol hydrochloride 40 mg tablet	No	N/A	
propylthiouracil 50 mg tablet	Yes	On the advice of an endocrine service (or in a rural/remote setting, an appropriate specialist)	
protamine sulfate 50 mg/5 mL injection, ampoule	No	N/A	
pseudoephedrine hydrochloride 60 mg tablet	Yes	For management of priapism as a complication of intracavernosal therapy	Pseudoephedrine is non formulary for use as a decongestant
psyllium husk powder 3.4 g powder for oral liquid, sachet	No	N/A	
pyrantel 100 mg/square block	Yes	Use in accordance with the local antimicrobial stewardship policy	
pyrantel 125 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
pyrazinamide 500 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
pyridostigmine bromide 10 mg tablet	No	N/A	
pyridostigmine bromide 60 mg tablet	No	N/A	
pyridoxine 100 mg/2 mL injection, ampoule	Yes	For management of suspected or confirmed pyridoxine dependent epilepsy OR on the advice of a clinical toxicology service for treatment of isoniazid poisoning	Special Access Scheme form must be submitted and informed consent for use obtained. Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
pyridoxine hydrochloride 100 mg tablet	No	N/A	
pyridoxine hydrochloride 25 mg tablet	No	N/A	
quetiapine 100 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
quetiapine 150 mg modified release tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
quetiapine 200 mg modified release tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
quetiapine 200 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
quetiapine 25 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
quetiapine 300 mg modified release tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
quetiapine 300 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
quetiapine 400 mg modified release tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
quetiapine 50 mg modified release tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
quinine dihydrochloride 600 mg/10 mL (6%) injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
quinine sulfate dihydrate 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
rabies vaccine injection, vial	Yes	Use in accordance with the Rabies and other lyssavirus infections (including Australian Bat Lyssavirus) – NSW Control Guideline for Public Health Units	For practical and safety purposes this medicine should be prescribed by brand name.
raloxifene hydrochloride 60 mg tablet	Yes	On the advice of an endocrine service (or in a rural/remote setting, an appropriate specialist)	
raltegravir 100 mg chewable tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
raltegravir 25 mg chewable tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
raltegravir 400 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
raltegravir 600 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
ramipril 1.25 mg tablet	No	N/A	
ramipril 10 mg tablet	No	N/A	
ramipril 2.5 mg tablet	No	N/A	
ramipril 5 mg tablet	No	N/A	
ranibizumab 1.65 mg/0.165 mL injection, syringe	Yes	For use as per PBS criteria OR for use in neonates	
ranibizumab 2.3 mg/0.23 mL injection, vial	Yes	For use as per PBS criteria OR for use in neonates	
rasagiline 1 mg tablet	Yes	For treatment of Parkinson's disease on the advice of a neurology service (or in a rural/remote setting, an appropriate specialist)	
rasburicase 1.5 mg injection, vial	Yes	For treatment or prevention of acute hyperuricaemia associated with tumour lysis on the advice of a haematology service (or in a rural/remote setting, an appropriate specialist)	
remdesivir 100 mg injection, vial	Yes	For management of COVID-19 in accordance with Agency for Clinical Innovation guidelines or a DTC approved protocol	For use by prescribers approved by the local DTC
remdesivir 100 mg/20 mL injection, vial	Yes	For management of COVID-19 in accordance with Agency for Clinical Innovation guidelines or a DTC approved protocol	For use by prescribers approved by the local DTC
remifentanil 1 mg injection, vial	Yes	For use by anaesthetic and neonatology services	
remifentanil 2 mg injection, vial	Yes	For use by anaesthetic and neonatology services	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
retinol acetate 300 microgram RE + riboflavin 2.5 mg + calcium pantothenate 6.5 mg + pyridoxine 2 mg + cyanocobalamin 2.5 microgram + ascorbic acid 80 mg + colecalciferol 5 microgram (200 units) + thiamine 2.5 mg + nicotinamide 16.1 mg + dl-alpha-tocopheryl acetate 17.88 mg (17.88 units) + folic acid 200 microgram + calcium 10 mg + chromium 25 microgram + copper 1 mg + iron 5 mg + iodine 150 microgram + magnesium 30 mg + manganese 1 mg + molybdenum 25 microgram + potassium 5 mg + selenium 25 microgram + zinc 5 mg tablet	No	N/A	
retinol palmitate 1050 microgram RE + colecalciferol 5.5 microgram (220 units) + dl-alpha-tocopherol 10.2 mg (11.333 units) + ascorbic acid 125 mg + cocarboxylase tetrahydrate 5.8 mg + riboflavin sodium phosphate 5.67 mg + pyridoxine hydrochloride 5.5 mg + cyanocobalamin 6 microgram + folic acid 414 microgram + dexpanthenol 16.15 mg + biotin 69 microgram + nicotinamide 46 mg injection, vial	No	N/A	
retinol palmitate 1500 microgram RE capsule	No	N/A	
retinol palmitate 1500 microgram RE/0.2 mL oral liquid	Yes	For use where solid oral dose form not suitable	
retinol palmitate 2210 units/mL + d-alpha-tocopheryl acetate 75 mg (102 units)/mL oral liquid	Yes	For use in neonate and paediatric patients	
retinol palmitate 450 microgram RE + colecalciferol 2.5 microgram (100 units) + calcium pantothenate 4.5 mg + thiamine nitrate 1 mg + nicotinamide 15 mg + riboflavin 1.2 mg + pyridoxine hydrochloride 2 mg + cyanocobalamin 1.2 microgram + biotin 50 microgram + folic acid 100 microgram + dl-alpha-tocopheryl acetate 10 mg (10 units) + ascorbic acid 25 mg + sodium ascorbate 28.1 mg + calcium 10 mg + phosphorus 7.7 mg + magnesium 5 mg + ferrous fumarate 4.71 mg (iron 1.5 mg) + zinc 1 mg + manganese 50 microgram chewable tablet	Yes	For use in paediatric patients only	
retinol palmitate 663 microgram RE/mL + colecalciferol 25 microgram (1000 units)/mL + d-alpha-tocopheryl acetate 75 mg (102 units)/mL oral liquid	Yes	For cystic fibrosis patients OR cholestatic liver disease patients	
retinol palmitate 690 microgram (2300 units)/10 mL + ergocalciferol 10 microgram (400 units)/10 mL + dl-alpha-tocopherol 6.4 mg (7 units)/10 mL + phytomenadione 200 microgram/10 mL injection, ampoule	No	N/A	
retinol palmitate 990 microgram (3300 units)/10 mL + ergocalciferol 5 microgram (200 units)/10 mL + dl-alpha-tocopherol 9.1 mg (10 units)/10 mL + phytomenadione 150 microgram/10 mL injection, ampoule	No	N/A	
ribavirin 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
riboflavin 100 mg tablet	Yes	For use in paediatric patients only	
riboflavin 200 mg tablet	Yes	For use in paediatric patients only	
rifabutin 150 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
rifampicin 100 mg/5 mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
rifampicin 150 mg + isoniazid 75 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
rifampicin 150 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
rifampicin 300 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	Due to a disruption to the supply of the Australian registered product, an alternative rifampicin 300 mg capsule product has been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act until 30 April 2024. Further information is available in the CEC Medication Safety Updates.
rifampicin 600 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
rifampicin 75 mg + isoniazid 50 mg + pyrazinamide 150 mg dispersible tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
rifampicin 75 mg + isoniazid 50 mg dispersible tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
rifapentine 150 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	Special Access Scheme form must be submitted and informed consent for use obtained
rifaximin 550 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
rilpivirine 25 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
riluzole 50 mg tablet	Yes	On the advice of a neurology service	
riociguat 1 mg tablet	Yes	For use as per PBS S100 HSD criteria	
riociguat 1.5 mg tablet	Yes	For use as per PBS S100 HSD criteria	
riociguat 2 mg tablet	Yes	For use as per PBS S100 HSD criteria	
riociguat 2.5 mg tablet	Yes	For use as per PBS S100 HSD criteria	
riociguat 500 microgram tablet	Yes	For use as per PBS S100 HSD criteria	
risedronate sodium 150 mg tablet	No	N/A	
risedronate sodium 30 mg tablet	No	N/A	
risedronate sodium 35 mg tablet	No	N/A	
risedronate sodium 5 mg tablet	No	N/A	
risperidone 1 mg tablet	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
risperidone 1 mg/mL oral liquid	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
risperidone 2 mg tablet	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist)	
risperidone 25 mg modified release injection, vial	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
risperidone 3 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
risperidone 37.5 mg modified release injection, vial	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
risperidone 4 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
risperidone 50 mg modified release injection, vial	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
risperidone 500 microgram tablet	Yes	On the advice of a mental health or paediatric service (or in a rural/remote setting, an appropriate specialist) OR for short-term management of behavioural disturbance	
ritonavir 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
rituximab 100 mg/10 mL injection, vial	Yes	For use as per registered indications OR off label use in accordance with a DTC approved protocol	
rituximab 500 mg/50 mL injection, vial	Yes	For use as per registered indications OR off label use in accordance with a DTC approved protocol	
rivaroxaban 10 mg tablet	Yes	For use as per PBS criteria	
rivaroxaban 15 mg tablet	Yes	For use as per PBS criteria	
rivaroxaban 2.5 mg tablet	Yes	For use as per PBS criteria	
rivaroxaban 20 mg tablet	Yes	For use as per PBS criteria	
rivastigmine 1.5 mg capsule	Yes	For use as per PBS criteria	
rivastigmine 4.6 mg/24 hours patch	Yes	For use as per PBS criteria OR on the advice of a clinical toxicologist for treatment of anticholinergic delirium	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
rivastigmine 9.5 mg/24 hours patch	Yes	For use as per PBS criteria OR on the advice of a clinical toxicologist for treatment of anticholinergic delirium	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
rizatriptan 10 mg wafer	No	N/A	
rocuronium bromide 50 mg/5 mL injection, vial	No	N/A	
romiplostim 250 microgram injection, vial	Yes	For use as per PBS S100 HSD criteria	
romiplostim 500 microgram injection, vial	Yes	For use as per PBS S100 HSD criteria	
ropivacaine 100 mg/100 mL + fentanyl 200 microgram/100 mL + sodium chloride 0.9% (900 mg/100 mL) injection, bag	No	N/A	
ropivacaine 200 mg/100 mL + fentanyl 200 microgram/100 mL + sodium chloride 0.9% (900 mg/100 mL) injection, bag	No	N/A	
ropivacaine 250 mg/250 mL + fentanyl 500 microgram/250 mL + sodium chloride 0.9% (2.25 g/250 mL) injection, bag	No	N/A	
ropivacaine 400 mg/200 mL + fentanyl 400 microgram/200 mL + sodium chloride 0.9% (1.8 g/200 mL) injection, bag	No	N/A	
ropivacaine 400 mg/200 mL + fentanyl 800 microgram/200 mL + sodium chloride 0.9% (1.8 g/200 mL) injection, bag	No	N/A	
ropivacaine hydrochloride 100 mg/10 mL injection, ampoule	No	N/A	
ropivacaine hydrochloride 150 mg/20 mL injection, ampoule	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
ropivacaine hydrochloride 20 mg/10 mL injection, ampoule	No	N/A	
ropivacaine hydrochloride 200 mg/100 mL + fentanyl 200 microgram/100 mL injection, bag	No	N/A	Facilities should determine most appropriate volume(s) to be stocked based on local usage patterns, cost and infection risk.
ropivacaine hydrochloride 200 mg/100 mL + fentanyl 400 microgram/100 mL injection, bag	No	N/A	Facilities should determine most appropriate volume(s) to be stocked based on local usage patterns, cost and infection risk.
ropivacaine hydrochloride 200 mg/100 mL injection, bag	No	N/A	
ropivacaine hydrochloride 200 mg/20 mL injection, ampoule	No	N/A	
ropivacaine hydrochloride 40 mg/20 mL injection, ampoule	No	N/A	
ropivacaine hydrochloride 400 mg/200 mL + fentanyl 400 microgram/200 mL injection, bag	No	N/A	Facilities should determine most appropriate volume(s) to be stocked based on local usage patterns, cost and infection risk.
ropivacaine hydrochloride 400 mg/200 mL + fentanyl 800 microgram/200 mL injection, bag	No	N/A	Facilities should determine most appropriate volume(s) to be stocked based on local usage patterns, cost and infection risk.
ropivacaine hydrochloride 400 mg/200 mL injection, bag	No	N/A	
ropivacaine hydrochloride 75 mg/10 mL injection, ampoule	No	N/A	
rosuvastatin 10 mg tablet	No	N/A	
rosuvastatin 20 mg tablet	No	N/A	
rosuvastatin 40 mg tablet	No	N/A	
rosuvastatin 5 mg tablet	No	N/A	
rotavirus live vaccine oral liquid, 1.5 mL tube	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
rotigotine 2 mg/24 hours patch	Yes	For use as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combination for Parkinson's disease OR where oral route not suitable	Seek the advice of a neurology service prior to changing route of administration for anti-parkinson therapy
rotigotine 4 mg/24 hours patch	Yes	For use as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combination for Parkinson's disease OR where oral route not suitable	Seek the advice of a neurology service prior to changing route of administration for anti-parkinson therapy
rotigotine 6 mg/24 hours patch	Yes	For use as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combination for Parkinson's disease OR where oral route not suitable	Seek the advice of a neurology service prior to changing route of administration for anti-parkinson therapy
rotigotine 8 mg/24 hours patch	Yes	For use as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combination for Parkinson's disease OR where oral route not suitable	Seek the advice of a neurology service prior to changing route of administration for anti-parkinson therapy
roxithromycin 150 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
roxithromycin 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
roxithromycin 50 mg dispersible tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
rufinamide 200 mg tablet	Yes	For use by neurology services for adjunctive therapy in the treatment of seizure associated with Lennox-Gastaut syndrome in patients 4 years and older	
rufinamide 400 mg tablet	Yes	For use by neurology services for adjunctive therapy in the treatment of seizure associated with Lennox-Gastaut syndrome in patients 4 years and older	
ruxolitinib 10 mg tablet	Yes	For treatment of graft vs host disease OR initial treatment of myelofibrosis	
ruxolitinib 5 mg tablet	Yes	For treatment of graft vs host disease OR initial treatment of myelofibrosis	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
sacubitril 24.3 mg + valsartan 25.7 mg tablet	Yes	On the advice of a cardiology service (or in a rural/remote setting, an appropriate specialist) AND for use as per PBS criteria	
sacubitril 48.6 mg + valsartan 51.4 mg tablet	Yes	On the advice of a cardiology service (or in a rural/remote setting, an appropriate specialist) AND for use as per PBS criteria	
s-adenosylmethionine 400 mg + cyanocobalamin 1 mg + riboflavin 20 mg + zinc amino acid chelate 50 mg (zinc 10 mg) + folic acid 90 microgram + pyridoxine hydrochloride 50 mg enteric tablet	Yes	On the advice of a metabolic service	For practical and safety purposes this medicine should be prescribed by brand name.
salbutamol 100 microgram/actuation inhalation, actuation	No	N/A	
salbutamol 2.5 mg/2.5 mL inhalation solution, ampoule	No	N/A	
salbutamol 5 mg/2.5 mL inhalation solution, ampoule	No	N/A	
salbutamol 5 mg/5 mL injection, ampoule	Yes	For use in critical care areas AND in accordance with a DTC approved protocol	
salbutamol 500 microgram/mL injection, ampoule	Yes	For use where inhaled therapy is inappropriate	
sapropterin dihydrochloride 100 mg soluble tablet	Yes	For use by metabolic services only AND as per PBS criteria	
secukinumab 150 mg/mL injection, pen device	Yes	For use as per PBS criteria	
selegiline hydrochloride 5 mg tablet	Yes	On the advice of a neurology service for treatment of Parkinson's disease	
selenium sulfide 2.5% shampoo	No	N/A	
semaglutide 1.34 mg/mL injection, 1.5 mL pen device	Yes	For use as per PBS criteria	Due to a disruption to the supply of the Australian registered product, alternative semaglutide 1.34 mg/mL injection products have been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act. Please refer to the TGA S19a approvals database for further details
semaglutide 1.34 mg/mL injection, 3 mL pen device	Yes	For use as per PBS criteria	Due to a disruption to the supply of the Australian registered product, alternative semaglutide 1.34 mg/mL injection products have been approved for supply under Section 19A (S19A) of the Therapeutic Goods Act. Please refer to the TGA S19a approvals database for further details
sennoside B 7.5 mg tablet	No	N/A	
sertraline 100 mg tablet	No	N/A	
sertraline 50 mg tablet	No	N/A	
sevelamer carbonate 800 mg tablet	Yes	On the advice of a renal service for the management of hyperphosphataemia AND as per PBS S100 HSD criteria	
sevelamer hydrochloride 800 mg tablet	Yes	On the advice of a renal service for the management of hyperphosphataemia AND as per PBS S100 HSD criteria	
sevoflurane 1 mL/mL inhalation solution	Yes	For use by anaesthetic or intensive care services only	
sildenafil 10 mg/12.5 mL injection, vial	Yes	For use by intensive care and neonatology services only	
sildenafil 100 mg tablet	Yes	On the advice of a cardiovascular service OR for use by a neonatology service	
sildenafil 20 mg tablet	Yes	For use as per PBS S100 HSD criteria OR on the advice of a cardiovascular service	
silibinin 350 mg injection, vial	Yes	On the advice of a clinical toxicology service for treatment of amatoxin poisoning	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126. Special Access Scheme form must be submitted and informed consent for use obtained
silver sulfadiazine 1% cream	No	N/A	
simethicone 100 mg capsule	No	N/A	
simethicone 40 mg/mL oral liquid	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
sirolimus 1 mg tablet	No	N/A	Careful monitoring of patients is mandatory
sirolimus 1 mg/mL oral liquid	Yes	For use where solid oral dose form not suitable	Careful monitoring of patients is mandatory
sirolimus 2 mg tablet	No	N/A	Careful monitoring of patients is mandatory
sirolimus 500 microgram tablet	No	N/A	Careful monitoring of patients is mandatory
sitagliptin 100 mg tablet	Yes	For use as per PBS criteria	
sitagliptin 50 mg tablet	Yes	For use as per PBS criteria	
SMOFlipid + Vitalipid N Infant + Soluvit N injection, 151 mL bag	Yes	For use by neonatal TPN services	
SMOFlipid + Vitalipid N Infant + Soluvit N injection, 45 mL syringe	Yes	For use by neonatal TPN services	
sodium acetate 1.64 g/10 mL injection, ampoule	Yes	For use in critical care areas only	
sodium alginate 500 mg/10 mL + sodium bicarbonate 267 mg/10 mL + calcium carbonate 160 mg/10 mL oral liquid	No	N/A	
sodium ascorbate 112.5 mg + ascorbic acid 150 mg chewable tablet	No	N/A	
sodium bicarbonate 1.76 g + sodium citrate 630 mg + citric acid 720 mg + tartaric acid 890 mg powder for oral liquid, 4 g sachet	No	N/A	
sodium bicarbonate 8.4% (8.4 g/100 mL) injection, vial	No	N/A	Use in accordance with a DTC approved protocol
sodium bicarbonate 8.4% (840 mg/10 mL) injection, vial	No	N/A	Use in accordance with a DTC approved protocol
sodium bicarbonate 840 mg capsule	No	N/A	
sodium chloride 0.45% (2.25 g/500 mL) injection, bag	No	N/A	
sodium chloride 0.9% (180 mg/20 mL) injection, ampoule	No	N/A	
sodium chloride 0.9% (2.25 g/250 mL) injection, bag	No	N/A	
sodium chloride 0.9% (2.25 g/250 mL) injection, bottle	No	N/A	
sodium chloride 0.9% (4.5 g/500 mL) injection, bag	No	N/A	
sodium chloride 0.9% (4.5 g/500 mL) injection, bottle	No	N/A	
sodium chloride 0.9% (450 mg/50 mL) injection, bag	No	N/A	
sodium chloride 0.9% (450 mg/50 mL) injection, bottle	No	N/A	
sodium chloride 0.9% (450 mg/50 mL) injection, vial	No	N/A	
sodium chloride 0.9% (9 g/L) injection, bag	No	N/A	
sodium chloride 0.9% (9 g/L) injection, bottle	No	N/A	
sodium chloride 0.9% (90 mg/10 mL) injection, ampoule	No	N/A	
sodium chloride 0.9% (900 mg/100 mL) injection, bag	No	N/A	
sodium chloride 0.9% (900 mg/100 mL) injection, bottle	No	N/A	
sodium chloride 0.9% (900 mg/100 mL) injection, vial	No	N/A	
sodium chloride 156.2 mg/62.5 mL + potassium citrate monohydrate 137.5 mg (potassium 1.3 mmol)/62.5 mL + glucose monohydrate 1 g/62.5 mL + citrate monohydrate 300 mg/62.5 mL oral liquid, sachet	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
sodium chloride 2.5 mg/mL + potassium citrate monohydrate 2.2 mg (potassium 0.02 mmol)/mL + glucose monohydrate 16 mg/mL + citrate monohydrate 4.8 mg/mL oral liquid	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
sodium chloride 2.63 g/500 mL + sodium gluconate 2.51 g/500 mL + sodium acetate trihydrate 1.84 g/500 mL + potassium chloride 185 mg (potassium 2.5 mmol)/500 mL + magnesium chloride hexahydrate 150 mg/500 mL injection, bag	Yes	For use in critical care areas only	For practical and safety purposes this medicine should be prescribed by brand name.
sodium chloride 23.4% (2.34 g/10 mL) injection, vial	Yes	For use in critical care areas only	Storage should be separated from other sodium chloride infusion bags to avoid selection error.
sodium chloride 3% (30 g/L) injection, bag	Yes	For use in critical care areas only	Only one volume of sodium chloride 3% infusion bags should be stocked in a clinical area where practicable. Strategies should be used to reduce selection error e.g., storing separately from other sodium chloride infusion bags
sodium chloride 3% (7.5 g/250 mL) injection, bag	Yes	For use in critical care areas only	Only one volume of sodium chloride 3% infusion bags should be stocked in a clinical area where practicable. Strategies should be used to reduce selection error e.g., storing separately from other sodium chloride infusion bags
sodium chloride 5% eye drops	Yes	For use by ophthalmology services only	
sodium chloride 5.26 g/L + sodium gluconate 5.02 g/L + sodium acetate trihydrate 3.68 g/L + potassium chloride 370 mg (potassium 5 mmol)/L + magnesium chloride hexahydrate 300 mg/L + glucose 5% (50 g/L) injection, bag	Yes	For use in paediatric critical care areas only	For practical and safety purposes this medicine should be prescribed by brand name.
sodium chloride 5.26 g/L + sodium gluconate 5.02 g/L + sodium acetate trihydrate 3.68 g/L + potassium chloride 370 mg (potassium 5 mmol)/L + magnesium chloride hexahydrate 300 mg/L injection, bag	Yes	For use in critical care areas only	For practical and safety purposes this medicine should be prescribed by brand name.
sodium chloride 530 mg + potassium citrate monohydrate 440 mg (potassium 4 mmol) + glucose 2.91 g + citric acid 880 mg powder for oral liquid, 4.9 g sachet	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
sodium chloride 6.4 mg/mL + potassium chloride 750 microgram/mL + calcium chloride dihydrate 480 microgram/mL + magnesium chloride 300 microgram/mL + sodium acetate 3.9 mg/mL + sodium citrate dihydrate 1.7 mg/mL solution	Yes	For use by ophthalmology services only	For practical and safety purposes this medicine should be prescribed by brand name.
sodium chloride 600 mg tablet	No	N/A	
sodium chloride 7.5% (18.75 g/250 mL) injection, bag	Yes	On the advice of a critical care service	Storage should be separated from other sodium chloride infusion bags to avoid selection error.
sodium citrate dihydrate 2.64 g/30 mL oral liquid	No	N/A	
sodium citrate dihydrate 450 mg/5 mL + lauryl sulfoacetate sodium 45 mg/5 mL + sorbitol 3.125 g/5 mL enema	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
sodium fusidate 2% ointment	Yes	Use in accordance with the local antimicrobial stewardship policy	
sodium fusidate 250 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
sodium lactate 1.61 g/500 mL + sodium chloride 3 g/500 mL + potassium chloride 200 mg (potassium 2.7 mmol)/500 mL + calcium chloride dihydrate 135 mg/500 mL injection, bag	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
sodium lactate 3.22 g/L + sodium chloride 6 g/L + potassium chloride 2.2 g (potassium 30 mmol)/L + calcium chloride dihydrate 270 mg/L injection, bag	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
sodium lactate 3.22 g/L + sodium chloride 6 g/L + potassium chloride 400 mg (potassium 5.4 mmol)/L + calcium chloride dihydrate 270 mg/L injection, bag	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
sodium nitrite 300 mg/10 mL injection, ampoule	Yes	On the advice of a clinical toxicology service for treatment of cyanide poisoning	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
sodium nitroprusside 50 mg/2 mL injection, vial	Yes	For use in ICU, CCU, ED or OT where cardiac monitoring is available	
sodium phenylbutyrate 483 mg/g granules	Yes	For the management of urea cycle disorders	
sodium picosulfate 10 mg + magnesium carbonate hydrate 7.87 g + citric acid 11.81 g powder for oral liquid, 20 g sachet	No	N/A	
sodium picosulfate 10.3 mg + magnesium carbonate hydrate 7.4 g + citric acid 12.2 g powder for oral liquid, 20 g sachet	No	N/A	
sodium picosulfate 7.5 mg/mL oral liquid, drop	Yes	For use where solid oral dose forms of stimulant laxatives are not suitable	
sodium polystyrene sulfonate 999.3 mg/g powder	No	N/A	
sodium tetradecyl sulfate 3% (60 mg/2 mL) injection, ampoule	No	N/A	
sodium thiosulfate pentahydrate 25% (12.5 g/50 mL) injection, vial	Yes	On the advice of a clinical toxicology service for treatment of cyanide poisoning	Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
sodium thiosulfate pentahydrate 25% (25 g/100 mL) injection, vial	Yes	For treatment of calciphylaxis in dialysis patients	Special Access Scheme form must be submitted and informed consent for use obtained
sofosbuvir 400 mg + velpatasvir 100 mg + voxilaprevir 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
sofosbuvir 400 mg + velpatasvir 100 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
solifenacin succinate 10 mg tablet	Yes	For detrusor overactivity in patients intolerant to oral oxybutynin	This medicine is not PBS listed, please discuss ongoing costs with the patient.
solifenacin succinate 5 mg tablet	Yes	For detrusor overactivity in patients intolerant to oral oxybutynin	This medicine is not PBS listed, please discuss ongoing costs with the patient.
somatropin 5 mg injection, chamber	Yes	On the advice of a paediatric endocrine service	
sotalol hydrochloride 160 mg tablet	No	N/A	
sotalol hydrochloride 80 mg tablet	No	N/A	
sotrovimab 500 mg/8 mL injection, vial	Yes	For use in accordance with the Agency for Clinical Innovation guidance	For use by prescribers approved by the local DTC
soya oil 20% (100 g/500 mL) injection, bottle	Yes	For use by TPN or metabolic services OR for use in local anaesthetic poisoning OR on advice of a clinical toxicology service for other poisoning indications	Clinical Toxicology advice is available 24/7 via the NSW Poisons Information Centre. Phone 131126
soya oil 30 g/500 mL + medium chain triglycerides 30 g/500 mL + olive oil 25 g/500 mL + fish oil 15 g/500 mL injection, bag	Yes	For use by TPN or metabolic services OR for use in local anaesthetic poisoning OR on advice of a clinical toxicology service for other poisoning indications	For practical and safety purposes this medicine should be prescribed by brand name.

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
soya oil 6 g/100 mL + medium chain triglycerides 6 g/100 mL + olive oil 5 g/100 mL + fish oil 3 g/100 mL injection, bag	Yes	For use by TPN or metabolic services OR for use in local anaesthetic poisoning OR on advice of a clinical toxicology service for other poisoning indications	For practical and safety purposes this medicine should be prescribed by brand name.
spironolactone 100 mg tablet	No	N/A	
spironolactone 25 mg tablet	No	N/A	
stiripentol 250 mg capsule	Yes	For use as per PBS criteria	
stiripentol 250 mg powder for oral liquid, sachet	Yes	For use where solid oral dose form not suitable	
succimer 200 mg capsule	Yes	On the advice of a clinical toxicology service for treatment of heavy metal poisoning	Special Access Scheme form must be submitted and informed consent for use obtained. Contact the local toxicology service or the NSW Poisons Information Centre for clinical toxicology advice via phone on 131126.
sucralfate 1 g tablet	No	N/A	
sucroferric oxyhydroxide 2.5 g (iron 500 mg) chewable tablet	Yes	For the management of hyperphosphataemia on the advice of a renal service (or in a rural/remote setting, an appropriate specialist) AND as per PBS S100 HSD criteria	
sucrose 24% oral liquid	Yes	For the management of minor procedural pain in neonates and infants under 4 months	
sugammadex 200 mg/2 mL injection, vial	Yes	For reversal of neuromuscular blockade caused by rocuronium or vecuronium in conjunction with neuromuscular monitoring	
sulfasalazine 500 mg enteric tablet	No	N/A	
sulthiame 200 mg tablet	Yes	On the advice of a paediatric neurologist	
sulthiame 50 mg tablet	Yes	On the advice of a paediatric neurologist	
sumatriptan 10 mg/actuation nasal spray, 1 actuation	No	N/A	
sumatriptan 100 mg tablet	No	N/A	
sumatriptan 20 mg/actuation nasal spray, 1 actuation	No	N/A	
sumatriptan 50 mg tablet	No	N/A	
sumatriptan 6 mg/0.5 mL injection, pen device	No	N/A	
sumatriptan 6 mg/0.5 mL injection, syringe	No	N/A	
suxamethonium chloride 100 mg/2 mL injection, ampoule	No	N/A	
tacrolimus 1 mg capsule	No	N/A	Careful monitoring of patients is mandatory
tacrolimus 1 mg modified release capsule	Yes	For use as per PBS S100 HSD criteria	
tacrolimus 2 mg capsule	No		Careful monitoring of patients is mandatory
tacrolimus 3 mg modified release capsule	Yes	For use as per PBS S100 HSD criteria	
tacrolimus 5 mg capsule	No	N/A	Careful monitoring of patients is mandatory
tacrolimus 5 mg modified release capsule	Yes	For use as per PBS S100 HSD criteria	
tacrolimus 5 mg/mL injection, ampoule	Yes	For patients unable to tolerate oral therapy	
tacrolimus 500 microgram capsule	No	N/A	Careful monitoring of patients is mandatory
tacrolimus 500 microgram modified release capsule	Yes	For use as per PBS S100 HSD criteria	
tacrolimus 750 microgram capsule	No	N/A	Careful monitoring of patients is mandatory
tadalafil 20 mg tablet	Yes	For use as per PBS S100 HSD criteria	
tamoxifen 20 mg tablet	No	N/A	
tamsulosin hydrochloride 400 microgram modified release tablet	Yes	For management of lower urinary tract symptoms in benign prostatic hyperplasia OR for management of renal colic	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
tapentadol 100 mg modified release tablet	Yes	On the advice of a pain service for chronic pain unresponsive to non-opioid analgesia. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
tapentadol 200 mg modified release tablet	Yes	On the advice of a pain service for chronic pain unresponsive to non-opioid analgesia. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
tapentadol 50 mg modified release tablet	Yes	On the advice of a pain service for chronic pain unresponsive to non-opioid analgesia. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
tapentadol 50 mg tablet	Yes	On the advice of a pain service. Other prescribers may be approved by your local DTC as specified in your LHD's High-Risk Medicines Register protocol, (refer to high risk medicines management policy PD2020_045)	
tar 1% + coal tar solution 1% + salicylic acid 2% solution	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
tar 1.6% gel	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
tar 2.3% + trolamine lauril sulfate 6% solution	No	N/A	For practical and safety purposes this medicine should be prescribed by brand name.
teduglutide 5 mg injection, vial	Yes	For use as per PBS S100 HSD criteria	
teicoplanin 400 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
telmisartan 40 mg tablet	No	N/A	
telmisartan 80 mg tablet	No	N/A	
temazepam 10 mg tablet	No	N/A	
temozolomide 100 mg capsule	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
temozolomide 140 mg capsule	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
temozolomide 180 mg capsule	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
temozolomide 20 mg capsule	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
temozolomide 250 mg capsule	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
temozolomide 5 mg capsule	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist) AND in accordance with an eviQ or approved protocol	
tenecteplase 50 mg injection, vial	Yes	For use in accordance with a DTC approved protocol OR Nurse Administered Thrombolysis (NAT) Protocol for ST Elevation Myocardial Infarction (STEMI)	
tenofovir alafenamide 10 mg + emtricitabine 200 mg + elvitegravir 150 mg + cobicistat 150 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	For practical and safety purposes this medicine should be prescribed by brand name.
tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg + efavirenz 600 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
tenofovir disoproxil fumarate 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
tenofovir disoproxil maleate 300 mg + emtricitabine 200 mg + efavirenz 600 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
tenofovir disoproxil maleate 300 mg + emtricitabine 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
tenofovir disoproxil maleate 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
tenofovir disoproxil phosphate 291 mg + emtricitabine 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
terbinafine 250 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
terbinafine hydrochloride 1% cream	No	N/A	
terbutaline sulfate 500 microgram/actuation powder for inhalation, actuation	No	N/A	
terbutaline sulfate 500 microgram/mL injection, ampoule	Yes	On the advice of an obstetrics service	
terlipressin 1.7 mg/10 mL injection, vial	Yes	For treatment of bleeding oesophageal varices and hepatorenal syndrome	
terlipressin 850 microgram/5 mL injection, vial	Yes	For treatment of bleeding oesophageal varices and hepatorenal syndrome	
terlipressin 850 microgram/8.5 mL injection, ampoule	Yes	For treatment of bleeding oesophageal varices and hepatorenal syndrome	
testosterone 1% (50 mg/5 g) gel, sachet	Yes	For use as per PBS criteria	
tetrabenazine 25 mg tablet	No	N/A	
tetracaine (amethocaine) 4% gel	No	N/A	
tetracaine (amethocaine) hydrochloride 0.5% eye drops, unit dose	No	N/A	
tetracaine (amethocaine) hydrochloride 1% eye drops, unit dose	No	N/A	
tetracosactide (tetracosactrin) 1 mg/mL modified release injection, ampoule	Yes	For management of infantile spasms OR on the advice of an endocrine service (or in a rural/remote setting, an appropriate specialist)	
tetracosactide (tetracosactrin) 250 microgram/mL injection, ampoule	No	N/A	
thalidomide 100 mg capsule	Yes	For use as per PBS S100 HSD criteria	
thalidomide 50 mg capsule	Yes	For use as per PBS S100 HSD criteria	
theophylline 200 mg modified release tablet	Yes	On the advice of a respiratory service	
theophylline 250 mg modified release tablet	Yes	On the advice of a respiratory service	
theophylline 300 mg modified release tablet	Yes	On the advice of a respiratory service	
thiamine 25 mg + riboflavin 25 mg + nicotinamide 70 mg + pantothenic acid 25 mg + pyridoxine 25 mg + cyanocobalamin 25 microgram + ascorbic acid 500 mg + biotin 50 microgram + folic acid 500 microgram + calcium 97.6 mg + magnesium 50 mg + zinc 5 mg effervescent tablet	No	N/A	
thiamine hydrochloride 100 mg tablet	No	N/A	
thiamine hydrochloride 100 mg/mL injection, vial	No	N/A	
thiamine hydrochloride 15 mg + riboflavin 15 mg + nicotinamide 50 mg + pantothenic acid (as calcium pantothenate) 23 mg + pyridoxine hydrochloride 10 mg + cyanocobalamin 10 microgram + ascorbic acid 500 mg + biotin 150 microgram + folic acid 400 microgram + calcium 100 mg + magnesium 100 mg + zinc 10 mg effervescent tablet	No	N/A	

Medicine name, strength, and form	Restricted?	Restriction	Additional information
thiamine hydrochloride 2.5 mg/5 mL + riboflavin sodium phosphate 2.5 mg (riboflavin 1.8 mg)/5 mL + nicotinamide 15 mg/5 mL + pyridoxine hydrochloride 750 microgram/5 mL + ascorbic acid 60 mg/5 mL + colecalciferol 5 microgram (200 units)/5 mL + ferric chloride hexahydrate 17.4 mg (iron 3.6 mg)/5 mL oral liquid	No	N/A	
thiamine hydrochloride 540 microgram/0.45 mL + riboflavin sodium phosphate 1.1 mg (riboflavin 800 microgram)/0.45 mL + nicotinamide 7.1 mg/0.45 mL + pyridoxine hydrochloride 135 microgram/0.45 mL + ascorbic acid 42.8 mg/0.45 mL + colecalciferol 10.1 microgram (404 units)/0.45 mL + retinol palmitate 490 microgram/0.45 mL oral liquid	No	N/A	
thiamine nitrate 15 mg + riboflavin 15 mg + nicotinamide 30 mg + calcium pantothenate 8 mg + pyridoxine hydrochloride 5 mg + cyanocobalamin 10 microgram + folic acid 150 microgram tablet	No	N/A	
thiamine nitrate 150 mg + riboflavin 150 mg + nicotinamide 150 mg + calcium pantothenate 150 mg + pyridoxine hydrochloride 150 mg + mecobalamin (co-methylcobalamin) 400 microgram + folic acid 500 microgram + biotin 150 microgram + choline bitartrate 75 mg + inositol 75 mg tablet	No	N/A	
thiamine nitrate 3.1 mg + riboflavin 3.6 mg + nicotinamide 40 mg + pyridoxine 4 mg + pantothenic acid (as sodium pantothenate) 15 mg + ascorbic acid 100 mg + biotin 60 microgram + folic acid 400 microgram + cyanocobalamin 5 microgram injection, vial	No	N/A	
thiamine nitrate 50 mg + riboflavin 25 mg + nicotinamide 50 mg + calcium pantothenate 50 mg + pyridoxine hydrochloride 50 mg + cyanocobalamin 50 microgram + ascorbic acid 100 mg + biotin 50 microgram + folic acid 200 microgram + inositol 50 microgram + choline bitartrate 50 microgram tablet	No	N/A	
thiopental sodium 470 mg injection, vial	Yes	For use in anaesthesia and critical care	
thiotepa 100 mg injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
thiotepa 15 mg injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
thyrotropin alfa 900 microgram injection, vial	Yes	For use by nuclear medicine or endocrine services only	
ticagrelor 90 mg tablet	Yes	For acute coronary syndromes as per PBS criteria AND on the advice of a cardiology service (or in a rural/remote setting, an appropriate specialist) OR for prevention of thrombotic complications post neurointerventional stenting procedures.	
tigecycline 50 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
tiger snake antivenom 3000 units injection, vial	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
timolol 0.5% eye drops	No		For practical and safety purposes this medicine should be prescribed by brand name.
timolol 0.5% eye drops	No		For practical and safety purposes this medicine should be prescribed by brand name.
tioguanine 40 mg tablet	Yes	For use by cancer services only (or in a rural/remote setting, an appropriate specialist)	
tiotropium 18 microgram powder for inhalation, 1 capsule	No	N/A	
tiotropium 2.5 microgram/actuation + olodaterol 2.5 microgram/actuation inhalation solution, actuation	Yes	For use as per PBS criteria	
tiotropium 2.5 microgram/actuation inhalation solution, actuation	No	N/A	
tirofiban 12.5 mg/50 mL injection, vial	Yes	For use in critical care areas only	Off label use is only allowed if it is in accordance with a DTC approved protocol
tixagevimab 150 mg/1.5 mL injection, vial (&) cilgavimab 150 mg/1.5 mL injection, vial	Yes	For use in accordance with the Agency for Clinical Innovation guidance	For use by prescribers approved by the local DTC
tobramycin 0.3% eye drops	Yes	Use in accordance with the local antimicrobial stewardship policy	
tobramycin 0.3% eye ointment	Yes	Use in accordance with the local antimicrobial stewardship policy	
tobramycin 28 mg powder for inhalation, 1 capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
tobramycin 300 mg/5 mL inhalation solution, ampoule	Yes	Use in accordance with the local antimicrobial stewardship policy	
tobramycin 80 mg/2 mL injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
tocilizumab 200 mg/10 mL injection, vial	Yes	For use as per PBS S100 HSD criteria OR for COVID-19 in accordance with the TGA approved indications OR for the management of cytokine-release syndrome or haemophagocytic lymphohistiocytosis/macrophage activating syndrome in accordance with an approved protocol	For COVID-19: for use by prescribers approved by the local DTC
tocilizumab 200 mg/10 mL injection, vial	Yes	For use as per PBS S100 HSD criteria OR for COVID-19 in accordance with the TGA approved indications OR for the management of cytokine-release syndrome or haemophagocytic lymphohistiocytosis/macrophage activating syndrome in accordance with an approved protocol	For COVID-19: for use by prescribers approved by the local DTC
tocilizumab 400 mg/20 mL injection, vial	Yes	For use as per PBS S100 HSD criteria OR for COVID-19 in accordance with the TGA approved indications OR for the management of cytokine-release syndrome or haemophagocytic lymphohistiocytosis/macrophage activating syndrome in accordance with an approved protocol	For COVID-19: for use by prescribers approved by the local DTC
tocilizumab 400 mg/20 mL injection, vial	Yes	For use as per PBS S100 HSD criteria OR for COVID-19 in accordance with the TGA approved indications OR for the management of cytokine-release syndrome or haemophagocytic lymphohistiocytosis/macrophage activating syndrome in accordance with an approved protocol	For COVID-19: for use by prescribers approved by the local DTC
tocilizumab 80 mg/4 mL injection, vial	Yes	For use as per PBS S100 HSD criteria OR for COVID-19 in accordance with the TGA approved indications OR for the management of cytokine-release syndrome or haemophagocytic lymphohistiocytosis/macrophage activating syndrome in accordance with an approved protocol	For COVID-19: for use by prescribers approved by the local DTC
tocilizumab 80 mg/4 mL injection, vial	Yes	For use as per PBS S100 HSD criteria OR for COVID-19 in accordance with the TGA approved indications OR for the management of cytokine-release syndrome or haemophagocytic lymphohistiocytosis/macrophage activating syndrome in accordance with an approved protocol	For COVID-19: for use by prescribers approved by the local DTC
tolvaptan 15 mg tablet	Yes	On the advice of an endocrine or renal service only	
topiramate 100 mg tablet	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
topiramate 15 mg capsule	Yes	For use where solid oral dose form not suitable	
topiramate 25 mg capsule	Yes	For use where solid oral dose form not suitable	
topiramate 25 mg tablet	No	N/A	
topiramate 50 mg capsule	Yes	For use where solid oral dose form not suitable	
topiramate 50 mg tablet	No	N/A	
topotecan 4 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
tozinameran 15 microgram/0.3 mL + famtozinameran 15 microgram/0.3 mL injection, 2.25 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
tozinameran 15 microgram/0.3 mL + riltozinameran 15 microgram/0.3 mL injection, 2.25 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
tozinameran 30 microgram/0.3 mL injection, 2.25 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
tozinameran injection, 0.45 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
tozinameran injection, 1.3 mL vial	Yes	For vaccination according to ATAGI guidelines OR for vaccination of staff eligible under the NSW Health PD2023_022 Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases	For practical and safety purposes this medicine should be prescribed by brand name.
trace elements neonatal injection, 10 mL syringe	Yes	For TPN use only	
tramadol hydrochloride 100 mg modified release tablet	No		
tramadol hydrochloride 100 mg/2 mL injection, ampoule	No	N/A	
tramadol hydrochloride 200 mg modified release tablet	No		
tramadol hydrochloride 50 mg capsule	No		
tramadol hydrochloride 50 mg modified release tablet	No		
tranexamic acid 1 g/10 mL injection, ampoule	No	N/A	Off label use is only allowed if it is in accordance with a DTC approved protocol
tranexamic acid 500 mg tablet	No	N/A	Off label use is only allowed if it is in accordance with a DTC approved protocol
tranexamic acid 500 mg/5 mL injection, ampoule	No	N/A	Off label use is only allowed if it is in accordance with a DTC approved protocol
tranylcypromine 10 mg tablet	Yes	On the advice of a mental health service	
trastuzumab 150 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
trastuzumab 60 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
trastuzumab 600 mg/5 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
trastuzumab emtansine 100 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
trastuzumab emtansine 160 mg injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
travoprost 0.004% eye drops	No	N/A	
tretinoin 0.025% cream	Yes	On the advice of a dermatology service (or in a rural/remote setting, an appropriate specialist)	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
tretinoin 10 mg capsule	Yes	For treatment of acute promyelocytic leukaemia in combination with arsenic trioxide AND authority to prescribe under clause 37 of the Poisons and Therapeutic Goods Regulation 2008 required	
triamcinolone acetonide 0.02% cream	No	N/A	
triamcinolone acetonide 0.02% ointment	No	N/A	
triamcinolone acetonide 0.09% + neomycin 0.225% + gramicidin 0.0225% + nystatin 90 000 units/mL ear drops	Yes	Use in accordance with the local antimicrobial stewardship policy	For practical and safety purposes this medicine should be prescribed by brand name.
triamcinolone acetonide 0.1% + neomycin 0.25% + gramicidin 0.025% + nystatin 100 000 units/g ointment	Yes	Use in accordance with the local antimicrobial stewardship policy	For practical and safety purposes this medicine should be prescribed by brand name.
triamcinolone acetonide 0.1% paste	No	N/A	
triamcinolone acetonide 10 mg/mL injection, ampoule	No	N/A	
triamcinolone acetonide 40 mg/mL injection, ampoule	No	N/A	
trihexyphenidyl (benzhexol) hydrochloride 2 mg tablet	No	N/A	
trihexyphenidyl (benzhexol) hydrochloride 5 mg tablet	No	N/A	
trimethoprim 160 mg + sulfamethoxazole 800 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
trimethoprim 300 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
trimethoprim 40 mg/5 mL + sulfamethoxazole 200 mg/5 mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
trimethoprim 80 mg + sulfamethoxazole 400 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
trimethoprim 80 mg/5 mL + sulfamethoxazole 400 mg/5 mL injection, ampoule	Yes	Use in accordance with the local antimicrobial stewardship policy	
triptorelin acetate 100 microgram/mL injection, syringe	Yes	On the advice of endocrine services for the diagnosis of precocious puberty	
tropicamide 0.5% eye drops, unit dose	No	N/A	
tropicamide 1% eye drops, unit dose	No	N/A	
tuberculin PPD (Mantoux) acellular intradermal skin test 50 tuberculin units/mL injection, vial	No	N/A	
ubidecarenone 150 mg capsule	Yes	For the management of primary coenzyme Q10 deficiency	
ubidecarenone 75 mg capsule	Yes	For the management of primary coenzyme Q10 deficiency	
ulipristal acetate 30 mg tablet	No		
umeclidinium 62.5 microgram powder for inhalation, actuation	No	N/A	
umeclidinium 62.5 microgram/actuation + vilanterol 25 microgram/actuation powder for inhalation, actuation	Yes	For use as per PBS criteria	
ursodeoxycholic acid 250 mg capsule	No	N/A	
ursodeoxycholic acid 50 mg/mL oral liquid	No	N/A	
ustekinumab 130 mg/26 mL injection, vial	Yes	For use as per PBS S100 HSD criteria	
valaciclovir 500 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
valganciclovir 450 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
valganciclovir 50 mg/mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
valine with carbohydrate containing 50 mg valine powder for oral liquid, 4 g sachet	Yes	For the management of maple syrup urine disease	For practical and safety purposes this medicine should be prescribed by brand name.
valproate sodium 100 mg tablet	No	N/A	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
valproate sodium 100 mg tablet	No	N/A	
valproate sodium 200 mg enteric tablet	No	N/A	
valproate sodium 200 mg enteric tablet	No	N/A	
valproate sodium 200 mg/5 mL oral liquid	No	N/A	
valproate sodium 200 mg/5 mL oral liquid	No	N/A	
valproate sodium 400 mg/4 mL injection, ampoule	No	N/A	
valproate sodium 400 mg/4 mL injection, ampoule	No	N/A	
valproate sodium 500 mg enteric tablet	No	N/A	
valproate sodium 500 mg enteric tablet	No	N/A	
valsartan 160 mg tablet	No	N/A	
valsartan 320 mg tablet	No	N/A	
valsartan 40 mg tablet	No	N/A	
valsartan 80 mg tablet	No	N/A	
vancomycin 1 g injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
vancomycin 125 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
vancomycin 500 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	
varenicline 1 mg tablet	Yes	For use where nicotine replacement therapy not clinically appropriate	
varenicline 500 microgram tablet (&) varenicline 1 mg tablet	Yes	For use where nicotine replacement therapy not clinically appropriate	
varicella-zoster live vaccine 1350 PFU injection, vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
varicella-zoster live vaccine 19 400 PFU injection, vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
varicella-zoster live vaccine 1995 PFU injection, vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
varicella-zoster virus glycoprotein E recombinant adjuvanted vaccine injection, vial	Yes	For use as per the Australian Immunisation Handbook	For practical and safety purposes this medicine should be prescribed by brand name.
vecuronium bromide 10 mg injection, vial	No	N/A	
vedolizumab 300 mg injection, vial	Yes	For use as per PBS S100 HSD criteria	
venetoclax 10 mg tablet	Yes	For use by haematology services only AND in accordance with an eviQ or approved protocol	
venetoclax 100 mg tablet	Yes	For use by haematology services only AND in accordance with an eviQ or approved protocol	
venetoclax 50 mg tablet	Yes	For use by haematology services only AND in accordance with an eviQ or approved protocol	
venlafaxine 150 mg modified release capsule	No	N/A	
venlafaxine 37.5 mg modified release capsule	No	N/A	
venlafaxine 75 mg modified release capsule	No	N/A	
verapamil hydrochloride 180 mg modified release tablet	No	N/A	
verapamil hydrochloride 240 mg modified release tablet	No	N/A	
verapamil hydrochloride 40 mg tablet	No	N/A	
verapamil hydrochloride 5 mg/2 mL injection, ampoule	No	N/A	
verapamil hydrochloride 80 mg tablet	No	N/A	
vigabatrin 500 mg powder for oral liquid, sachet	Yes	For use where solid oral dose form not suitable	
vigabatrin 500 mg tablet	Yes	On the advice of a paediatric neurologist	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
vinblastine sulfate 10 mg/10 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
vincristine sulfate 1 mg/mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
vincristine sulfate 2 mg/2 mL injection, vial	Yes	For use by cancer services only AND in accordance with an eviQ or approved protocol	
vinorelbine 50 mg/5 mL injection, vial	Yes	For use as per PBS criteria AND in accordance with an eviQ or approved protocol	
vitamin A 2500 units + betacarotene 3 mg + thiamine hydrochloride 1.5 mg + riboflavin 1.7 mg + pyridoxine hydrochloride 1.9 mg + cyanocobalamin 3 microgram + nicotinamide 20 mg + biotin 100 microgram + folic acid 200 microgram + ascorbic acid 100 mg + pantothenic acid (as calcium pantothenate) 12 mg + colecalciferol 11 microgram (440 units) + dl-alpha-tocopherol 135 mg (150 units) + phytomenadione 150 microgram + zinc amino acid chelate 37.5 mg (zinc 7.5 mg) capsule	Yes	For cystic fibrosis patients OR cholestatic liver disease patients	
voriconazole 200 mg injection, vial	Yes	Use in accordance with the local antimicrobial stewardship policy	Patients should be transitioned to oral therapy as soon as feasible
voriconazole 200 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
voriconazole 40 mg/mL powder for oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
voriconazole 50 mg tablet	Yes	Use in accordance with the local antimicrobial stewardship policy	
warfarin sodium 1 mg tablet	No	N/A	Coumadin is the only brand approved for initiation. Not all brands of Warfarin are bioequivalent.
warfarin sodium 2 mg tablet	No	N/A	Coumadin is the only brand approved for initiation. Not all brands of Warfarin are bioequivalent.
warfarin sodium 5 mg tablet	No	N/A	Coumadin is the only brand approved for initiation. Not all brands of Warfarin are bioequivalent.
xylometazoline hydrochloride 0.05% nasal spray	No	N/A	
xylometazoline hydrochloride 0.1% nasal spray	No	N/A	
zidovudine 100 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
zidovudine 250 mg capsule	Yes	Use in accordance with the local antimicrobial stewardship policy	
zidovudine 50 mg/5 mL oral liquid	Yes	Use in accordance with the local antimicrobial stewardship policy	
zidovudine 200 mg/20 mL injection, vial	Yes	For prevention of maternal to child transmission of HIV	Special Access Scheme form must be submitted and informed consent for use obtained
zinc 11.3 mg/mL oral liquid	Yes	For use where solid oral dose form not suitable	
zinc 50 mg capsule	No	N/A	
zinc chloride 10.6 mg/2 mL injection, vial	No	N/A	
zinc oxide 10.75% + peru balsam 1.88% + benzyl benzoate 1.25% ointment	Yes	For short-term use up to 7 days	For practical and safety purposes this medicine should be prescribed by brand name.
zinc oxide 300 mg + peru balsam 50 mg + benzyl benzoate 33 mg suppository	Yes	For short-term use up to 7 days	For practical and safety purposes this medicine should be prescribed by brand name.
zinc oxide 7.5% + lidocaine (lignocaine) 1.5% ointment	Yes	For short-term use up to 7 days	For practical and safety purposes this medicine should be prescribed by brand name.
zinc sulfate 50 mg/mL injection, vial	No	N/A	
ziprasidone 20 mg capsule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
ziprasidone 20 mg injection, vial	Yes	On the advice of a mental health service	
ziprasidone 40 mg capsule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	

NSW Medicines Formulary

This list is updated frequently, NSW Health Clinicians are advised to view and search the Formulary via the online platform when connected to a NSW Health network.

Medicine name, strength, and form	Restricted?	Restriction	Additional information
ziprasidone 60 mg capsule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
ziprasidone 80 mg capsule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
zoledronic acid 4 mg/5 mL injection, vial	No	N/A	
zoledronic acid 5 mg/100 mL injection, vial	No	N/A	
zonisamide 25 mg capsule	Yes	On the advice of a neurology service AND as per PBS criteria	
zonisamide 50 mg capsule	Yes	On the advice of a neurology service AND as per PBS criteria	
zuclopenthixol 10 mg tablet	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
zuclopenthixol acetate 100 mg/2 mL injection, ampoule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
zuclopenthixol acetate 50 mg/mL injection, ampoule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	
zuclopenthixol decanoate 200 mg/mL injection, ampoule	Yes	On the advice of a mental health service (or in a rural/remote setting, an appropriate specialist)	